EU Local Number,Report Type,EV Gateway Receipt Date,Primary Source Qualification,Primary Source Country for Regulatory Purposes,Literature Reference,Patient Age Group,Patient Age Group (as per reporter),Parent Child Report,Patient Sex,Reaction List PT (Duration – Outcome - Seriousness Criteria),Suspect/interacting Drug List (Drug Char - Indication PT - Action taken - [Duration - Dose - Route]),Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - [Duration - Dose - Route]),ICSR Form
EU-EC-10006825281,Spontaneous,2020-10-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Cytopenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Myelofibrosis - Unknown - [n/a - n/a - Unknown]),<BR><BR>[FEDRATINIB] (S - Myelofibrosis - Dose reduced - [n/a - n/a - Oral]),<BR><BR>[FEDRATINIB] (S - n/a - Dose reduced - [n/a - 300mg - Oral]),<BR><BR>[FEDRATINIB] (S - n/a - Dose reduced - [n/a - n/a - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006825281&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006828652,Spontaneous,2020-10-09 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,Pancytopenia (n/a - Unknown - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia recurrent - Drug withdrawn - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Off label use - Drug withdrawn - [n/a - n/a - n/a]),<BR><BR>[ENASIDENIB] (S - Acute myeloid leukaemia recurrent - Drug withdrawn - [n/a - 100mg - Oral]),<BR><BR>[ENASIDENIB] (S - Off label use - Drug withdrawn - [n/a - 100mg - Oral]),<BR><BR>[ENASIDENIB] (S - n/a - Drug withdrawn - [n/a - 100mg - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006828652&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006810420,Spontaneous,2020-10-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,Cardiac failure (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006810420&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006800633,Spontaneous,2020-10-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abnormal faeces (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Back disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Back pain (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Body temperature increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Chills (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>General physical health deterioration (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Gingival discolouration (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Gingival swelling (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Neutropenia (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nutritional condition abnormal (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Off label use (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Weight abnormal (n/a - Unknown - Caused/Prolonged Hospitalisation)","VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 100mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Dose not changed - [n/a - 200mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Dose not changed - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose not changed - [n/a - 100mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose not changed - [n/a - 107mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose not changed - [n/a - 200mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose not changed - [n/a - 400mg - Unknown])","FRESUBIN ENERGY DRINK [CAFFEINE, CARBOHYDRATES NOS, CHOLINE, FATS NOS, MINERALS NOS, PROTEINS NOS, VITAMINS NOS] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[CEFUROXIME SODIUM] (C - Prophylaxis - n/a - [n/a - 250mg - n/a]),<BR><BR>[CIPROFLOXACIN HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 582mg - n/a]),<BR><BR>[DRONABINOL] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[LATANOPROST] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM, HYDRATE] (C - Thyroid hormone replacement therapy - n/a - [n/a - 75ug - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - 45.1mg - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - 45.1mg - n/a]),<BR><BR>[POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - 100mg - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006800633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006793552,Spontaneous,2020-10-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anaemia (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Blood creatinine increased (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Blood pressure decreased (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Crystal urine present (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Foreign body in gastrointestinal tract (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myxoid liposarcoma (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Oxygen saturation decreased (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Platelet transfusion (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary mass (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary oedema (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Renal failure (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Urinary retention (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>White blood cell count decreased (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","POSACONAZOLE [POSACONAZOLE] (S - Prophylaxis - Not applicable - [n/a - n/a - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Oral]),<BR><BR>[VENETOCLAX] (S - n/a - Not applicable - [n/a - n/a - Oral])","[ACICLOVIR, ACICLOVIR SODIUM] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - Blood uric acid - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCARBAMIDE] (C - Neoplasm malignant - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOFLOXACIN, LEVOFLOXACIN ANHYDROUS] (C - Infection - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE SODIUM] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006793552&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006796301,Spontaneous,2020-10-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Bone marrow failure (n/a - Recovered/Resolved - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 100mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - 100mg - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006796301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006796731,Spontaneous,2020-10-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Cerebral haemorrhage (n/a - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 75mg/kg - Intravenous (not otherwise specified)]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006796731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006788389,Spontaneous,2020-10-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Full blood count decreased (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006788389&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006788428,Spontaneous,2020-10-02 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Erythema (8d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Incorrect product formulation administered (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - 120mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006788428&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006789108,Spontaneous,2020-10-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bone marrow failure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Antiemetic supportive care - Unknown - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chemotherapy - Unknown - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Polyuria - Unknown - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Prophylaxis - Unknown - [n/a - n/a - n/a]),<BR><BR>[ACLARUBICIN HYDROCHLORIDE] (S - Antiemetic supportive care - Unknown - [n/a - n/a - n/a]),<BR><BR>[ACLARUBICIN HYDROCHLORIDE] (S - Chemotherapy - Unknown - [n/a - 20mg - Intravenous drip]),<BR><BR>[ACLARUBICIN HYDROCHLORIDE] (S - Polyuria - Unknown - [n/a - n/a - n/a]),<BR><BR>[ACLARUBICIN HYDROCHLORIDE] (S - Prophylaxis - Unknown - [n/a - n/a - n/a]),<BR><BR>[CYTARABINE] (S - Antiemetic supportive care - Unknown - [n/a - n/a - n/a]),<BR><BR>[CYTARABINE] (S - Chemotherapy - Unknown - [n/a - .2g - Intravenous drip]),<BR><BR>[CYTARABINE] (S - Polyuria - Unknown - [n/a - n/a - n/a]),<BR><BR>[CYTARABINE] (S - Prophylaxis - Unknown - [n/a - n/a - n/a])","[GLUCOSE, ANHYDROUS] (C - Product used for unknown indication - n/a - [n/a - 250mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 250mL - Intravenous drip]),<BR><BR>[STERILISED WATER FOR INJECTIONS] (C - Product used for unknown indication - n/a - [n/a - .4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006789108&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006791454,Spontaneous,2020-10-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Acute febrile neutrophilic dermatosis (n/a - Recovered/Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 75mg/m2 - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006791454&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006771322,Spontaneous,2020-09-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Thrombocytopenia (n/a - Unknown - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - n/a - [n/a - 138mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006771322&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006773208,Spontaneous,2020-09-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bone marrow failure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Chemotherapy - Drug withdrawn - [8d - 100mg - Subcutaneous]),<BR><BR>[ACLARUBICIN HYDROCHLORIDE] (S - Chemotherapy - Not applicable - [3d - 20mg - Intravenous drip]),<BR><BR>[CYTARABINE] (S - Chemotherapy - Drug withdrawn - [5d - .2g - Intravenous drip])","[GLUCOSE, GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS] (C - Vehicle solution use - n/a - [3d - 100mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - Vehicle solution use - n/a - [5d - 250mL - Intravenous drip]),<BR><BR>[STERILE WATER] (C - Vehicle solution use - n/a - [8d - 4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006773208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006758783,Spontaneous,2020-09-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Generalised oedema (1mo - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006758783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006758789,Spontaneous,2020-09-28 00:00:00,Healthcare Professional,Non European Economic Area,Matsumoto K. A Case of Myelodysplastic Syndrome with Trisomy 8 Accompanied by Behcet&apos;s Disease. The 658th Kanto Regional Meeting of the Japanese Society of Internal Medicine.,65-85 Years,Not Specified,No,Female,"Behcet's syndrome (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Oesophageal ulcer (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Recovering/Resolving - Results in Death, Other Medically Important Condition),<BR><BR>Stomatitis (n/a - Unknown - Results in Death, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Not applicable - [n/a - n/a - Intravenous drip])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006758789&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006745981,Spontaneous,2020-09-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anaemia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Blood count abnormal (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Catheter site infection (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hair colour changes (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Post procedural complication (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Thrombosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 100mg - Oral]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a])","ELIQUIS [APIXABAN] (C - Anticoagulant therapy - n/a - [n/a - n/a - Unknown]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID, ASPIRIN BP] (C - Anticoagulant therapy - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Fungal infection - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CARVEDILOL] (C - Cardiac disorder - n/a - [n/a - n/a - Unknown]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - Unknown]),<BR><BR>[DILTIAZEM, DILTIAZEM HYDROCHLORIDE] (C - Cardiac disorder - n/a - [n/a - n/a - Unknown]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Blood cholesterol - n/a - [n/a - n/a - Unknown]),<BR><BR>[SIMVASTATIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006745981&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006747727,Spontaneous,2020-09-25 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Blood count abnormal (n/a - Unknown - ),<BR><BR>Bone marrow myelogram abnormal (n/a - Unknown - ),<BR><BR>Neutrophil count abnormal (n/a - Unknown - ),<BR><BR>Platelet count abnormal (n/a - Unknown - ),<BR><BR>Therapy non-responder (n/a - Unknown - ),<BR><BR>White blood cell count abnormal (n/a - Unknown - )",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006747727&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006740107,Spontaneous,2020-09-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Beta haemolytic streptococcal infection (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sepsis (8d - Recovered/Resolved - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - 111mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - 60mg - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006740107&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006740188,Spontaneous,2020-09-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Ileal ulcer (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oesophageal ulcer (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006740188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006740472,Spontaneous,2020-09-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Urinary retention (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006740472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006727471,Spontaneous,2020-09-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Rash erythematous (8d - Recovered/Resolved - ),"VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Subcutaneous]),<BR><BR>[ENASIDENIB] (S - Acute myeloid leukaemia - Unknown - [n/a - 1{DF} - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006727471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006728655,Spontaneous,2020-09-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Febrile bone marrow aplasia (90d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Therapeutic response shortened (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 476mg - Subcutaneous]),"[ALFUZOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DRY EXTRACT OF THYME (7-13:1), EXTRACTION SOLVENT: WATER, DRY EXTRACT OF THYME (7-13:1), EXTRACTION SOLVENT: WATER, LIQUID EXTRACT FROM MARSHMALLOW ROOT (DER 1:12-14), EXTRACTION SOLVENT: WATER, FENOTEROL HYDROBROMIDE, IPRATROPIUM BROMIDE, FENOTEROL HYDROBROMIDE, IPRATROPIUM BROMIDE ANHYDROUS, FENOTEROL HYDROBROMIDE, IPRATROPIUM BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PAROXETINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006728655&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006734640,Spontaneous,2020-09-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pneumonia (n/a - Recovered/Resolved - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006734640&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006726800,Spontaneous,2020-09-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Depression (n/a - Not Recovered/Not Resolved - ),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006726800&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006715818,Spontaneous,2020-09-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Hyperhidrosis (9d - Recovered/Resolved - ),VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 140mg - Subcutaneous]),"VENCLYXTO 100 MG FILM COATED TABLETS [VENETOCLAX] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[D,L-LYSINE ACETYLSALICYLATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LACTULOSE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MIANSERIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006715818&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006702406,Spontaneous,2020-09-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal distension (1a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Anosmia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Diarrhoea (1a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (1a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Feeding disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (1a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Prosopagnosia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Weight decreased (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006702406&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006692846,Spontaneous,2020-09-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Stomatitis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006692846&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006684370,Spontaneous,2020-09-15 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Anaemia (n/a - Unknown - ),"VIDAZA [AZACITIDINE] (S - Angioimmunoblastic T-cell lymphoma - Unknown - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Off label use - Unknown - [n/a - n/a - n/a])","CYTARABINE [CYTARABINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CALCIUM FOLINATE, CALCIUM LEVOFOLINATE, CALCIUM LEVOFOLINATE PENTAHYDRATE, FOLINIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CARBOPLATIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CYCLOPHOSPHAMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PREDNISONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006684370&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006684864,Spontaneous,2020-09-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Neutropenia (n/a - Unknown - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Ileal ulcer - Drug withdrawn - [n/a - 100mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Off label use - Drug withdrawn - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006684864&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006686550,Spontaneous,2020-09-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Results in Death),<BR><BR>Pancytopenia (n/a - Fatal - Results in Death),<BR><BR>Septic shock (n/a - Fatal - Results in Death)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - 400mg - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006686550&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006689271,Spontaneous,2020-09-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Aplasia (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Febrile neutropenia (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pancytopenia (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Thrombocytopenia (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - 400mg - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006689271&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006678854,Spontaneous,2020-09-14 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Anaemia (2d - Recovered/Resolved - ),<BR><BR>C-reactive protein increased (6d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - n/a - Drug withdrawn - [n/a - n/a - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","GRANISETRON [GRANISETRON] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALIZAPRIDE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [13d - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - n/a - n/a - [13d - n/a - Unknown]),<BR><BR>[CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, COLECALCIFEROL CONCENTRATE (OILY FORM)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIMETINDENE MALEATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROMORPHONE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LINEZOLID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LORAZEPAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE, MAGNESIUM OXIDE, HEAVY] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[METAMIZOLE SODIUM, METAMIZOLE SODIUM MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOCLOPRAMIDE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MORPHINE SULFATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PETHIDINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PIPERACILLIN SODIUM, TAZOBACTAM SODIUM, PIPERACILLIN, TAZOBACTAM] (C - Product used for unknown indication - n/a - [8d - n/a - Unknown]),<BR><BR>[PIPERACILLIN SODIUM, TAZOBACTAM SODIUM, PIPERACILLIN, TAZOBACTAM] (C - n/a - n/a - [8d - n/a - Unknown]),<BR><BR>[PLATELET CONCENTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PLATELET CONCENTRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Intravenous drip]),<BR><BR>[POTASSIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM HYDROGEN CARBONATE, CITRIC ACID ANHYDROUS, POTASSIUM CITRATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM CITRATE, CITRIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM HYDROGEN CARBONATE, CITRIC ACID ANHYDROUS, POTASSIUM CITRATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM CITRATE, CITRIC ACID] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM, POTASSIUM CHLORIDE, POTASSIUM GLYCEROPHOSPHATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM HYDROGEN TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Intravenous drip]),<BR><BR>[PREDNISOLONE SODIUM SUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RANITIDINE, RANITIDINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RANITIDINE, RANITIDINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[RED BLOOD CELLS] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RED BLOOD CELLS] (C - n/a - n/a - [n/a - n/a - Unknown])...","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006678854&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006669513,Spontaneous,2020-09-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute myeloid leukaemia (n/a - Fatal - Results in Death),<BR><BR>Drug ineffective (n/a - Fatal - Results in Death)","MYLOTARG [GEMTUZUMAB OZOGAMICIN] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006669513&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006656670,Spontaneous,2020-09-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Neutropenia (n/a - Fatal - Results in Death),<BR><BR>Sepsis (n/a - Fatal - Results in Death)","VIDAZA [AZACITIDINE] (S - Ileal ulcer - Unknown - [n/a - 100mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Off label use - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006656670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006650980,Spontaneous,2020-09-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 137mg - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - 137mg - Intravenous drip])","FEBUXOSTAT [FEBUXOSTAT] (C - Hyperuricaemia - n/a - [n/a - 20mg - Unknown]),<BR><BR>[BEZAFIBRATE] (C - Dyslipidaemia - n/a - [n/a - 200mg - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - Constipation - n/a - [n/a - 990mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006650980&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006651300,Spontaneous,2020-09-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Cytopenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Delirium (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Drug withdrawn - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006651300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006643472,Spontaneous,2020-09-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Ventricular tachycardia (n/a - Unknown - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006643472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006643534,Spontaneous,2020-09-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Atrial fibrillation (n/a - Unknown - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 75mg/m2 - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - 75mg/m2 - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006643534&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006643571,Spontaneous,2020-09-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pneumonia (n/a - Recovered/Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006643571&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006643605,Spontaneous,2020-09-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Acute febrile neutrophilic dermatosis (n/a - Unknown - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006643605&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006643624,Spontaneous,2020-09-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Immune system disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006643624&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006643752,Spontaneous,2020-09-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Haemoglobin abnormal (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Intravenous drip]),VENETOCLAX [VENETOCLAX] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Unknown]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006643752&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006633797,Spontaneous,2020-09-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Cytopenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Delirium (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006633797&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006621551,Spontaneous,2020-09-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,White blood cell count decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),"TACROLIMUS [TACROLIMUS, TACROLIMUS MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VFEND [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006621551&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006622485,Spontaneous,2020-09-03 00:00:00,Healthcare Professional,Non European Economic Area,Sawamura D. A Case of Myelodysplastic Syndrome with Acute Fibrinous and Organizing Pneumonia. The 59th Meeting of the Chugoku Shikoku Regional Meeting of the Japan Society of Hematology. 2020 JUN 27;.,More than 85 Years,Not Specified,No,Female,Organising pneumonia (n/a - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006622485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006624079,Spontaneous,2020-09-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Cellulitis (21d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Haematoma (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Immunodeficiency (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Injection site reaction (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose not changed - [n/a - n/a - Intravenous drip])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ATORVASTATIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BISACODYL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METRONIDAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006624079&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006617361,Spontaneous,2020-09-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Haematoma muscle (n/a - Unknown - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 100mg - Subcutaneous]),"CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006617361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006618193,Spontaneous,2020-09-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Immunodeficiency (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006618193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006618312,Spontaneous,2020-09-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Altered state of consciousness (n/a - Unknown - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006618312&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006608341,Spontaneous,2020-09-01 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Thrombocytosis (n/a - Recovered/Resolved - Other Medically Important Condition),"NIVESTIM [FILGRASTIM] (S - Neutropenia - Not applicable - [n/a - n/a - Subcutaneous]),<BR><BR>VENCLYXTO [VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 400mg - Oral]),<BR><BR>VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 840mg - Subcutaneous]),<BR><BR>[AMIKACIN] (S - Febrile neutropenia - Not applicable - [n/a - n/a - Intravenous (not otherwise specified)]),<BR><BR>[PIPERACILLIN, PIPERACILLIN, TAZOBACTAM] (S - Febrile neutropenia - Drug withdrawn - [n/a - n/a - Intravenous (not otherwise specified)]),<BR><BR>[VALACICLOVIR HYDROCHLORIDE] (S - Antiviral prophylaxis - Dose not changed - [n/a - 1{DF} - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006608341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006612334,Spontaneous,2020-09-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cytopenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","CYTARABINE [CYTARABINE] (S - Myelodysplastic syndrome - Unknown - [n/a - .015g - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Subcutaneous]),<BR><BR>[IDARUBICIN HYDROCHLORIDE] (S - Myelodysplastic syndrome - Unknown - [n/a - 10mg - Intravenous drip]),<BR><BR>[IDARUBICIN HYDROCHLORIDE] (S - n/a - Unknown - [n/a - 10mg - Intravenous drip])","[SODIUM CHLORIDE] (C - Myelodysplastic syndrome - n/a - [n/a - 40mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 1mL - Subcutaneous]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 40mL - Intravenous drip]),<BR><BR>[STERILE WATER] (C - Product used for unknown indication - n/a - [n/a - 4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006612334&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006604484,Spontaneous,2020-08-31 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Haemoptysis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lung neoplasm malignant (n/a - Unknown - Other Medically Important Condition),<BR><BR>Platelet disorder (n/a - Unknown - Other Medically Important Condition)","VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006604484&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006605383,Spontaneous,2020-08-31 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Diarrhoea (1d - Recovered/Resolved - ),"REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","GRANISETRON [GRANISETRON] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AZITHROMYCIN, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN HYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BISACODYL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BUDESONIDE, BUDESONIDE, MICRONISED] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, COLECALCIFEROL CONCENTRATE (OILY FORM)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOBETASOL PROPIONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[COLECALCIFEROL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIMENHYDRINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE, MAGNESIUM OXIDE, HEAVY] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOCLOPRAMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RAMIPRIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RANITIDINE, RANITIDINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006605383&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006607973,Spontaneous,2020-08-31 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Myelofibrosis (n/a - Unknown - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Unknown - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Intravenous drip])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006607973&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006594027,Spontaneous,2020-08-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Interstitial lung disease (1mo - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 80mg - Subcutaneous]),"ELIQUIS 5 MG FILM-COATED TABLETS [APIXABAN] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[DIGOXIN] (C - n/a - n/a - [n/a - .25mg - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 500mg - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - 1g - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - 15mg - n/a]),<BR><BR>[VALSARTAN] (C - n/a - n/a - [n/a - 80mg - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006594027&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006594271,Spontaneous,2020-08-28 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Injection site reaction (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006594271&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006589179,Spontaneous,2020-08-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute myeloid leukaemia recurrent (n/a - Unknown - ),<BR><BR>Treatment failure (n/a - Unknown - )","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Unknown]),<BR><BR>[ENASIDENIB] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006589179&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006591092,Spontaneous,2020-08-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Recovered/Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006591092&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006593659,Spontaneous,2020-08-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dysuria (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urinary retention (n/a - Recovering/Resolving - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006593659&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006579301,Spontaneous,2020-08-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Generalised oedema (n/a - Not Recovered/Not Resolved - ),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006579301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006583476,Spontaneous,2020-08-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Results in Death),<BR><BR>Cardiac arrest (n/a - Fatal - Results in Death)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006583476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006583481,Spontaneous,2020-08-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Renal impairment (n/a - Recovering/Resolving - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Drug withdrawn - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006583481&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006551992,Spontaneous,2020-08-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,T-cell lymphoma recurrent (n/a - Unknown - ),"VIDAZA [AZACITIDINE] (S - Angioimmunoblastic T-cell lymphoma - Unknown - [n/a - n/a - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - Off label use - Unknown - [n/a - n/a - n/a]),<BR><BR>[ROMIDEPSIN] (S - Angioimmunoblastic T-cell lymphoma - Unknown - [n/a - 14mg/m2 - Unknown]),<BR><BR>[ROMIDEPSIN] (S - Off label use - Unknown - [n/a - n/a - n/a])","[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006551992&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006542363,Spontaneous,2020-08-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Cellulitis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 135mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006542363&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006542366,Spontaneous,2020-08-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Febrile neutropenia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Influenza A virus test positive (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006542366&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006543471,Spontaneous,2020-08-19 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Alanine aminotransferase increased (10d - Recovered/Resolved - ),<BR><BR>Alanine aminotransferase increased (21d - Recovered/Resolved - ),<BR><BR>Aspartate aminotransferase increased (10d - Recovered/Resolved - ),<BR><BR>Aspartate aminotransferase increased (3d - Recovered/Resolved - ),<BR><BR>Gamma-glutamyltransferase increased (125d - Recovered/Resolved - ),<BR><BR>Injection site reaction (178d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (7d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (24d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>White blood cell count decreased (24d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (28d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (30d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (n/a - Not Recovered/Not Resolved - )","LENALIDOMIDE [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","ADENURIC [FEBUXOSTAT] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>EXJADE [DEFERASIROX] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CEFPODOXIME, CEFPODOXIME PROXETIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, COLECALCIFEROL CONCENTRATE (OILY FORM)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FLUVASTATIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RAMIPRIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RANITIDINE, RANITIDINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006543471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006547806,Spontaneous,2020-08-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Anaemia (n/a - Unknown - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 130mg - Intravenous drip]),"GLASDEGIB [GLASDEGIB] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Oral]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOSTRIDIUM BUTYRICUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIMENHYDRINATE, DIMENHYDRINATE BP] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ESOMEPRAZOLE MAGNESIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANISETRON HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROXYANTHRACENE GLYCOSIDES, SENNOSIDES] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAVASTATIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM POLYSTYRENE SULPHONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006547806&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006531377,Spontaneous,2020-08-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blast cells present (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemoglobin abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neutrophil count abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Platelet count abnormal (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Oral]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006531377&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006537639,Spontaneous,2020-08-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Skin reaction (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [1d - 156mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose not changed - [1d - n/a - Intravenous drip])","ENTRESTO [VALSARTAN, SACUBITRIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>HUMALOG [INSULIN LISPRO] (C - Product used for unknown indication - n/a - [n/a - n/a - Subcutaneous]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - 40mg - Oral]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - 100mg - Oral]),<BR><BR>[AMLODIPINE BESILATE] (C - Product used for unknown indication - n/a - [n/a - 10mg - Oral]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Product used for unknown indication - n/a - [n/a - 25mg - Oral]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - 5mg - Oral]),<BR><BR>[INSULIN GLARGINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Subcutaneous]),<BR><BR>[SIMVASTATIN] (C - Product used for unknown indication - n/a - [n/a - 40mg - Oral]),<BR><BR>[THIAMINE HYDROCHLORIDE, CYANOCOBALAMIN, LIVER EXTRACT, PYRIDOXINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 100mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006537639&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006537768,Spontaneous,2020-08-18 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Acute myeloid leukaemia refractory (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blood count abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bone marrow disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemoglobin abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neutrophil count abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Platelet count abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>White blood cell disorder (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006537768&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006531125,Spontaneous,2020-08-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Bone marrow failure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 100mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - 100mg - Subcutaneous]),<BR><BR>[CYTARABINE HYDROCHLORIDE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - .015g - Subcutaneous]),<BR><BR>[CYTARABINE HYDROCHLORIDE] (S - n/a - Drug withdrawn - [n/a - .015g - Subcutaneous]),<BR><BR>[OMACETAXINE MEPESUCCINATE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 1mg - Intravenous drip]),<BR><BR>[OMACETAXINE MEPESUCCINATE] (S - n/a - Drug withdrawn - [n/a - 2mg - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 1mL - Subcutaneous]),<BR><BR>[SODIUM CHLORIDE] (S - n/a - Drug withdrawn - [n/a - 1mL - Subcutaneous])","[GLUCOSE, GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS] (C - Myelodysplastic syndrome - n/a - [n/a - 500mL - Intravenous drip]),<BR><BR>[GLUCOSE, GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS] (C - n/a - n/a - [n/a - 500mL - Intravenous drip]),<BR><BR>[STERILE WATER] (C - Myelodysplastic syndrome - n/a - [n/a - 4mL - Subcutaneous]),<BR><BR>[STERILE WATER] (C - n/a - n/a - [n/a - 4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006531125&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006515635,Spontaneous,2020-08-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Interstitial lung disease (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 120mg - Subcutaneous]),"[ASCORBIC ACID] (C - Vitamin supplementation - Unknown - [n/a - n/a - Oral]),<BR><BR>[CYANOCOBALAMIN] (C - Vitamin supplementation - Unknown - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006515635&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006522265,Spontaneous,2020-08-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Interstitial lung disease (n/a - Recovering/Resolving - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006522265&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006512770,Spontaneous,2020-08-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute myeloid leukaemia recurrent (n/a - Unknown - Other Medically Important Condition),<BR><BR>Therapy partial responder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Transformation to acute myeloid leukaemia (n/a - Unknown - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - n/a - Intravenous drip])","ARANESP [DARBEPOETIN ALFA] (C - Cytopenia - n/a - [n/a - n/a - Unknown]),<BR><BR>DARBEPOETIN ALFA [DARBEPOETIN ALFA] (C - Cytopenia - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LENOGRASTIM] (C - Cytopenia - n/a - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[OMEPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006512770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006497736,Spontaneous,2020-08-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Acute myeloid leukaemia recurrent (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),"[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - 200mg - Unknown]),<BR><BR>[HYDROXYCARBAMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006497736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006502409,Spontaneous,2020-08-12 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Febrile bone marrow aplasia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Infection (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - 124mg - Subcutaneous]),"[ALFUZOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DIPOTASSIUM CLORAZEPATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PIRIBEDIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PYGEUM AFRICANUM, PYGEUM AFRICANUM EXTRACT] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006502409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006503943,Spontaneous,2020-08-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Neutropenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 74mg - Subcutaneous]),"[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAVASTATIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006503943&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006503953,Spontaneous,2020-08-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (9d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (9d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (9d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","VENCLYXTO 100 MG FILM COATED TABLETS [VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 400mg - Oral]),<BR><BR>VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 140mg - Subcutaneous])","[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CEFTRIAXONE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METRONIDAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006503953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006505864,Spontaneous,2020-08-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pericarditis (n/a - Unknown - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 50mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Thrombocytopenia - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006505864&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006506193,Spontaneous,2020-08-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Application site discolouration (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Application site erythema (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Application site irritation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Application site reaction (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Injection site cellulitis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Injection site erythema (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Medication error (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 120mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006506193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006491634,Spontaneous,2020-08-11 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Infection (6d - Recovered/Resolved - ),<BR><BR>Injection site reaction (82d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (169d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Weight increased (19d - Recovered/Resolved - )","LENALIDOMIDE [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","HUMALOG [INSULIN LISPRO] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>JARDIANCE [EMPAGLIFLOZIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>LEVEMIR [INSULIN DETEMIR] (C - Product used for unknown indication - n/a - [804d - n/a - Unknown]),<BR><BR>LEVEMIR [INSULIN DETEMIR] (C - n/a - n/a - [804d - n/a - Unknown]),<BR><BR>[CYANOCOBALAMIN, VITAMIN B12] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - Product used for unknown indication - n/a - [713d - n/a - Unknown]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - n/a - n/a - [713d - n/a - Unknown]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[NEBIVOLOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[NEBIVOLOL] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM HYDROGEN CARBONATE, CITRIC ACID ANHYDROUS, POTASSIUM CITRATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM CITRATE, CITRIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TORASEMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006491634&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006487102,Spontaneous,2020-08-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute myeloid leukaemia recurrent (n/a - Unknown - ),<BR><BR>Thrombocytosis (46d - Recovered/Resolved - )","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose reduced - [n/a - 100mg - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose reduced - [n/a - 50mg - Intravenous drip])",[HYDROXYCARBAMIDE] (C - Cytoreductive surgery - n/a - [n/a - n/a - Oral]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006487102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006487730,Spontaneous,2020-08-10 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Anaemia (58d - Recovered/Resolved - ),<BR><BR>Eosinophilia (7d - Recovered/Resolved - ),<BR><BR>Infection (n/a - Recovering/Resolving - ),<BR><BR>Neutrophil count decreased (14d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (17d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (56d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (6d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (20d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (6d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (14d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (18d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (24d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (4d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (6d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (76d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 2.5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>PROTOPIC [TACROLIMUS, TACROLIMUS MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIMENHYDRINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE, METHYLPREDNISOLONE ACETATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOCLOPRAMIDE, METOCLOPRAMIDE DIHYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE, METOCLOPRAMIDE HYDROCHLORIDE PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006487730&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006489119,Spontaneous,2020-08-10 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Acute graft versus host disease in liver (56d - Recovered/Resolved - ),<BR><BR>Chronic graft versus host disease (n/a - Not Recovered/Not Resolved - )","LENALIDOMIDE [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - n/a - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","FILGRASTIM [FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AZITHROMYCIN, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN HYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CANDESARTAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ETHANOL, KALIUM BICHROMICUM DIL. D4, CARBO VEGETABILIS DIL. D8, CALCIUM SULFURICUM D4 DIL., CINNABARIS D8 DIL., SILICEA D8 DIL., THUJA OCCIDENTALIS DIL. D8, HYDRASTIS CANADENSIS DIL. D4] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GABAPENTIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL SUCCINATE, METOPROLOL SUCCINATE (PH. EUR.)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006489119&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006476970,Spontaneous,2020-08-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Acute myeloid leukaemia (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Blood creatinine increased (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Renal atrophy (n/a - Unknown - Results in Death, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006476970&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006478778,Spontaneous,2020-08-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chronic lymphocytic leukaemia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemoglobin decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Spinal cord disorder (n/a - Unknown - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 170mg - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Not applicable - [n/a - 170mg - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006478778&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006472002,Spontaneous,2020-08-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Breast mass (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Constipation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cyanosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Deformity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Leukopenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasal congestion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oedema peripheral (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Refractory anaemia with an excess of blasts - Unknown - [n/a - 75mg/m2 - Intravenous (not otherwise specified)]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [4y - 75mg/m2 - Intravenous (not otherwise specified)]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [4y - n/a - Intravenous (not otherwise specified)]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Refractory anaemia with an excess of blasts - Unknown - [n/a - 400mg - Oral]),<BR><BR>[VENETOCLAX] (S - n/a - Unknown - [n/a - 100mg - Oral]),<BR><BR>[VENETOCLAX] (S - n/a - Unknown - [n/a - 2{DF} - Oral]),<BR><BR>[VENETOCLAX] (S - n/a - Unknown - [n/a - 4{DF} - Oral])","IRON [IRON] (C - Product used for unknown indication - n/a - [n/a - 325mg - Oral]),<BR><BR>JANUVIA [SITAGLIPTIN, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - 50mg - Oral]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - 100mg - Oral]),<BR><BR>[ALOE VERA] (C - Product used for unknown indication - n/a - [n/a - 470mg - Oral]),<BR><BR>[AMLODIPINE BESILATE] (C - Product used for unknown indication - n/a - [n/a - 5mg - Oral]),<BR><BR>[CHROMIUM PICOLINATE] (C - Product used for unknown indication - n/a - [n/a - 200ug - Oral]),<BR><BR>[CINNAMON BARK] (C - Product used for unknown indication - n/a - [n/a - 500mg - Oral]),<BR><BR>[CYANOCOBALAMIN] (C - Product used for unknown indication - n/a - [n/a - 500ug - Oral]),<BR><BR>[FERUMOXYTOL] (C - Product used for unknown indication - n/a - [n/a - 510mg - Intravenous (not otherwise specified)]),<BR><BR>[FOLATE SODIUM] (C - Product used for unknown indication - n/a - [n/a - 1mg - Oral]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Product used for unknown indication - n/a - [n/a - 20mg - Oral]),<BR><BR>[GLIMEPIRIDE] (C - Product used for unknown indication - n/a - [n/a - 4mg - Oral]),<BR><BR>[IRON, IRON SUCROSE] (C - Product used for unknown indication - n/a - [n/a - 200mg - Intravenous (not otherwise specified)]),<BR><BR>[IRON, IRON SUCROSE] (C - n/a - n/a - [n/a - 200mg - Intravenous (not otherwise specified)]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [n/a - 75ug - Oral]),<BR><BR>[LOSARTAN POTASSIUM] (C - Product used for unknown indication - n/a - [n/a - 50mg - Oral]),<BR><BR>[LYSINE] (C - Product used for unknown indication - n/a - [n/a - 500mg - Oral]),<BR><BR>[METFORMIN, SAXAGLIPTIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - 25mg - Oral]),<BR><BR>[POTASSIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 20meq - Oral]),<BR><BR>[PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE] (C - Product used for unknown indication - n/a - [n/a - 10mg - Oral]),<BR><BR>[SILYBUM MARIANUM, SILYBUM MARIANUM EXTRACT] (C - Product used for unknown indication - n/a - [n/a - 500mg - Oral]),<BR><BR>[THIOCTIC ACID] (C - Product used for unknown indication - n/a - [n/a - 100mg - Oral]),<BR><BR>[UBIDECARENONE] (C - Product used for unknown indication - n/a - [n/a - 10mg - Oral]),<BR><BR>[UBIDECARENONE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006472002&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006472344,Spontaneous,2020-08-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Child,No,Female,Remission not achieved (n/a - Unknown - Other Medically Important Condition),"MYLOTARG [GEMTUZUMAB OZOGAMICIN] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),<BR><BR>[FLUDARABINE PHOSPHATE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006472344&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006456106,Spontaneous,2020-08-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Multiple organ dysfunction syndrome (4d - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Pancytopenia (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (7d - Fatal - Results in Death, Caused/Prolonged Hospitalisation)","REVLIMID [LENALIDOMIDE] (S - 5q minus syndrome - Not applicable - [n/a - 10mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Not applicable - [n/a - 110mg - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006456106&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006444508,Spontaneous,2020-08-03 00:00:00,Healthcare Professional,Non European Economic Area,"Mansfield AS, Jatoi A.. Asphyxiation with a Fentanyl Patch. Case Reports in Oncology. 2013;6:242–244",18-64 Years,Adult,No,Male,"Asphyxia (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Communication disorder (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Decreased eye contact (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Depressed level of consciousness (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Depressed mood (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Feeling of despair (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypotension (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Incorrect route of product administration (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Intentional product misuse (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Medication error (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Mental impairment (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Mental status changes (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Overdose (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Product use in unapproved indication (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Renal failure (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Subdural haematoma (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Thrombocytopenia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tonic convulsion (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","AZACITIDINE [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>FENTANYL - TRANSDERMAL SYSTEM  (S - Pain - Unknown - [n/a - 100ug - Transdermal]),<BR><BR>FENTANYL [FENTANYL, FENTANYL CITRATE] (S - Pain - Not applicable - [n/a - 100ug - Transdermal]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Unknown - [n/a - n/a - n/a])","HYDROXYCARBAMIDE [HYDROXYCARBAMIDE] (C - Chronic myelomonocytic leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>HYDROXYCARBAMIDE [HYDROXYCARBAMIDE] (C - Dyspnoea - Not applicable - [n/a - n/a - Unknown]),<BR><BR>HYDROXYCARBAMIDE [HYDROXYCARBAMIDE] (C - Pruritus - Not applicable - [n/a - n/a - Unknown]),<BR><BR>NALOXONE [NALOXONE, NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Intravenous drip])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006444508&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006435078,Spontaneous,2020-07-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Neutropenia (n/a - Recovering/Resolving - Other Medically Important Condition),VIDAZA 25 MG/ML POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 130mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006435078&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006438346,Spontaneous,2020-07-31 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Gastrointestinal haemorrhage (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 75mg/m2 - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006438346&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006440384,Spontaneous,2020-07-31 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Drug resistance (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006440384&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006429483,Spontaneous,2020-07-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Clostridium difficile infection (16d - Recovered/Resolved - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Clostridium difficile infection (2d - Recovered/Resolved - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Concussion (n/a - Unknown - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Fall (0d - Recovered/Resolved - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Gastrointestinal haemorrhage (14d - Recovered/Resolved - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Gastrointestinal haemorrhage (2d - Recovered/Resolved - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Haematoma infection (4d - Recovered/Resolved - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (1d - Recovered/Resolved - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (10d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Sepsis (n/a - Recovering/Resolving - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Soft tissue infection (4d - Recovered/Resolved - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Staphylococcal infection (4d - Recovered/Resolved - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - 75mg/m2 - Intravenous drip]),<BR><BR>[EPINEPHRINE, LIDOCAINE HYDROCHLORIDE] (S - Procedural pain - Unknown - [n/a - n/a - Subcutaneous]),<BR><BR>[MONOCLONAL ANTIBODIES, GRANULOCYTE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 40mg - Intravenous drip]),<BR><BR>[MONOCLONAL ANTIBODIES, GRANULOCYTE] (S - n/a - Drug withdrawn - [n/a - 40mg - Intravenous drip]),<BR><BR>[POTASSIUM CHLORIDE] (S - Hypokalaemia - Unknown - [n/a - 40meq - Intravenous drip]),<BR><BR>[POTASSIUM CHLORIDE] (S - n/a - Unknown - [n/a - 20meq - Intravenous drip]),<BR><BR>[POTASSIUM CHLORIDE] (S - n/a - Unknown - [n/a - 40meq - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (S - Dehydration - Unknown - [21d - 1000mg - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (S - Hypotension - Unknown - [21d - 1000mL - Intravenous drip])","DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - Premedication - n/a - [n/a - 10mg - Intravenous drip]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - Premedication - n/a - [n/a - 16mg - Intravenous drip]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - n/a - n/a - [n/a - 4mg - Intravenous drip]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - n/a - n/a - [n/a - 8mg - Intravenous drip]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Infection prophylaxis - n/a - [n/a - 500mg - Oral]),<BR><BR>MYCAMINE [MICAFUNGIN, MICAFUNGIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - 100mg - Intravenous drip]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - Infection prophylaxis - n/a - [n/a - 300mg - Oral]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - n/a - n/a - [n/a - n/a - Oral]),<BR><BR>PALONOSETRON [PALONOSETRON] (C - Premedication - n/a - [n/a - .25mg - Intravenous drip]),<BR><BR>[ACICLOVIR, ACICLOVIR BP] (C - Infection prophylaxis - n/a - [n/a - 400mg - Oral]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Hyperlipidaemia - n/a - [n/a - 40mg - Oral]),<BR><BR>[ATROPINE SULFATE PH. EUR., DIPHENOXYLATE HYDROCHLORIDE BP, ATROPINE SULFATE, DIPHENOXYLATE HYDROCHLORIDE] (C - Diarrhoea - n/a - [n/a - n/a - Oral]),<BR><BR>[ATROPINE SULFATE PH. EUR., DIPHENOXYLATE HYDROCHLORIDE BP, ATROPINE SULFATE, DIPHENOXYLATE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral]),<BR><BR>[DIPHENHYDRAMINE] (C - Premedication - n/a - [n/a - 50mg - Intravenous drip]),<BR><BR>[ESCITALOPRAM OXALATE] (C - Product used for unknown indication - n/a - [n/a - 10mg - Oral]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - Depression - n/a - [n/a - 10mg - Oral]),<BR><BR>[FERROUS SULFATE] (C - Anaemia - n/a - [50d - 325mg - Oral]),<BR><BR>[FERROUS SULFATE] (C - n/a - n/a - [50d - 325mg - Oral]),<BR><BR>[GENTAMICIN] (C - Ear haemorrhage - n/a - [n/a - .3% - Oral]),<BR><BR>[HUMAN PLATELET, ALLOGENIC] (C - Thrombocytopenia - n/a - [n/a - 1[iU] - Intravenous drip]),<BR><BR>[HUMAN PLATELET, ALLOGENIC] (C - n/a - n/a - [n/a - 1[iU] - Intravenous drip]),<BR><BR>[LACTOBACILLUS] (C - Asthenia - n/a - [n/a - n/a - Oral]),<BR><BR>[LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE OXIDE] (C - Diarrhoea - n/a - [n/a - 2mg - Oral]),<BR><BR>[LORAZEPAM] (C - Premedication - n/a - [n/a - 1mg - Subcutaneous]),<BR><BR>[MEGESTROL ACETATE] (C - Decreased appetite - n/a - [n/a - 40mg - Oral]),<BR><BR>[MIRTAZAPINE] (C - Colitis ulcerative - n/a - [n/a - 15mg - Oral]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM] (C - Colitis ulcerative - n/a - [n/a - 40mg - Oral]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 8mg - Oral]),<BR><BR>[PARACETAMOL] (C - Premedication - n/a - [n/a - 650mg - Oral]),<BR><BR>[PIPERACILLIN, TAZOBACTAM] (C - Product used for unknown indication - n/a - [n/a - 3.375mg - Intravenous drip]),<BR><BR>[PREDNISONE] (C - Colitis ulcerative - n/a - [n/a - 10mg - Oral]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - 10mg - Oral]),<BR><BR>[PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 10mg - Oral]),<BR><BR>[PROCHLORPERAZINE] (C - Nausea - n/a - [n/a - 10mg - Oral]),<BR><BR>[PROCHLORPERAZINE] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - 50mg - Oral]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 50mg - Oral]),<BR><BR>[SODIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 3mL - Respiratory (inhalation)]),<BR><BR>[WHOLE BLOOD] (C - Anaemia - n/a - [n/a - 1[iU] - Intravenous drip]),<BR><BR>[WHOLE BLOOD] (C - n/a - n/a - [n/a - 1[iU] - Intravenous drip])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006429483&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006429702,Spontaneous,2020-07-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Blast cell count increased (n/a - Unknown - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006429702&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006430340,Spontaneous,2020-07-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pruritus (10d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Rash (10d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","LENALIDOMIDE [LENALIDOMIDE] (S - Blood disorder - Dose reduced - [n/a - 25mL - Oral]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - n/a - Dose reduced - [n/a - 12.5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Blood disorder - Dose reduced - [n/a - 100mg - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose reduced - [n/a - 50mg - Intravenous drip])","[SODIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 100mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 100mL - Intravenous drip])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006430340&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006430805,Spontaneous,2020-07-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Enterococcal sepsis (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Hepatic failure (79d - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Multiple organ dysfunction syndrome (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),"PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastrooesophageal reflux disease - n/a - [n/a - 200mg - Unknown]),<BR><BR>[CO-TRIMOXAZOLE, SULFAMETHOXAZOLE, TRIMETHOPRIM, TRIMETHOPRIM BP, SULFAMETHOXAZOLE BP] (C - Prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[PHENOXYMETHYLPENICILLIN] (C - Prophylaxis - n/a - [n/a - 500mg - Unknown]),<BR><BR>[PREDNISOLONE] (C - Graft versus host disease - n/a - [n/a - 4mg - Unknown]),<BR><BR>[PREDNISONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR] (C - Antiviral prophylaxis - n/a - [n/a - 500mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006430805&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006421852,Spontaneous,2020-07-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anaemia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Differentiation syndrome (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperleukocytosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombocytopenia (n/a - Recovered/Resolved - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),<BR><BR>[ENASIDENIB] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 100mg - Oral]),<BR><BR>[ENASIDENIB] (S - n/a - Drug withdrawn - [n/a - 100mg - Oral]),<BR><BR>[ENASIDENIB] (S - n/a - Drug withdrawn - [n/a - 50mg - Oral])","POSACONAZOLE [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ATORVASTATIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LANSOPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006421852&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006421885,Spontaneous,2020-07-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Enteritis infectious (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lumbar vertebral fracture (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Sleep apnoea syndrome (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Urinary retention (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Subcutaneous]),"FEBUXOSTAT [FEBUXOSTAT] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>GLASDEGIB [GLASDEGIB] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALFACALCIDOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE BESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AZULENE SODIUM SULFONATE] (C - Product used for unknown indication - n/a - [n/a - .033% - Unknown]),<BR><BR>[BETAMETHASONE VALERATE, GENTAMICIN SULFATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CALCIUM L-ASPARTATE HYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DOMPERIDONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANISETRON HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HEPARINOID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROXYANTHRACENE GLYCOSIDES, SENNOSIDES] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[NAFTOPIDIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM L-ASPARTATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SPIRONOLACTONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TADALAFIL] (C - Acute myeloid leukaemia - n/a - [n/a - 5mg - Oral]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TRAMADOL HYDROCHLORIDE, PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006421885&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006424812,Spontaneous,2020-07-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Bronchopulmonary aspergillosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Intra-abdominal haematoma (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Liver function test abnormal (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Pseudomonal sepsis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Thrombocytopenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","LEVOFLOXACIN [LEVOFLOXACIN] (S - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - n/a - [3d - 1{DF} - Unknown]),<BR><BR>XOSPATA [GILTERITINIB] (S - Acute myeloid leukaemia - Drug withdrawn - [19d - 3{DF} - Oral]),<BR><BR>[ENOXAPARIN, ENOXAPARIN SODIUM] (S - Product used for unknown indication - n/a - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006424812&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006414961,Spontaneous,2020-07-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Haemoglobin abnormal (n/a - Unknown - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Not applicable - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006414961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006417615,Spontaneous,2020-07-28 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,White blood cell count decreased (158d - Recovered/Resolved - ),"REVLIMID [LENALIDOMIDE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Drug withdrawn - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 2.5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Drug withdrawn - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown])","NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>TAMIFLU [OSELTAMIVIR, OSELTAMIVIR PHOSPHATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN TRIHYDRATE, POTASSIUM CLAVULANATE, AMOXICILLIN, CLAVULANIC ACID, AMOXICILLIN, POTASSIUM CLAVULANATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIHYDROCODEINE HYDRORHODANIDE, DIHYDROCODEINE THIOCYANATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM POLYSTYRENE SULPHONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006417615&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006410551,Spontaneous,2020-07-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Eructation (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Gastric pH decreased (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Musculoskeletal pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Skin cancer (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>White blood cell count increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","GILTERITINIB [GILTERITINIB] (S - Acute myeloid leukaemia - Unknown - [n/a - 120mg - Oral]),<BR><BR>GILTERITINIB [GILTERITINIB] (S - n/a - Unknown - [n/a - 120mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),<BR><BR>[ZOLPIDEM TARTRATE] (S - Insomnia - Unknown - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006410551&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006404431,Spontaneous,2020-07-25 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Blood creatinine increased (91d - Recovered/Resolved - ),<BR><BR>Granulocytes abnormal (21d - Recovered/Resolved - ),<BR><BR>Neutrophil count abnormal (n/a - Recovering/Resolving - ),<BR><BR>Neutrophil count decreased (21d - Recovered/Resolved - ),<BR><BR>Syncope (0d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Product used for unknown indication - Drug withdrawn - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - n/a - Drug withdrawn - [n/a - 2.5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - n/a - Drug withdrawn - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Unknown])","[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AZITHROMYCIN, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN HYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, COLECALCIFEROL CONCENTRATE (OILY FORM)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLESONIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FINASTERIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LACTULOSE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[NEBIVOLOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SIMVASTATIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALSARTAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006404431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006400383,Spontaneous,2020-07-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Leukaemia (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Nosocomial infection (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Respiratory failure (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Urinary tract infection (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 100mg - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006400383&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006389177,Spontaneous,2020-07-23 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Anaemia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Constipation (17d - Recovered/Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (0d - Recovered/Resolved - ),<BR><BR>Neutropenia (20d - Recovered/Resolved - ),<BR><BR>Neutropenia (6d - Recovered/Resolved - ),<BR><BR>Neutropenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin disorder (n/a - Not Recovered/Not Resolved - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, COLECALCIFEROL CONCENTRATE (OILY FORM)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLEMASTINE, CLEMASTINE FUMARATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLEMASTINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIMETINDENE MALEATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006389177&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006394439,Spontaneous,2020-07-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute myeloid leukaemia (n/a - Unknown - ),<BR><BR>Therapy non-responder (n/a - Unknown - )","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - 100mg - Unknown]),<BR><BR>[ENASIDENIB] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Unknown])","ANTHRACYCLINE [NULL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CYTARABINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [n/a - 150mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006394439&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006394915,Spontaneous,2020-07-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Agranulocytosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),VIDAZA 25 MG/ML POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - n/a - Unknown - [n/a - n/a - n/a]),CRESEMBA 100 MG HARD CAPSULES [ISAVUCONAZONIUM SULFATE] (C - n/a - Unknown - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006394915&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006386469,Spontaneous,2020-07-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac failure (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Haemorrhage (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Hypertension (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Myelodysplastic syndrome (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Pleural effusion (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary oedema (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary vascular disorder (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006386469&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006348102,Spontaneous,2020-07-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Oedema peripheral (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Weight fluctuation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 107mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006348102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006354244,Spontaneous,2020-07-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 32mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006354244&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006355774,Spontaneous,2020-07-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cardiac failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cardiotoxicity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition)","VENCLYXTO [VENETOCLAX] (S - Chloroma - Drug withdrawn - [n/a - 200mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Subcutaneous]),<BR><BR>[CYTARABINE] (S - Product used for unknown indication - Not applicable - [n/a - 3760mg - Intravenous drip]),<BR><BR>[CYTARABINE] (S - n/a - Not applicable - [8d - 30mg - Intravenous drip]),<BR><BR>[CYTARABINE] (S - n/a - Not applicable - [n/a - n/a - Intravenous drip]),<BR><BR>[FLUDARABINE] (S - Product used for unknown indication - Not applicable - [n/a - 57mg - Intravenous drip]),<BR><BR>[FLUDARABINE] (S - n/a - Not applicable - [n/a - 57mg - Intravenous drip]),<BR><BR>[IDARUBICIN] (S - Product used for unknown indication - Not applicable - [n/a - 15mg - Intravenous drip]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (I - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","AZACITIDINE [AZACITIDINE] (C - Transplant - n/a - [n/a - n/a - Unknown]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - Granulocyte count decreased - n/a - [n/a - n/a - Unknown]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Product used for unknown indication - n/a - [n/a - 15mg - Unknown]),<BR><BR>[CO-TRIMOXAZOLE, SULFAMETHOXAZOLE, TRIMETHOPRIM, TRIMETHOPRIM BP, SULFAMETHOXAZOLE BP] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - Diabetes mellitus - n/a - [n/a - 40[iU] - Unknown]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - Diabetes mellitus - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - Product used for unknown indication - n/a - [n/a - 30mg - Unknown]),<BR><BR>[NADROPARIN, NADROPARIN CALCIUM] (C - Product used for unknown indication - n/a - [n/a - .6mL - Unknown]),<BR><BR>[OXYCODONE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006355774&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006343985,Spontaneous,2020-07-15 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,Treatment failure (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006343985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006344754,Spontaneous,2020-07-15 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006344754&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006345444,Spontaneous,2020-07-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Haemoglobin decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pelvic pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006345444&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006346702,Spontaneous,2020-07-15 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Injection site inflammation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006346702&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006333108,Spontaneous,2020-07-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Leukaemia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 400mg - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006333108&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006333729,Spontaneous,2020-07-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Epistaxis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytopenia (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Unknown - [n/a - n/a - n/a]),"[ALLOPURINOL] (C - n/a - n/a - [n/a - 300mg - n/a]),<BR><BR>[BISOPROLOL FUMARATE] (C - n/a - n/a - [n/a - 1.25mg - Oral]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 15mg - Oral]),<BR><BR>[LEVOFLOXACIN, LEVOFLOXACIN HEMIHYDRATE] (C - n/a - n/a - [n/a - 500mg - Oral]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - .4mg - Oral]),<BR><BR>[TRANEXAMIC ACID] (C - n/a - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006333729&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006329785,Spontaneous,2020-07-13 00:00:00,Healthcare Professional,Non European Economic Area,Kakuwa T. Mucor Pulmonary embolism is a patient with Myelodysplastic syndrome. Respiratory Medicine case report. 2020;.,More than 85 Years,Not Specified,No,Male,"Disseminated intravascular coagulation (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Mucormycosis (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Multiple organ dysfunction syndrome (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Transformation to acute myeloid leukaemia (n/a - Unknown - Results in Death, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Unknown]),"[ETHAMBUTOL, ETHAMBUTOL HYDROCHLORIDE] (C - Pulmonary tuberculosis - n/a - [n/a - n/a - Unknown]),<BR><BR>[ISONIAZID] (C - Pulmonary tuberculosis - n/a - [n/a - n/a - Unknown]),<BR><BR>[OXYGEN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RIFAMPICIN] (C - Pulmonary tuberculosis - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006329785&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006332037,Spontaneous,2020-07-13 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Cerebral haemorrhage (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Intentional product use issue (n/a - Unknown - )","DUPIXENT [DUPILUMAB] (S - Dermatosis - Not applicable - [n/a - n/a - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [6d - n/a - Subcutaneous]),<BR><BR>[HYDROXYCARBAMIDE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006332037&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006308508,Spontaneous,2020-07-09 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pruritus (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Rash (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Acute myelomonocytic leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),<BR><BR>[IVOSIDENIB] (S - Acute myelomonocytic leukaemia - Drug withdrawn - [n/a - 250mg - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006308508&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006301302,Spontaneous,2020-07-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute kidney injury (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Gastric disorder (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Inflammation (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Rash macular (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006301302&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006302924,Spontaneous,2020-07-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Pyoderma gangrenosum (n/a - Unknown - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Intravenous (not otherwise specified)]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006302924&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006304114,Spontaneous,2020-07-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Bone marrow failure (n/a - Unknown - Caused/Prolonged Hospitalisation),"CYTARABINE [CYTARABINE] (S - Acute myeloid leukaemia - Unknown - [n/a - .05g - Intrathecal]),<BR><BR>METHOTREXATE [METHOTREXATE] (S - Acute myeloid leukaemia - Unknown - [n/a - 5mg - Intrathecal]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Intravenous drip]),<BR><BR>[CYTARABINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 3g - Intravenous drip]),<BR><BR>[CYTARABINE] (S - n/a - Unknown - [n/a - 3.5g - Intravenous drip])","DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - Chemotherapy - n/a - [n/a - 5mg - Intrathecal]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - n/a - n/a - [n/a - 500mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - Solvent sensitivity - n/a - [n/a - 3mL - Intrathecal]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 500mL - Intravenous drip]),<BR><BR>[STERILE WATER] (C - Solvent sensitivity - n/a - [n/a - 4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006304114&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006304392,Spontaneous,2020-07-08 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Anaemia (n/a - Recovering/Resolving - ),<BR><BR>Constipation (148d - Recovered/Resolved - ),<BR><BR>Fatigue (161d - Recovered/Resolved - ),<BR><BR>Haematoma (15d - Recovered/Resolved - ),<BR><BR>Injection site reaction (104d - Recovered/Resolved - ),<BR><BR>Nausea (190d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (110d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (51d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Product used for unknown indication - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Unknown])","FILGRASTIM [FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>GRANISETRON [GRANISETRON] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>GRANISETRON [GRANISETRON] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR.] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALIZAPRIDE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [13d - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - n/a - n/a - [13d - n/a - Unknown]),<BR><BR>[CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, COLECALCIFEROL CONCENTRATE (OILY FORM)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIMETINDENE MALEATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROMORPHONE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LINEZOLID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LORAZEPAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MACROGOL 3350, SODIUM CITRATE, SODIUM LAURYL SULFOACETATE, SODIUM CITRATE, SODIUM LAURYL SULFOACETATE, SORBITOL 70%, LIQUID (CRYSTALLISING), SODIUM CITRATE, SORBITOL (E420), SODIUM LAURYL SULFOACETATE, SODIUM CITRATE, SORBITOL SOLUTION 70% (CRYSTALLISING) (PH. EUR.), SODIUM LAURYL SULFOACETATE, SODIUM LAURYL SULFOACETATE, TRISODIUM CITRATE, SORBITOL 70%, LIQUID (CRYSTALLISING), SORBITOL (E420), SODIUM LAURYL SULFOACETATE, SORBITOL (E420), SODIUM LAURYL SULFOACETATE, SODIUM CITRATE DIHYDRATE, SORBITOL, LIQUID (CRYSTALLISING), SODIUM CITRATE, SODIUM LAURYL SULFOACETATE, SORBITOL, LIQUID (CRYSTALLISING), SODIUM CITRATE, SODIUM LAURYL SULFOACETATE 70%] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE, MAGNESIUM OXIDE, HEAVY] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[METAMIZOLE SODIUM, METAMIZOLE SODIUM MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOCLOPRAMIDE, METOCLOPRAMIDE DIHYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE, METOCLOPRAMIDE HYDROCHLORIDE PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MORPHINE SULFATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[NITRENDIPINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PETHIDINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PIPERACILLIN SODIUM, TAZOBACTAM SODIUM, PIPERACILLIN, TAZOBACTAM] (C - Product used for unknown indication - n/a - [8d - n/a - Unknown])...","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006304392&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006307004,Spontaneous,2020-07-08 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Neutrophil count decreased (35d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (45d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (n/a - Not Recovered/Not Resolved - )","REVLIMID [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose reduced - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose reduced - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose reduced - [n/a - n/a - Unknown])","CARBIDOPA, LEVODOPA [CARBIDOPA, LEVODOPA] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BROMAZEPAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN A] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOBETASOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[DEXAMETHASONE PHOSPHATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[HUMAN PLATELET, ALLOGENIC] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE, METHYLPREDNISOLONE ACETATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM, POTASSIUM CHLORIDE, POTASSIUM GLYCEROPHOSPHATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM HYDROGEN TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAMIPEXOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[QUETIAPINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RED BLOOD CELLS] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TORASEMIDE, TORASEMIDE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ZOPICLONE] (C - Product used for unknown indication - n/a - [10d - n/a - Unknown]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [10d - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006307004&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006307143,Spontaneous,2020-07-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood bilirubin increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Febrile neutropenia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Haemolytic anaemia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovered/Resolved - ),<BR><BR>Myelodysplastic syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pancytopenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pulseless electrical activity (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Sepsis (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Serum ferritin increased (n/a - Unknown - )","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Unknown]),<BR><BR>YESCARTA [AXICABTAGENE CILOLEUCEL] (S - Diffuse large B-cell lymphoma - Not applicable - [n/a - 68mL - Intravenous (not otherwise specified)])","APIXABAN [APIXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[HUMAN PLATELET, ALLOGENIC] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Glucose tolerance impaired - n/a - [n/a - n/a - n/a]),<BR><BR>[RED BLOOD CELLS] (C - n/a - n/a - [n/a - 1[iU] - n/a - More in ICSR])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006307143&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006307151,Spontaneous,2020-07-08 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Hypertension (6d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (111d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (149d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (34d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (5d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (7d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (8d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (20d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (30d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (6d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 2.5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","CICLOSPORIN [CICLOSPORIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>CICLOSPORIN [CICLOSPORIN] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPICILLIN SODIUM, SULBACTAM, AMPICILLIN SODIUM, SULBACTAM SODIUM, AMPICILLIN, SULBACTAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ATOVAQUONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN A] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN A] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [51d - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [51d - n/a - Unknown]),<BR><BR>[CODEINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM CITRATE, MAGNESIUM OXIDE, MAGNESIUM OXIDE, HEAVY, MAGNESIUM CITRATE DIBASIC PENTAHYDRATE, MAGNESIUM SULFATE HEPTAHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM CITRATE, MAGNESIUM OXIDE, MAGNESIUM OXIDE, HEAVY, MAGNESIUM CITRATE DIBASIC PENTAHYDRATE, MAGNESIUM SULFATE HEPTAHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOCLOPRAMIDE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[MOXONIDINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MOXONIDINE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[NATAMYCIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[PREDNISOLONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULTAMICILLIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALSARTAN, HYDROCHLOROTHIAZIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALSARTAN, HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006307151&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006296171,Spontaneous,2020-07-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Skin reaction (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006296171&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006297647,Spontaneous,2020-07-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Leukopenia (n/a - Recovering/Resolving - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 100mg - Intravenous drip]),<BR><BR>[OMACETAXINE MEPESUCCINATE] (S - Acute myeloid leukaemia - Unknown - [n/a - 2mg - Intravenous drip])","[GLUCOSE, GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS] (C - Premedication - n/a - [n/a - 250mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - Premedication - n/a - [n/a - 100mL - Intravenous drip]),<BR><BR>[WHOLE BLOOD] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006297647&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006286703,Spontaneous,2020-07-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anaemia (78d - Recovered/Resolved - ),<BR><BR>Diarrhoea (12d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (20d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (48d - Recovered/Resolved - ),<BR><BR>Vomiting (0d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Product used for unknown indication - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Unknown])","FILGRASTIM [FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AZITHROMYCIN, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN HYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CANDESARTAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GABAPENTIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL SUCCINATE, METOPROLOL SUCCINATE (PH. EUR.)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006286703&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006287502,Spontaneous,2020-07-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site bruising (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Laboratory test abnormal (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Red blood cell count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 400mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Dose not changed - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006287502&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006277107,Spontaneous,2020-07-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Oesophagitis ulcerative (n/a - Recovering/Resolving - Other Medically Important Condition),"JAKAVI [RUXOLITINIB, RUXOLITINIB PHOSPHATE] (S - Acute myeloid leukaemia - Unknown - [n/a - 30mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [32d - 191mg - Subcutaneous - More in ICSR]),<BR><BR>[LEVOFLOXACIN, LEVOFLOXACIN HEMIHYDRATE] (S - Product used for unknown indication - Unknown - [2d - 500mg - Oral]),<BR><BR>[PIPERACILLIN SODIUM, TAZOBACTAM SODIUM, PIPERACILLIN, TAZOBACTAM] (S - Product used for unknown indication - Unknown - [11d - 4.5g - Intravenous (not otherwise specified)])","[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - Product used for unknown indication - Unknown - [n/a - 40mg - Oral]),<BR><BR>[CLOPIDOGREL] (C - Product used for unknown indication - Unknown - [n/a - 75mg - Oral]),<BR><BR>[ENALAPRIL MALEATE, HYDROCHLOROTHIAZIDE] (C - Product used for unknown indication - Unknown - [n/a - 10mg - Oral]),<BR><BR>[FLUCONAZOLE] (C - Product used for unknown indication - Unknown - [n/a - 200mg - Oral]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - Unknown - [n/a - 800mg - Oral]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - Unknown - [n/a - 500mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006277107&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006279470,Spontaneous,2020-07-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Neutropenia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 100mg - Unknown]),"CYTARABINE [CYTARABINE] (C - Acute myeloid leukaemia - n/a - [n/a - 20mg - Intravenous drip]),<BR><BR>[OMACETAXINE MEPESUCCINATE] (C - Acute myeloid leukaemia - n/a - [n/a - 1mg - Intravenous drip])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006279470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006281728,Spontaneous,2020-07-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Constipation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemoglobin abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injection site pain (n/a - Unknown - Other Medically Important Condition)","VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),<BR><BR>[ALLOPURINOL] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),<BR><BR>[GRANISETRON HYDROCHLORIDE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006281728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006281842,Spontaneous,2020-07-03 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Anaemia (33d - Recovered/Resolved - ),"LENALIDOMIDE [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","FILGRASTIM [FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AZITHROMYCIN, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN HYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CANDESARTAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GABAPENTIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL SUCCINATE, METOPROLOL SUCCINATE (PH. EUR.)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006281842&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006283375,Spontaneous,2020-07-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Neutropenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pancytopenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 57mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Off label use - Dose not changed - [n/a - 57mg - Unknown])","[LOSARTAN POTASSIUM] (C - Product used for unknown indication - n/a - [n/a - 50mg - Unknown]),<BR><BR>[METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RETINOL ACETATE, THIAMINE HYDROCHLORIDE, ASCORBIC ACID, CALCIUM PANTOTHENATE, CYANOCOBALAMIN, DIAZEPAM, NICOTINAMIDE, PYRIDOXINE, RIBOFLAVIN, COBALTOUS SULFATE, COPPER SULFATE, FERROUS SULFATE, MAGNESIUM OXIDE, MANGANESE SULFATE, SODIUM FLUORIDE, ZINC SULPHATE, ALPHATOCOPHEROL ACETATE, CALCIUM PHOSPHATE, POTASSIUM SULPHATE, MOLYBDENUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006283375&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006268970,Spontaneous,2020-07-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Oesophagitis ulcerative (n/a - Recovering/Resolving - Other Medically Important Condition),"JAKAVI [RUXOLITINIB, RUXOLITINIB PHOSPHATE] (S - n/a - Not applicable - [n/a - 30mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [32d - 191mg - Subcutaneous]),<BR><BR>[LEVOFLOXACIN, LEVOFLOXACIN HEMIHYDRATE] (S - n/a - Not applicable - [2d - 500mg - Oral]),<BR><BR>[PIPERACILLIN, TAZOBACTAM] (S - n/a - Drug withdrawn - [11d - 13.5g - Intravenous (not otherwise specified)])","[ATORVASTATIN] (C - n/a - n/a - [n/a - 40mg - Oral]),<BR><BR>[CLOPIDOGREL] (C - n/a - n/a - [n/a - 75mg - Oral]),<BR><BR>[CYANOCOBALAMIN] (C - n/a - n/a - [n/a - 1000ug - Subcutaneous]),<BR><BR>[ENALAPRIL MALEATE, HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - 10mg - Oral]),<BR><BR>[FLUCONAZOLE] (C - n/a - n/a - [n/a - 200mg - Oral]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - 800mg - Oral]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - n/a - n/a - [n/a - 500mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006268970&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006270406,Spontaneous,2020-07-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Febrile neutropenia (13d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Febrile neutropenia (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Intravenous drip]),"GRANISETRON [GRANISETRON] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 3mg - Unknown]),<BR><BR>GRANISETRON [GRANISETRON] (C - n/a - n/a - [n/a - 3mg - Unknown]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Prophylaxis - n/a - [43d - 500mg - Unknown]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - n/a - n/a - [43d - 500mg - Unknown]),<BR><BR>[AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Febrile neutropenia - n/a - [n/a - 200mg - Unknown]),<BR><BR>[BENZETHONIUM CHLORIDE] (C - Infection prophylaxis - n/a - [n/a - 200mg - Unknown]),<BR><BR>[CARBAZOCHROME] (C - Haemorrhage prophylaxis - n/a - [n/a - 90mg - Unknown]),<BR><BR>[CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Pyrexia - n/a - [n/a - 600mg - Unknown]),<BR><BR>[FAMOTIDINE] (C - Prophylaxis against gastrointestinal ulcer - n/a - [n/a - 20mg - Unknown]),<BR><BR>[FLUCONAZOLE] (C - Infection prophylaxis - n/a - [56d - 200mg - Unknown]),<BR><BR>[FLUCONAZOLE] (C - n/a - n/a - [56d - 200mg - Unknown]),<BR><BR>[HEPARINOID] (C - Dry skin prophylaxis - n/a - [13d - n/a - Unknown]),<BR><BR>[HEPARINOID] (C - n/a - n/a - [13d - n/a - Unknown]),<BR><BR>[LOXOPROFEN SODIUM HYDRATE] (C - Back pain - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MEROPENEM, MEROPENEM ANHYDROUS] (C - Febrile neutropenia - n/a - [n/a - 2g - Unknown]),<BR><BR>[MEROPENEM, MEROPENEM ANHYDROUS] (C - n/a - n/a - [n/a - 2g - Unknown]),<BR><BR>[MEROPENEM, MEROPENEM ANHYDROUS] (C - n/a - n/a - [n/a - 3g - Unknown]),<BR><BR>[METHYL SALICYLATE] (C - Nausea - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOCLOPRAMIDE] (C - Nausea - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Febrile neutropenia - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM CHLORIDE, SODIUM CHLORIDE] (C - Dry eye - n/a - [n/a - n/a - Unknown]),<BR><BR>[PREDNISOLONE VALERATE ACETATE] (C - Eczema - n/a - [n/a - n/a - Unknown]),<BR><BR>[RAMELTEON] (C - Product used for unknown indication - n/a - [n/a - 8mg - Unknown]),<BR><BR>[REBAMIPIDE] (C - Prophylaxis against gastrointestinal ulcer - n/a - [n/a - 300mg - Unknown]),<BR><BR>[SODIUM HYDROGEN CARBONATE] (C - Prophylaxis - n/a - [n/a - 6g - Unknown]),<BR><BR>[ZOLPIDEM TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006270406&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006273102,Spontaneous,2020-07-02 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Renal impairment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006273102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006259144,Spontaneous,2020-07-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cerebral haemorrhage (n/a - Fatal - Results in Death),"DUPIXENT 300 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE [DUPILUMAB] (S - Dermatosis - Not applicable - [n/a - n/a - Subcutaneous]),<BR><BR>VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 146mg - Subcutaneous]),<BR><BR>[HYDROXYCARBAMIDE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006259144&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006252459,Spontaneous,2020-06-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Rash (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Renal impairment (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia, Myelodysplastic syndrome - n/a - [n/a - 120mg - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006252459&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006237653,Spontaneous,2020-06-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Febrile neutropenia (12d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (19d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 75mg/m2 - Subcutaneous]),"VORICONAZOLE [VORICONAZOLE] (C - Pneumonia - n/a - [n/a - 300mg - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID, ASPIRIN BP] (C - Cerebral infarction - n/a - [n/a - 100mg - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - 10mg - Unknown]),<BR><BR>[AZILSARTAN] (C - Hypertension - n/a - [n/a - 40mg - Unknown]),<BR><BR>[CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE] (C - Prophylaxis against dehydration - n/a - [n/a - 500mL - Unknown]),<BR><BR>[LOXOPROFEN SODIUM HYDRATE] (C - Back pain - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[RABEPRAZOLE SODIUM] (C - Gastritis prophylaxis - n/a - [n/a - 10mg - Unknown]),<BR><BR>[SODIUM PICOSULFATE MONOHYDRATE] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[TOCOPHERYL NICOTINATE] (C - Dyslipidaemia - n/a - [n/a - 300mg - Unknown]),<BR><BR>[WHOLE BLOOD] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006237653&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006239017,Spontaneous,2020-06-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Acute leukaemia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Depression (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Haemoglobin decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Neutrophil count decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Panic disorder (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Red blood cell count decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Therapeutic response decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>White blood cell count decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Acute leukaemia - Drug withdrawn - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 75mg/m2 - Unknown])",VENETOCLAX [VENETOCLAX] (C - Acute leukaemia - n/a - [n/a - 400mg - Unknown]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006239017&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006231207,Spontaneous,2020-06-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Full blood count decreased (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006231207&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006233861,Spontaneous,2020-06-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute myeloid leukaemia recurrent (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neutrophil count decreased (39d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition)","VENCLYXTO [VENETOCLAX] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Oral]),<BR><BR>VENCLYXTO [VENETOCLAX] (S - n/a - Unknown - [n/a - 200mg - Oral]),<BR><BR>VENCLYXTO [VENETOCLAX] (S - n/a - Unknown - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown])","[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - 300mg - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - Product used for unknown indication - n/a - [n/a - 10mg - n/a]),<BR><BR>[BISOPROLOL FUMARATE, BISOPROLOL FUMARATE, ACETYLSALICYLIC ACID, BISOPROLOL HEMIFUMARATE] (C - Product used for unknown indication - n/a - [n/a - 10mg - n/a]),<BR><BR>[CHLORHEXIDINE GLUCONATE, SODIUM EDETATE, SODIUM HYDROGEN CARBONATE, SACCHARIN SODIUM, MACROGOL] (C - Product used for unknown indication - n/a - [n/a - 20mL - n/a]),<BR><BR>[DIMETICONE, METOCLOPRAMIDE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 5mg - n/a]),<BR><BR>[MIRTAZAPINE] (C - Product used for unknown indication - n/a - [n/a - 300mg - n/a]),<BR><BR>[NICORANDIL, NICOTINE] (C - Product used for unknown indication - n/a - [n/a - 10mg - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - 40mg - n/a]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - 500mg - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETROLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - Product used for unknown indication - n/a - [n/a - 50mg - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006233861&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006217783,Spontaneous,2020-06-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pancytopenia (n/a - Recovering/Resolving - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 140mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006217783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006221984,Spontaneous,2020-06-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bone marrow failure (n/a - Recovered/Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Subcutaneous]),"CYTARABINE [CYTARABINE] (C - Acute myeloid leukaemia - n/a - [n/a - 35mg - Unknown]),<BR><BR>[OMACETAXINE MEPESUCCINATE] (C - Acute myeloid leukaemia - n/a - [n/a - 2mg - Intravenous drip])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006221984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006223818,Spontaneous,2020-06-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Pneumonia (n/a - Fatal - Results in Death),<BR><BR>Suspected COVID-19 (n/a - Fatal - Results in Death)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006223818&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006225040,Spontaneous,2020-06-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bacterial infection (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006225040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006213286,Spontaneous,2020-06-23 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Anaemia (227d - Recovered/Resolved - ),<BR><BR>C-reactive protein increased (7d - Recovered/Resolved - ),<BR><BR>Injection site reaction (25d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (141d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (304d - Recovered/Resolved - ),<BR><BR>Rash maculo-papular (7d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (42d - Recovered/Resolved - )","LENALIDOMIDE [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>LENALIDOMIDE [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Intravenous drip])","ADENURIC [FEBUXOSTAT] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>CASPOFUNGIN [CASPOFUNGIN, CASPOFUNGIN ACETATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>GRANISETRON [GRANISETRON] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>PROTOPIC [TACROLIMUS, TACROLIMUS MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>PROTOPIC [TACROLIMUS, TACROLIMUS MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CEFPODOXIME, CEFPODOXIME PROXETIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CEFPODOXIME, CEFPODOXIME PROXETIL] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[CETYLPYRIDINIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLARITHROMYCIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[COLISTIN SULFATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LIDOCAINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LINEZOLID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE, METHYLPREDNISOLONE ACETATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE, METHYLPREDNISOLONE ACETATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PIPERACILLIN SODIUM, TAZOBACTAM SODIUM, PIPERACILLIN, TAZOBACTAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM PICOSULFATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006213286&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006216889,Spontaneous,2020-06-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Thrombocytopenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Subcutaneous]),"[CYTARABINE] (C - Myelodysplastic syndrome - n/a - [n/a - 100mg - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - Myelodysplastic syndrome - n/a - [n/a - 100mL - Intravenous drip]),<BR><BR>[STERILISED WATER FOR INJECTIONS] (C - Myelodysplastic syndrome - n/a - [n/a - 4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006216889&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006209295,Spontaneous,2020-06-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Drug intolerance (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Full blood count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Gastrointestinal haemorrhage (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Haemoglobin decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Staphylococcal infection (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>White blood cell count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - 5q minus syndrome - Unknown - [n/a - n/a - Unknown]),"CYTARABINE [CYTARABINE] (C - 5q minus syndrome - n/a - [n/a - n/a - Unknown]),<BR><BR>[GLASDEGIB] (C - 5q minus syndrome - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006209295&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006203115,Spontaneous,2020-06-20 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Graft versus host disease in liver (83d - Recovered/Resolved - ),<BR><BR>Graft versus host disease in skin (4d - Recovered/Resolved - ),<BR><BR>Graft versus host disease in skin (7d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (22d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (6d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Product used for unknown indication - Not applicable - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myeloid leukaemia - Not applicable - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - n/a])","GRANISETRON [GRANISETRON] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>LANTUS [INSULIN GLARGINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALMASILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BISACODYL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CEFPODOXIME, CEFPODOXIME PROXETIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CYANOCOBALAMIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIMENHYDRINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIMENHYDRINATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FUROSEMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[MEGLUMINE AMIDOTRIZOATE, SODIUM AMIDOTRIZOATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOCLOPRAMIDE, METOCLOPRAMIDE DIHYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE, METOCLOPRAMIDE HYDROCHLORIDE PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[PHLOROGLUCINOL DIHYDRATE, PHLOROGLUCINOL DIHYDRATE, 1,3,5 - TRIMETHOXYBENZENE, TRIMETHYLPHLOROGLUCINOL, PHLOROGLUCINOL DIHYDRATE, TROSPIUM, TROSPIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM POLYSTYRENE SULPHONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM POLYSTYRENE SULPHONATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006203115&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006195800,Spontaneous,2020-06-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Haemoglobin decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Therapeutic product effect decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>White blood cell count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Intravenous drip]),"CYTARABINE [CYTARABINE] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown]),<BR><BR>DAURISMO [GLASDEGIB] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006195800&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006188002,Spontaneous,2020-06-18 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Anaemia (168d - Recovered/Resolved - ),<BR><BR>Constipation (9d - Recovered/Resolved - ),<BR><BR>Dyspnoea (16d - Recovered/Resolved - ),<BR><BR>Epistaxis (0d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site reaction (199d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>White blood cell count decreased (161d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006188002&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006189458,Spontaneous,2020-06-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (72d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Neutrophil count decreased (98d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Platelet count decreased (119d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (72d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","REVLIMID [LENALIDOMIDE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - n/a - Not applicable - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Subcutaneous])","VORICONAZOLE [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, COLECALCIFEROL CONCENTRATE (OILY FORM)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL SUCCINATE, METOPROLOL SUCCINATE (PH. EUR.)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL SUCCINATE, METOPROLOL SUCCINATE (PH. EUR.)] (C - n/a - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006189458&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006189752,Spontaneous,2020-06-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cardiac dysfunction (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006189752&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006189757,Spontaneous,2020-06-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Gastrointestinal haemorrhage (34d - Fatal - Results in Death, Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 75mg/m2 - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myeloproliferative neoplasm - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006189757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006191667,Spontaneous,2020-06-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Neutropenia (n/a - Unknown - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Subcutaneous]),"CYTARABINE [CYTARABINE] (C - Acute myeloid leukaemia - n/a - [n/a - 15mg - Intravenous drip]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - Product used for unknown indication - n/a - [n/a - 300mg - Unknown]),<BR><BR>[SODIUM CHLORIDE] (C - Acute myeloid leukaemia - n/a - [n/a - 100mL - Intravenous drip]),<BR><BR>[STERILE WATER] (C - Acute myeloid leukaemia - n/a - [n/a - 4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006191667&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006191669,Spontaneous,2020-06-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bone marrow failure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"CYTARABINE [CYTARABINE] (S - Chemotherapy - Drug withdrawn - [n/a - .015g - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 100mg - Subcutaneous]),<BR><BR>[OMACETAXINE MEPESUCCINATE] (S - Chemotherapy - Drug withdrawn - [n/a - 1mg - Intravenous drip])","[GLUCOSE, GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS] (C - Acute myeloid leukaemia - n/a - [n/a - 50mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - Acute myeloid leukaemia - n/a - [n/a - 1.5mL - Subcutaneous]),<BR><BR>[STERILE WATER] (C - Acute myeloid leukaemia - n/a - [n/a - 4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006191669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006193034,Spontaneous,2020-06-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Febrile neutropenia (14d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Staphylococcal infection (14d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 100mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Drug withdrawn - [n/a - 200mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Drug withdrawn - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 75mg/m2 - Intravenous drip])","APIXABAN [APIXABAN] (C - Pulmonary embolism - n/a - [n/a - 5mg - Oral]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - Chemotherapy side effect prophylaxis - n/a - [n/a - 10mg - Intravenous drip]),<BR><BR>ENOXAPARIN SODIUM [ENOXAPARIN SODIUM] (C - Pulmonary embolism - n/a - [n/a - 80mg - Subcutaneous]),<BR><BR>GRANISETRON [GRANISETRON] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 1000ug - Intravenous drip]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Infection prophylaxis - n/a - [n/a - 500mg - Oral]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Infection prophylaxis - n/a - [n/a - 400mg - Oral]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [12d - 300mg - Oral]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [12d - 300mg - Oral]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [12d - 600mg - Oral]),<BR><BR>[ASCORBIC ACID, ERGOCALCIFEROL, CYANOCOBALAMIN, NICOTINAMIDE, PYRIDOXINE, THIAMINE, RETINOL] (C - Macular degeneration - n/a - [n/a - 1{DF} - Oral]),<BR><BR>[FEXOFENADINE HYDROCHLORIDE] (C - Rhinitis allergic - n/a - [n/a - 10mg - Oral]),<BR><BR>[INFLUENZA A VIRUS A/CALIFORNIA/7/2009 X-179A (H1N1) HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)] (C - Infection prophylaxis - n/a - [n/a - .5mL - Intramuscular]),<BR><BR>[LIDOCAINE, PRILOCAINE, PRILOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE] (C - Catheter site pain - n/a - [n/a - n/a - Topical]),<BR><BR>[ONDANSETRON] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 8mg - Oral]),<BR><BR>[OXYGEN] (C - Acute respiratory failure - n/a - [n/a - n/a - Nasal]),<BR><BR>[PROPYLENE GLYCOL, MACROGOL] (C - Dry eye - n/a - [n/a - 2[drp] - Ophthalmic]),<BR><BR>[VITAMINS NOS] (C - Macular degeneration - n/a - [n/a - 1{DF} - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006193034&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006180875,Spontaneous,2020-06-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bone marrow failure (n/a - Recovering/Resolving - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Acute monocytic leukaemia - Not applicable - [7d - 100mg - Subcutaneous]),<BR><BR>[CYTARABINE] (S - Acute monocytic leukaemia - Not applicable - [7d - 35mg - n/a]),<BR><BR>[OMACETAXINE MEPESUCCINATE] (S - Acute monocytic leukaemia - Not applicable - [7d - 2mg - Intravenous drip])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006180875&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006183844,Spontaneous,2020-06-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Acute myeloid leukaemia (n/a - Fatal - Results in Death),<BR><BR>Off label use (n/a - Fatal - Results in Death)","VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006183844&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006184055,Spontaneous,2020-06-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Platelet count decreased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [7d - 100mg - Subcutaneous]),<BR><BR>[CYTARABINE] (S - Myelodysplastic syndrome - Not applicable - [7d - 100mg - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (S - Myelodysplastic syndrome - Not applicable - [7d - 100mL - Intravenous drip]),<BR><BR>[STERILE WATER] (S - Myelodysplastic syndrome - Not applicable - [7d - 4mL - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006184055&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006174745,Spontaneous,2020-06-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Bronchopulmonary aspergillosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Neutropenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Neutropenia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 400mg - Oral]),<BR><BR>[VENETOCLAX] (S - n/a - Dose not changed - [n/a - 100mg - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006174745&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006165214,Spontaneous,2020-06-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Agranulocytosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cardiac failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Deep vein thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diabetic metabolic decompensation (n/a - Unknown - Other Medically Important Condition)","CYTARABINE [CYTARABINE] (S - n/a - Not applicable - [36d - 3760mg - Intravenous drip]),<BR><BR>CYTARABINE [CYTARABINE] (S - n/a - Not applicable - [8d - 30mg - Unknown]),<BR><BR>CYTARABINE [CYTARABINE] (S - n/a - Not applicable - [8d - 3760mg - Intravenous drip]),<BR><BR>VENCLYXTO [VENETOCLAX] (S - n/a - Dose not changed - [n/a - 200mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose not changed - [n/a - 80mg/m2 - Subcutaneous]),<BR><BR>[FLUDARABINE] (S - Chloroma - Not applicable - [n/a - 57mg - Intravenous drip]),<BR><BR>[FLUDARABINE] (S - n/a - Not applicable - [36d - 57mg - Intravenous drip]),<BR><BR>[IDARUBICIN] (S - n/a - Not applicable - [3d - 15mg - Intravenous drip])","FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [5d - n/a - n/a - More in ICSR]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - 15mg - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - Product used for unknown indication - n/a - [n/a - 40[iU] - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - n/a - n/a - [n/a - 30mg - n/a]),<BR><BR>[NADROPARIN, NADROPARIN CALCIUM] (C - n/a - n/a - [n/a - .6mL - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - 4000mg - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006165214&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006166847,Spontaneous,2020-06-15 00:00:00,Healthcare Professional,European Economic Area,Nicorescu I. Predisposition to transformation from myelodysplastic syndrome into acute myeloid leukemia case presentation. Oncohematology. 51:48-50.,65-85 Years,Not Specified,No,Female,"Acute myeloid leukaemia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemorrhage (n/a - Recovered/Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Subcutaneous]),"CAPECITABINE [CAPECITABINE] (C - Rectal adenocarcinoma - n/a - [n/a - n/a - Unknown]),<BR><BR>[ERYTHROPOIETIN] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown]),<BR><BR>[RED BLOOD CELLS] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006166847&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006167587,Spontaneous,2020-06-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Red blood cell count abnormal (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Intravenous drip]),"[ERYTHROPOIETIN] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown]),<BR><BR>[WHOLE BLOOD] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006167587&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006168191,Spontaneous,2020-06-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Decreased interest (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Toxicity to various agents (n/a - Recovered/Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 150mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006168191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006168640,Spontaneous,2020-06-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Renal failure (n/a - Recovering/Resolving - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 100mg - Subcutaneous]),[STERILE WATER] (C - Product used for unknown indication - n/a - [n/a - 4mL - Subcutaneous]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006168640&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006170438,Spontaneous,2020-06-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Agranulocytosis (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)",VIDAZA 25 MG/ML POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Intravenous (not otherwise specified)]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006170438&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006161420,Spontaneous,2020-06-13 00:00:00,Healthcare Professional,European Economic Area,Not available,3-11 Years,Not Specified,No,Male,Red blood cell schistocytes present (n/a - Recovering/Resolving - ),"VENCLYXTO 100 MG FILM COATED TABLETS [VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 1{DF} - Oral]),<BR><BR>VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - Subcutaneous])","[AMOXICILLIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLUCOSE, ANHYDROUS, GLUCOSE, ANHYDROUS, POTASSIUM CHLORIDE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, GLUCOSE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PIPERACILLIN SODIUM, TAZOBACTAM SODIUM, PIPERACILLIN, TAZOBACTAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VANCOMYCIN, VANCOMYCIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006161420&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006162822,Spontaneous,2020-06-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hyperglycaemia (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Hyperkalaemia (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Hyponatraemia (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Ketoacidosis (n/a - Recovering/Resolving - Life Threatening)",VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Leukaemia - Drug withdrawn - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006162822&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006160735,Spontaneous,2020-06-12 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Anaemia (56d - Recovered/Resolved - ),<BR><BR>Anaemia (6d - Recovered/Resolved - ),<BR><BR>Middle ear inflammation (19d - Recovered/Resolved - ),<BR><BR>Nausea (0d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (8d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>White blood cell count decreased (14d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (20d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Unknown])","GRANISETRON [GRANISETRON] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [52d - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - n/a - n/a - [52d - n/a - Unknown]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE, METHYLPREDNISOLONE ACETATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006160735&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006154724,Spontaneous,2020-06-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oedema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Product administration error (n/a - Unknown - )","VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - n/a - Intravenous drip])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006154724&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006154778,Spontaneous,2020-06-11 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Decreased appetite (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site reaction (118d - Recovered/Resolved - )","VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","INSUMAN RAPID [INSULIN HUMAN, INSULIN HUMAN REGULAR (RDNA)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM CITRATE, MAGNESIUM OXIDE, MAGNESIUM OXIDE, HEAVY, MAGNESIUM CITRATE DIBASIC PENTAHYDRATE, MAGNESIUM SULFATE HEPTAHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOCLOPRAMIDE, METOCLOPRAMIDE DIHYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE, METOCLOPRAMIDE HYDROCHLORIDE PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOCLOPRAMIDE, METOCLOPRAMIDE DIHYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE, METOCLOPRAMIDE HYDROCHLORIDE PH. EUR.] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006154778&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006130883,Spontaneous,2020-06-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Bone marrow failure (n/a - Recovering/Resolving - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Subcutaneous]),<BR><BR>[CYTARABINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 3g - Intravenous drip])",[SODIUM CHLORIDE] (C - Chemotherapy - n/a - [n/a - 500mL - Intravenous drip]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006130883&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006119768,Spontaneous,2020-06-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac failure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Oedema peripheral (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary arterial hypertension (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","NOXAFIL [POSACONAZOLE] (S - Infection prophylaxis - Drug withdrawn - [n/a - 300mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 75mg/m2 - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006119768&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006122316,Spontaneous,2020-06-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Female,"Asthenia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Decreased appetite (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Diarrhoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Failure to thrive (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation)","PACLITAXEL [PACLITAXEL] (S - Triple negative breast cancer - Not applicable - [n/a - 80mg/m2 - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Unknown]),<BR><BR>[CARBOPLATIN] (S - Triple negative breast cancer - Not applicable - [n/a - n/a - Intravenous drip]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Triple negative breast cancer - Not applicable - [n/a - 600mg/m2 - Intravenous drip]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - n/a - Not applicable - [n/a - 500mg/m2 - Intravenous drip]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - Triple negative breast cancer - Not applicable - [n/a - 60mg/m2 - Intravenous drip]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (S - n/a - Not applicable - [n/a - 50mg/m2 - Intravenous drip]),<BR><BR>[VELIPARIB] (S - Triple negative breast cancer - Not applicable - [n/a - n/a - Oral])","GRANISETRON [GRANISETRON] (C - Nausea - n/a - [n/a - 3.1mg - Transdermal]),<BR><BR>GRANISETRON [GRANISETRON] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[CARVEDILOL] (C - Hypertension - n/a - [n/a - 12.5mg - Oral]),<BR><BR>[ESCITALOPRAM OXALATE] (C - Depressed mood - n/a - [n/a - 20mg - Oral]),<BR><BR>[LIDOCAINE, PRILOCAINE, PRILOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - Topical]),<BR><BR>[LOPERAMIDE HYDROCHLORIDE] (C - Diarrhoea - n/a - [n/a - 2mg - Oral]),<BR><BR>[LORAZEPAM] (C - Nausea - n/a - [n/a - 1mg - Oral]),<BR><BR>[LORAZEPAM] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[MELOXICAM] (C - Musculoskeletal pain - n/a - [n/a - 1{DF} - Oral]),<BR><BR>[NYSTATIN, DIPHENHYDRAMINE, HYDROCORTISONE] (C - Stomatitis - n/a - [n/a - n/a - Unknown]),<BR><BR>[OMEPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastritis - n/a - [n/a - 20mg - Oral]),<BR><BR>[ONDANSETRON HYDROCHLORIDE] (C - Nausea - n/a - [n/a - n/a - Oral]),<BR><BR>[ONDANSETRON HYDROCHLORIDE] (C - n/a - n/a - [n/a - 8mg - Intravenous drip]),<BR><BR>[OXYCODONE HYDROCHLORIDE, PARACETAMOL] (C - Musculoskeletal pain - n/a - [n/a - n/a - Oral]),<BR><BR>[PARACETAMOL] (C - Headache - n/a - [n/a - 1000mg - Oral]),<BR><BR>[PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE] (C - Nausea - n/a - [n/a - 25mg - Oral]),<BR><BR>[PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Hyperlipidaemia - n/a - [n/a - 20mg - Oral]),<BR><BR>[SUCRALFATE] (C - Gastritis - n/a - [n/a - 1g - Oral]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Musculoskeletal pain - n/a - [n/a - 50mg - Oral]),<BR><BR>[VALSARTAN] (C - Hypertension - n/a - [n/a - 160mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006122316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006124381,Spontaneous,2020-06-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Acute myeloid leukaemia (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),"EPOETIN ALFA [EPOETIN ALFA] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TINZAPARIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006124381&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006126006,Spontaneous,2020-06-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Acute myeloid leukaemia recurrent (n/a - Unknown - ),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia refractory - Unknown - [n/a - 100mg - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006126006&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006114065,Spontaneous,2020-06-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Infection (n/a - Fatal - Results in Death),<BR><BR>Neutropenia (n/a - Fatal - Results in Death)","VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006114065&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006109854,Spontaneous,2020-06-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Bone marrow failure (n/a - Recovering/Resolving - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [8d - 100mg - Subcutaneous]),<BR><BR>[CYTARABINE] (S - Acute myeloid leukaemia - Not applicable - [5d - 3g - Intravenous drip])",[SODIUM CHLORIDE] (C - Vehicle solution use - n/a - [5d - 500mL - Intravenous drip]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006109854&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006111857,Spontaneous,2020-06-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Infection (n/a - Fatal - Results in Death),<BR><BR>Neutropenia (n/a - Fatal - Results in Death)","VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - 200mg - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006111857&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006097324,Spontaneous,2020-06-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Acute myeloid leukaemia recurrent (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia recurrent - Unknown - [n/a - 100mg/m2 - Unknown]),"[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006097324&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006097742,Spontaneous,2020-06-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Bone marrow failure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006097742&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006086818,Spontaneous,2020-05-29 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Hypertension (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neutrophil count decreased (8d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Product used for unknown indication - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Unknown])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID, ASPIRIN BP] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALIZAPRIDE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALIZAPRIDE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[BECLOMETASONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOBETASOL PROPIONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[DEXAMETHASONE PHOSPHATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Ophthalmic]),<BR><BR>[FLUCONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HEPARIN, HEPARIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROMORPHONE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006086818&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006087620,Spontaneous,2020-05-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pneumonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 75mg/m2 - Subcutaneous]),"GRANISETRON [GRANISETRON] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 2mg - Oral]),<BR><BR>[BENZETHONIUM CHLORIDE] (C - Infection prophylaxis - n/a - [n/a - 1mL - Topical]),<BR><BR>[BROTIZOLAM] (C - Insomnia - n/a - [n/a - .25mg - Oral]),<BR><BR>[FEXOFENADINE HYDROCHLORIDE] (C - Rhinitis - n/a - [n/a - 60mg - Oral]),<BR><BR>[HEPARINOID] (C - Dry skin - n/a - [n/a - n/a - n/a]),<BR><BR>[HEPARINOID] (C - Dry skin prophylaxis - n/a - [n/a - .5g - Topical]),<BR><BR>[IFENPRODIL TARTRATE] (C - Cerebrovascular accident - n/a - [n/a - 20mg - Oral]),<BR><BR>[MAGNESIUM OXIDE] (C - Constipation prophylaxis - n/a - [n/a - 330mg - Oral]),<BR><BR>[OLMESARTAN MEDOXOMIL] (C - Hypertension - n/a - [n/a - n/a - Oral]),<BR><BR>[PANTETHINE] (C - Constipation prophylaxis - n/a - [n/a - 100mg - Oral]),<BR><BR>[PIRENOXINE] (C - Cataract - n/a - [n/a - n/a - Intraocular]),<BR><BR>[PLACEBO] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Oral]),<BR><BR>[PLACEBO] (C - n/a - n/a - [n/a - n/a - Oral]),<BR><BR>[SODIUM PICOSULFATE] (C - Constipation - n/a - [n/a - n/a - Oral]),<BR><BR>[TRANILAST] (C - Eye pruritus - n/a - [n/a - 1[drp] - Intraocular]),<BR><BR>[ZOLPIDEM TARTRATE] (C - Insomnia - n/a - [n/a - 5mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006087620&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006091879,Spontaneous,2020-05-29 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Lung infiltration (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006091879&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006077262,Spontaneous,2020-05-28 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Anaemia (21d - Recovered/Resolved - ),<BR><BR>Anaemia (22d - Recovered/Resolved - ),<BR><BR>Anaemia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Bronchitis (14d - Recovered/Resolved - ),<BR><BR>Infection (18d - Recovered/Resolved - ),<BR><BR>Infection (6d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (0d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (13d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (27d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (6d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (13d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (14d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (5d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (6d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (7d - Recovered/Resolved - ),<BR><BR>Rhinitis (4d - Recovered/Resolved - ),<BR><BR>Rhinitis (7d - Recovered/Resolved - ),<BR><BR>Skin disorder (12d - Recovered/Resolved - ),<BR><BR>Skin disorder (9d - Recovered/Resolved - ),<BR><BR>Upper respiratory tract infection (7d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (0d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (18d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (34d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (7d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 2.5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Unknown])","[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR BP] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BETAMETHASONE VALERATE, FUSIDIC ACID, BETAMETHASONE VALERATE, FUSIDIC ACID HEMIHYDRATE, BETAMETHASONE, ANHYDROUS FUSIDIC ACID, BETAMETHASONE, FUSIDIC ACID HEMIHYDRATE, BETAMETHASONE, FUSIDIC ACID PH. EUR., FUSIDIC ACID HEMIHYDRATE, BETAMETHASONE VALERATE (PH. EUR.), FUSIDIC ACID, BETAMETHASONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CEFTIBUTEN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CEFTIBUTEN] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOBUTINOL HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CORTISONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[DICLOFENAC SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ENOXAPARIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ENOXAPARIN SODIUM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANISETRON, GRANISETRON HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANISETRON, GRANISETRON HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[OMEPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006077262&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006080369,Spontaneous,2020-05-28 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Chronic graft versus host disease (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphocyte count decreased (96d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Unknown])","CARBIDOPA, LEVODOPA [CARBIDOPA, LEVODOPA] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BROMAZEPAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN A] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOBETASOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[DEXAMETHASONE PHOSPHATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[HUMAN PLATELET, ALLOGENIC] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE, METHYLPREDNISOLONE ACETATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM, POTASSIUM CHLORIDE, POTASSIUM GLYCEROPHOSPHATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM HYDROGEN TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAMIPEXOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[QUETIAPINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RED BLOOD CELLS] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),<BR><BR>[TORASEMIDE, TORASEMIDE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ZOPICLONE] (C - Product used for unknown indication - n/a - [10d - n/a - Unknown]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [10d - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006080369&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006082719,Spontaneous,2020-05-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pyoderma gangrenosum (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 145mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006082719&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006072656,Spontaneous,2020-05-27 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Anaemia (n/a - Not Recovered/Not Resolved - ),"REVLIMID [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 2.5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - n/a])","CARBIDOPA, LEVODOPA [CARBIDOPA, LEVODOPA] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VFEND [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BROMAZEPAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN A] (C - Product used for unknown indication - n/a - [122d - n/a - Unknown]),<BR><BR>[CICLOSPORIN A] (C - n/a - n/a - [122d - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOBETASOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[DEXAMETHASONE PHOSPHATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Ophthalmic]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE, METHYLPREDNISOLONE ACETATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM, POTASSIUM CHLORIDE, POTASSIUM GLYCEROPHOSPHATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM HYDROGEN TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[PRAMIPEXOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[QUETIAPINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TORASEMIDE, TORASEMIDE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ZOPICLONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006072656&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006073531,Spontaneous,2020-05-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Bone marrow failure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 70mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chemotherapy - Unknown - [n/a - 100mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - 100mg - Subcutaneous])","CYTARABINE [CYTARABINE] (C - Chemotherapy - n/a - [n/a - 50mg - Intrathecal]),<BR><BR>CYTARABINE [CYTARABINE] (C - n/a - n/a - [n/a - .05g - Intrathecal]),<BR><BR>CYTARABINE [CYTARABINE] (C - n/a - n/a - [n/a - .1g - Intravenous drip]),<BR><BR>CYTARABINE [CYTARABINE] (C - n/a - n/a - [n/a - 3.5g - Intravenous drip]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Chemotherapy - n/a - [n/a - 10mg - Intrathecal]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - 10mg - Intrathecal]),<BR><BR>[DEXAMETHASONE SODIUM PHOSPHATE] (C - Adjuvant therapy - n/a - [n/a - 5mg - Intrathecal]),<BR><BR>[DEXAMETHASONE SODIUM PHOSPHATE] (C - n/a - n/a - [n/a - 5mg - Intrathecal]),<BR><BR>[GLUCOSE, GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS] (C - Product used for unknown indication - n/a - [n/a - 250mL - Intravenous drip]),<BR><BR>[OMACETAXINE MEPESUCCINATE] (C - Chemotherapy - n/a - [n/a - 4mg - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 3mL - Intrathecal]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 3mL - Intrathecal]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 500mL - Intravenous drip]),<BR><BR>[STERILE WATER] (C - Product used for unknown indication - n/a - [12d - 4mL - Subcutaneous]),<BR><BR>[STERILE WATER] (C - n/a - n/a - [12d - 4mL - Subcutaneous]),<BR><BR>[STERILE WATER] (C - n/a - n/a - [12d - 500mL - Intravenous drip])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006073531&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006073694,Spontaneous,2020-05-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hepatic function abnormal (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Leukopenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytopenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Chronic myeloid leukaemia - Drug withdrawn - [n/a - 100mg - Subcutaneous]),<BR><BR>[HYDROXYCARBAMIDE] (S - Chronic myeloid leukaemia - Drug withdrawn - [n/a - .5g - Oral])",[STERILE WATER] (C - Chronic myeloid leukaemia - n/a - [n/a - 4mL - Subcutaneous]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006073694&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006073982,Spontaneous,2020-05-27 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Graft versus host disease in skin (6d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (8d - Recovered/Resolved - ),<BR><BR>Pancytopenia (43d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - n/a - Drug withdrawn - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Unknown])","NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALIZAPRIDE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMOXICILLIN SODIUM, CLAVULANIC ACID, AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN TRIHYDRATE, POTASSIUM CLAVULANATE, AMOXICILLIN, CLAVULANIC ACID, AMOXICILLIN, POTASSIUM CLAVULANATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ENALAPRIL, HYDROCHLOROTHIAZIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROXYCARBAMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE, METHYLPREDNISOLONE ACETATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006073982&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006074749,Spontaneous,2020-05-27 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Neutrophil count decreased (51d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (59d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (45d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>White blood cell count decreased (186d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (18d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - 2.5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","CARBIDOPA, LEVODOPA [CARBIDOPA, LEVODOPA] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>LEVODOPA [LEVODOPA] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VFEND [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BROMAZEPAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN A] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOBETASOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[DEXAMETHASONE PHOSPHATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Ophthalmic]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE, METHYLPREDNISOLONE ACETATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM, POTASSIUM CHLORIDE, POTASSIUM GLYCEROPHOSPHATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM HYDROGEN TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[PRAMIPEXOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[QUETIAPINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RED BLOOD CELLS] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TORASEMIDE, TORASEMIDE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ZOPICLONE] (C - Product used for unknown indication - n/a - [10d - n/a - Unknown]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [10d - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006074749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006065956,Spontaneous,2020-05-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haematocrit decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemoglobin decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immunodeficiency (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Unevaluable event (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 20mL - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006065956&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006065967,Spontaneous,2020-05-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Recovered/Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 128mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006065967&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006066496,Spontaneous,2020-05-26 00:00:00,Healthcare Professional,Non European Economic Area,"Kenichiro M. A case of MDS presented with sweet syndrome like skin eruption after the administration of azacitidine. 464th Keiji Regional and professor Toshihiro tanaks retirement memorial meeting of dermatologist. Hirofumi T. A case of sweet syndrome like symptoms which presented due to the administration of azazitidine. Japanese Journal of dermatology.",18-64 Years,Not Specified,No,Male,Acute febrile neutrophilic dermatosis (n/a - Recovering/Resolving - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006066496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006052558,Spontaneous,2020-05-22 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Pruritus (7d - Recovered/Resolved - ),<BR><BR>Rash erythematous (7d - Recovered/Resolved - )",VIDAZA 25 MG/ML POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 100mg - Subcutaneous]),"PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Dyspepsia - n/a - [n/a - 20mg - Oral]),<BR><BR>RETACRIT [EPOETIN ALFA, EPOETIN ZETA] (C - Anaemia - n/a - [n/a - 40[iU] - Subcutaneous]),<BR><BR>ZARZIO 30 MU/0.5 ML SOLUTION FOR INJECTION OR INFUSION IN PRE-FILLED SYRINGE [FILGRASTIM] (C - Neutropenia - n/a - [n/a - n/a - Subcutaneous]),<BR><BR>[ALLOPURINOL] (C - Blood uric acid - n/a - [n/a - 300mg - Oral]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - 5mg - Oral]),<BR><BR>[ISPAGHULA, ISPAGHULA HUSK, SENNA PODS, ISPAGHULA SEED, SENNA PODS, TINNEVELLY, ISPAGHULA SEED, SENNA PODS, TINNEVELLY, ISPAGHULA HUSK, PLANTAGO SEED, SENNA PODS, SENNA PODS, ALEXANDRIAN, ISPAGHULA HUSK, SENNA PODS, TINNEVELLY, ISPAGHULA HUSK, SENNA PODS, TINNEVELLY, ISPAGHULA HUSK, PLANTAGINIS OVATAE SEMEN, SENNA PODS, TINNEVELLY, PLANTAGO OVATA FORSK(SEED), ISPAGHULA HUSK] (C - Constipation - n/a - [n/a - n/a - Oral]),<BR><BR>[NYSTATIN] (C - Oral candidiasis - n/a - [n/a - 2{DF} - Oral]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 8mg - Oral]),<BR><BR>[PARACETAMOL] (C - Bone pain - n/a - [n/a - 1mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006052558&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006052599,Spontaneous,2020-05-22 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Anaemia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Blood lactate dehydrogenase decreased (15d - Recovered/Resolved - ),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gamma-glutamyltransferase decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoalbuminaemia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nutritional condition abnormal (n/a - Not Recovered/Not Resolved - ),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ATOVAQUONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006052599&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006052667,Spontaneous,2020-05-22 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Adrenal insufficiency (18d - Recovered/Resolved - ),<BR><BR>Anaemia (298d - Recovered/Resolved - ),<BR><BR>C-reactive protein abnormal (274d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Infection (279d - Recovered/Resolved - ),<BR><BR>Injection site reaction (244d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (295d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (15d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (37d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (523d - Recovered/Resolved - ),<BR><BR>Rhinitis (4d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (298d - Recovered/Resolved - )","LENALIDOMIDE [LENALIDOMIDE] (S - Product used for unknown indication - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Unknown])","ADENURIC [FEBUXOSTAT] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>ADENURIC [FEBUXOSTAT] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>EXJADE [DEFERASIROX] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>INVANZ [ERTAPENEM, ERTAPENEM SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[CEFPODOXIME PROXETIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CEFPODOXIME PROXETIL] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[CEFPODOXIME, CEFPODOXIME PROXETIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDRATED, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE, CIPROFLOXACIN HYDROCHLORIDE, HYDROCORTISONE, CIPROFLOXACIN LACTATE, CIPROFLOXACIN, HYDROCORTISONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLARITHROMYCIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLARITHROMYCIN] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[FLUCONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FLUCONAZOLE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [14d - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [14d - n/a - Unknown]),<BR><BR>[MAGNESIUM CITRATE, MAGNESIUM OXIDE, MAGNESIUM OXIDE, HEAVY, MAGNESIUM CITRATE DIBASIC PENTAHYDRATE, MAGNESIUM SULFATE HEPTAHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METAMIZOLE SODIUM, METAMIZOLE SODIUM MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MOXIFLOXACIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MOXIFLOXACIN] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RAMIPRIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[RANITIDINE, RANITIDINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM POLYSTYRENE SULPHONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM POLYSTYRENE SULPHONATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[TORASEMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TORASEMIDE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[UBIDECARENONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])...","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006052667&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006053425,Spontaneous,2020-05-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pneumonia fungal (101d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous])","COAPROVEL [HYDROCHLOROTHIAZIDE, IRBESARTAN] (C - Hypertension - n/a - [n/a - 300mg - Oral]),<BR><BR>RASBURICASE [RASBURICASE] (C - Prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[ANHYDROUS LIDOCAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE, EPINEPHRINE, LIDOCAINE HYDROCHLORIDE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE MONOHYDRATE] (C - Pain - n/a - [n/a - 10mL - Topical]),<BR><BR>[CEFUROXIME, CEFUROXIME AXETIL, CEFUROXIME SODIUM] (C - Infection prophylaxis - n/a - [n/a - 500mg - Oral]),<BR><BR>[GLICLAZIDE] (C - Diabetes mellitus - n/a - [n/a - 60mg - Oral]),<BR><BR>[GLUCOSE, GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS] (C - Prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - 75mg - Oral]),<BR><BR>[NEFOPAM] (C - Chest pain - n/a - [n/a - 20mg - Intravenous drip]),<BR><BR>[OFLOXACIN, OFLOXACIN HYDROCHLORIDE] (C - Infection prophylaxis - n/a - [n/a - 200mg - Oral]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 8mg - Oral]),<BR><BR>[OXAZEPAM] (C - Prophylaxis - n/a - [n/a - n/a - Oral]),<BR><BR>[PLACEBO] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Oral]),<BR><BR>[POTASSIUM CHLORIDE, POTASSIUM CHLORIDE, ETHYLCELLULOSE MICROENCAPSULATED 80-90%] (C - Hypokalaemia - n/a - [n/a - 1200mg - Oral]),<BR><BR>[POTASSIUM CHLORIDE, POTASSIUM CHLORIDE, ETHYLCELLULOSE MICROENCAPSULATED 80-90%] (C - n/a - n/a - [n/a - 600mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006053425&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006053427,Spontaneous,2020-05-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Febrile neutropenia (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 75mg/m2 - Intravenous drip]),"MICAFUNGIN [MICAFUNGIN] (C - Antifungal prophylaxis - n/a - [6d - 100mg - Intravenous drip]),<BR><BR>MICAFUNGIN [MICAFUNGIN] (C - n/a - n/a - [6d - 100mg - Intravenous drip]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - n/a - n/a - [n/a - n/a - Oral]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Coronary artery disease - n/a - [5d - 5mg - Oral]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [5d - 2.5mg - Oral]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [5d - 2.5mg - Oral]),<BR><BR>[GLUCOSAMINE, CHONDROITIN] (C - Arthropathy - n/a - [n/a - n/a - Oral]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - Hypertension - n/a - [n/a - 30mg - Oral]),<BR><BR>[LEVOFLOXACIN HEMIHYDRATE] (C - Antibiotic prophylaxis - n/a - [n/a - 500mg - Oral]),<BR><BR>[LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - 20mg - Oral]),<BR><BR>[ONDANSETRON] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 16mg - Oral]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [n/a - 16mg - Intravenous drip]),<BR><BR>[TRAMADOL HYDROCHLORIDE] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL HYDROCHLORIDE] (C - Toothache - n/a - [n/a - 50mg - Oral]),<BR><BR>[VALACICLOVIR] (C - Antiviral prophylaxis - n/a - [n/a - 500mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006053427&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006053563,Spontaneous,2020-05-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Febrile neutropenia (9d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (9d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Arthritis - n/a - [n/a - 400mg - Oral]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Viral infection - n/a - [n/a - 500mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Viral infection - n/a - [n/a - 400mg - Oral]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [n/a - 100mg - Oral]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - 5mg - Oral]),<BR><BR>[DIPHENHYDRAMINE HYDROCHLORIDE] (C - Pruritus - n/a - [n/a - 25mg - Oral]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Hypertension - n/a - [n/a - 8mg - Oral]),<BR><BR>[FLUCONAZOLE] (C - Viral infection - n/a - [n/a - 100mg - Oral]),<BR><BR>[HYDROCHLOROTHIAZIDE, LISINOPRIL] (C - Hypertension - n/a - [n/a - n/a - Oral]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - 17g - Oral]),<BR><BR>[ONDANSETRON] (C - Nausea - n/a - [n/a - 8mg - Oral]),<BR><BR>[ONDANSETRON] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[PLACEBO] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Oral]),<BR><BR>[PLACEBO] (C - n/a - n/a - [n/a - n/a - Oral]),<BR><BR>[SENNOSIDE A+B] (C - Constipation prophylaxis - n/a - [n/a - 8.5mg - Oral]),<BR><BR>[SERENOA REPENS] (C - Supplementation therapy - n/a - [n/a - 500mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006053563&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006053564,Spontaneous,2020-05-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute kidney injury (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cardiac failure congestive (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myocardial infarction (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (10d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 75mg/m2 - Subcutaneous]),"INSULIN GLULISINE [INSULIN GLULISINE] (C - Diabetes mellitus - n/a - [n/a - 10[iU] - Subcutaneous]),<BR><BR>[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - Enterococcal infection - n/a - [4d - 500mg - Oral]),<BR><BR>[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - Mucosal inflammation - n/a - [4d - 500mg - Oral]),<BR><BR>[CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE] (C - Prophylaxis - n/a - [n/a - 1000mL - Intravenous drip]),<BR><BR>[CODEINE] (C - Headache - n/a - [n/a - 15mg - Oral]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - Depression - n/a - [n/a - 10mg - Oral]),<BR><BR>[FUROSEMIDE] (C - Acute kidney injury - n/a - [6d - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Cardiac failure congestive - n/a - [6d - 40mg - Intravenous drip]),<BR><BR>[FUROSEMIDE] (C - Fluid overload - n/a - [6d - 80mg - Oral]),<BR><BR>[FUROSEMIDE] (C - Generalised oedema - n/a - [6d - 40mg - Intravenous drip]),<BR><BR>[GABAPENTIN] (C - Peripheral sensory neuropathy - n/a - [n/a - 100mg - Oral]),<BR><BR>[METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - 12.5mg - Oral]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - 20mg - Oral]),<BR><BR>[OXYGEN] (C - Hypoxia - n/a - [n/a - 6L - Unknown]),<BR><BR>[PARACETAMOL] (C - Headache - n/a - [n/a - 650mg - Oral]),<BR><BR>[PLACEBO] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Oral]),<BR><BR>[PLACEBO] (C - n/a - n/a - [n/a - n/a - Oral]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Dyslipidaemia - n/a - [n/a - 10mg - Oral]),<BR><BR>[SODIUM CHLORIDE] (C - Prophylaxis - n/a - [n/a - 8000mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 1000mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 250mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 500mL - Intravenous drip]),<BR><BR>[VALACICLOVIR] (C - Antiviral prophylaxis - n/a - [6d - 500mg - Oral]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [6d - 500mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006053564&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006053566,Spontaneous,2020-05-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (53d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Diarrhoea (7d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (10d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Acute myocardial infarction - n/a - [n/a - 75mg - Oral]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Acute myocardial infarction - n/a - [n/a - 80mg - Oral]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ALIZAPRIDE] (C - Nausea - n/a - [n/a - 50mg - Oral]),<BR><BR>[ALIZAPRIDE] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [n/a - 300mg - Oral]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - 300mg - Oral]),<BR><BR>[ALPRAZOLAM] (C - Insomnia - n/a - [n/a - .5mg - Oral]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [n/a - .25mg - Oral]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Tension headache - n/a - [n/a - 50mg - Oral]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 25mg - Oral]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 40mg - Oral]),<BR><BR>[BARIUM SULFATE] (C - Prophylaxis - n/a - [n/a - 2L - Oral]),<BR><BR>[BISACODYL] (C - Constipation - n/a - [n/a - 5mg - Oral]),<BR><BR>[BISACODYL] (C - n/a - n/a - [n/a - 5mg - Oral]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [n/a - 2.5mg - Oral]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - 2.5mg - Oral]),<BR><BR>[BUMETANIDE] (C - Fluid retention - n/a - [n/a - 1mg - Oral]),<BR><BR>[BUMETANIDE] (C - Oedema peripheral - n/a - [n/a - 2mg - Oral]),<BR><BR>[BUMETANIDE] (C - n/a - n/a - [n/a - 1mg - Intravenous drip]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Diarrhoea - n/a - [n/a - 500mg - Oral]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Infection prophylaxis - n/a - [n/a - 500mg - Oral]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Neutropenia - n/a - [n/a - 500mg - Oral]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - 1000mg - Oral]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - 500mg - Oral]),<BR><BR>[CYANOCOBALAMIN, RIBOFLAVIN, THIAMINE NITRATE, PYRIDOXINE HYDROCHLORIDE] (C - Vitamin B12 deficiency - n/a - [n/a - n/a - Oral]),<BR><BR>[DISODIUM PHOSPHATE DODECAHYDRATE, SODIUM DIHYDROGEN PHOSPHATE] (C - Colonoscopy - n/a - [n/a - n/a - Rectal]),<BR><BR>[GLUCOSE, GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS] (C - Prophylaxis - n/a - [n/a - 5000mL - Intravenous drip]),<BR><BR>[GLUCOSE, GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS] (C - n/a - n/a - [n/a - 4000mL - Intravenous drip]),<BR><BR>[GLUCOSE, GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS] (C - n/a - n/a - [n/a - 7000mL - Intravenous drip]),<BR><BR>[LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE OXIDE] (C - Diarrhoea - n/a - [38d - 2mg - Oral]),<BR><BR>[LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE OXIDE] (C - n/a - n/a - [38d - 2mg - Oral]),<BR><BR>[LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE OXIDE] (C - n/a - n/a - [38d - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Prophylaxis - n/a - [n/a - 20mg - Oral]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - Headache - n/a - [n/a - 500mg - Oral]),<BR><BR>[PERINDOPRIL, PERINDOPRIL ARGININE, PERINDOPRIL TERT-BUTYLAMIN MONOHYDRATE, PERINDOPRIL TERT-BUTYLAMINE] (C - Hypertension - n/a - [n/a - 5mg - Oral]),<BR><BR>[PERINDOPRIL, PERINDOPRIL ARGININE, PERINDOPRIL TERT-BUTYLAMIN MONOHYDRATE, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - 5mg - Oral]),<BR><BR>[PLACEBO] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Oral]),<BR><BR>[PLACEBO] (C - n/a - n/a - [n/a - n/a - Oral])...","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006053566&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006053567,Spontaneous,2020-05-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Sepsis (9d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 75mg/m2 - Subcutaneous]),"DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - Prophylaxis - n/a - [n/a - 4mg - Intravenous drip]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [n/a - 300mg - Oral]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - 5mg - Oral]),<BR><BR>[CHLORAMPHENICOL] (C - Device related infection - n/a - [n/a - 1{DF} - Transdermal]),<BR><BR>[CHLORAMPHENICOL] (C - Groin infection - n/a - [n/a - 1{DF} - Transdermal]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Infection prophylaxis - n/a - [n/a - 500mg - Oral]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - 1{DF} - Transdermal]),<BR><BR>[FAMOTIDINE] (C - Prophylaxis - n/a - [n/a - 40mg - Oral]),<BR><BR>[FLUCONAZOLE] (C - Infection prophylaxis - n/a - [n/a - 400mg - Oral]),<BR><BR>[OMEPRAZOLE] (C - Dyspepsia - n/a - [n/a - 20mg - Oral]),<BR><BR>[PLACEBO] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Oral]),<BR><BR>[PLACEBO] (C - n/a - n/a - [n/a - n/a - Oral]),<BR><BR>[SODIUM CHLORIDE SOLUTION 0.9%] (C - Prophylaxis - n/a - [n/a - 10L - Intravenous drip])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006053567&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006054170,Spontaneous,2020-05-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pneumonia (24d - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006054170&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006043666,Spontaneous,2020-05-21 00:00:00,Healthcare Professional,Non European Economic Area,"Saini L, Chua N. Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine. Leukemia and Lymphoma. 2016 DEC 08;1-3.",18-64 Years,Adult,No,Male,"Acute myeloid leukaemia (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Acute myeloid leukaemia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malignant neoplasm progression (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myositis (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Off label use (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Product use in unapproved indication (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Second primary malignancy (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","ADCETRIS [BRENTUXIMAB VEDOTIN] (S - Hodgkin's disease - Unknown - [n/a - n/a - Unknown]),<BR><BR>BRENTUXIMAB VEDOTIN [BRENTUXIMAB VEDOTIN] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Intravenous (not otherwise specified)]),<BR><BR>CARMUSTINE [CARMUSTINE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>CYTARABINE [CYTARABINE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Intrathecal]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>NIVOLUMAB [NIVOLUMAB] (S - Hodgkin's disease - Unknown - [n/a - 3mg/kg - Intravenous (not otherwise specified)]),<BR><BR>NIVOLUMAB [NIVOLUMAB] (S - n/a - Not applicable - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Hodgkin's disease - Not applicable - [n/a - 75mg/m2 - Subcutaneous]),<BR><BR>[BENDAMUSTINE, BENDAMUSTINE HYDROCHLORIDE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Intravenous (not otherwise specified)]),<BR><BR>[BLEOMYCIN SULFATE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[CHLORAMBUCIL] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[CISPLATIN] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Intravenous (not otherwise specified)]),<BR><BR>[DACARBAZINE, DACARBAZINE CITRATE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[DOXORUBICIN HYDROCHLORIDE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[ETOPOSIDE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[ETOPOSIDE] (S - n/a - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[GEMCITABINE HYDROCHLORIDE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[MELPHALAN] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[PREDNISOLONE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[PREDNISONE] (S - Hodgkin's disease - Unknown - [n/a - n/a - Unknown]),<BR><BR>[PREDNISONE] (S - n/a - Not applicable - [5d - 100mg - Oral]),<BR><BR>[PREDNISONE] (S - n/a - Not applicable - [n/a - 10mg - n/a]),<BR><BR>[PROCARBAZINE, PROCARBAZINE HYDROCHLORIDE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VINBLASTINE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VINBLASTINE] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[VINCRISTINE SULFATE] (S - Hodgkin's disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VINCRISTINE SULFATE] (S - Hodgkin's disease - n/a - [n/a - n/a - Unknown]),<BR><BR>[VINCRISTINE SULFATE] (S - n/a - Not applicable - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006043666&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006037500,Spontaneous,2020-05-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute myeloid leukaemia (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Anaemia (n/a - Recovering/Resolving - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>C-reactive protein increased (7d - Recovered/Resolved - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Recovered/Resolved With Sequelae - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Febrile neutropenia (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Infection (n/a - Recovered/Resolved - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Leukaemia (15d - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Neutrophil count abnormal (17d - Recovered/Resolved - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Pancytopenia (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Platelet count abnormal (3d - Recovered/Resolved - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Platelet disorder (5d - Recovered/Resolved - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>White blood cell count abnormal (10d - Recovered/Resolved - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>White blood cell count abnormal (17d - Recovered/Resolved - Results in Death, Caused/Prolonged Hospitalisation)","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - n/a - Drug withdrawn - [n/a - 2.5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - n/a - Unknown])","EXJADE [DEFERASIROX] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[COLECALCIFEROL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ISPAGHULA, PLANTAGO INDICA, PSYLLIUM SEED] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOCLOPRAMIDE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MOXIFLOXACIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MOXIFLOXACIN] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[OCTENIDINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PIPERACILLIN SODIUM, TAZOBACTAM SODIUM, PIPERACILLIN, TAZOBACTAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006037500&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006027558,Spontaneous,2020-05-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pyoderma gangrenosum (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 72.5mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006027558&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006030508,Spontaneous,2020-05-19 00:00:00,Healthcare Professional,European Economic Area,Treatment of secondary acute myeloid leukaemia with Azacitidine.,65-85 Years,Not Specified,No,Female,"Anaemia (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Bone marrow failure (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Cardiac failure (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 75mg/m2 - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Off label use - Not applicable - [n/a - 75mg/m2 - Subcutaneous])","[HYDROXYCARBAMIDE] (C - Cytoreductive surgery - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROXYCARBAMIDE] (C - n/a - n/a - [n/a - 1.5g - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006030508&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006030883,Spontaneous,2020-05-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Neutropenia (49d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (98d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Thrombocytopenia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Not applicable - [n/a - n/a - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 75mg/m2 - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Not applicable - [n/a - 37.5mg/m2 - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Not applicable - [n/a - 75mg/m2 - Subcutaneous])","CAPSAICIN [CAPSAICIN] (C - Arthritis - n/a - [n/a - n/a - Unknown]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - Stomatitis - n/a - [n/a - .001% - Unknown]),<BR><BR>FEBUXOSTAT [FEBUXOSTAT] (C - Prophylaxis - n/a - [n/a - 60mg - Unknown]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Infection prophylaxis - n/a - [82d - 250mg - Unknown]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - n/a - n/a - [82d - 250mg - Unknown]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - n/a - n/a - [82d - 500mg - Unknown]),<BR><BR>[BEPOTASTINE BESILATE] (C - Eczema asteatotic - n/a - [159d - 20mg - Unknown]),<BR><BR>[BEPOTASTINE BESILATE] (C - n/a - n/a - [159d - 20mg - Unknown]),<BR><BR>[CAMPHOR, RACEMIC, METHYL SALICYLATE] (C - Arthritis - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOBETASOL PROPIONATE] (C - Eczema asteatotic - n/a - [32d - .1% - Unknown]),<BR><BR>[CLOBETASOL PROPIONATE] (C - n/a - n/a - [32d - .1% - Unknown]),<BR><BR>[HEPARINOID] (C - Eczema asteatotic - n/a - [53d - .6% - Unknown]),<BR><BR>[HEPARINOID] (C - n/a - n/a - [53d - .6% - Unknown]),<BR><BR>[HYDROXYANTHRACENE GLYCOSIDES, SENNOSIDES] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROXYETHYL SALICYLATE] (C - Musculoskeletal pain - n/a - [n/a - n/a - Unknown]),<BR><BR>[KETOPROFEN] (C - Back pain - n/a - [n/a - n/a - Unknown]),<BR><BR>[KETOPROFEN] (C - Musculoskeletal pain - n/a - [n/a - 40mg - Unknown]),<BR><BR>[KETOPROFEN] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[LOXOPROFEN SODIUM HYDRATE] (C - Arthralgia - n/a - [n/a - n/a - Unknown]),<BR><BR>[LUBIPROSTONE] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[MEROPENEM, MEROPENEM ANHYDROUS] (C - Liver abscess - n/a - [n/a - 3g - Unknown]),<BR><BR>[PARACETAMOL] (C - Arthritis - n/a - [68d - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Osteoarthritis - n/a - [68d - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [68d - n/a - Unknown]),<BR><BR>[SODIUM CHLORIDE, GLUCOSE, SODIUM-L-LACTATE] (C - Prophylaxis - n/a - [n/a - 8000mL - Unknown]),<BR><BR>[SODIUM GUALENATE HYDRATE] (C - Infection prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM HYALURONATE] (C - Dry eye - n/a - [n/a - .3% - Unknown]),<BR><BR>[SODIUM HYDROGEN CARBONATE, SODIUM DIHYDROGEN PHOSPHATE ANHYDROUS] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Aspartate aminotransferase increased - n/a - [n/a - 600mg - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - n/a - n/a - [n/a - 200mg - Unknown]),<BR><BR>[ZOLPIDEM TARTRATE] (C - Insomnia - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006030883&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006024680,Spontaneous,2020-05-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Haemoglobin decreased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>White blood cell count increased (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006024680&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006025483,Spontaneous,2020-05-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Bone marrow failure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 70mg - Subcutaneous]),"CYTARABINE [CYTARABINE] (C - Chemotherapy - n/a - [n/a - .05g - Intrathecal]),<BR><BR>CYTARABINE [CYTARABINE] (C - n/a - n/a - [n/a - 4g - Intravenous drip]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Chemotherapy - n/a - [n/a - 10mg - Intrathecal]),<BR><BR>[DEXAMETHASONE SODIUM PHOSPHATE] (C - Adjuvant therapy - n/a - [n/a - 5mg - Intrathecal]),<BR><BR>[SODIUM CHLORIDE] (C - Product used for unknown indication - n/a - [5d - 3mL - Intrathecal]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [5d - 4mL - Subcutaneous]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [5d - 500mL - Intravenous drip]),<BR><BR>[STERILISED WATER FOR INJECTIONS] (C - Product used for unknown indication - n/a - [n/a - 4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006025483&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006018149,Spontaneous,2020-05-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Human bocavirus infection (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Interstitial lung disease (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 139.5mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006018149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006014535,Spontaneous,2020-05-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blast cell count increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blood test abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cytopenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Unknown])",DECITABINE [DECITABINE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006014535&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006018802,Spontaneous,2020-05-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Hyperkalaemia (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Multiple organ dysfunction syndrome (2d - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Renal failure (2d - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Tumour lysis syndrome (2d - Fatal - Results in Death, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - 100mg - Oral]),<BR><BR>[VENETOCLAX] (S - n/a - Not applicable - [n/a - 200mg - Oral])","[FLUCONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[PIPERACILLIN SODIUM, TAZOBACTAM SODIUM, PIPERACILLIN, TAZOBACTAM] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[TRANEXAMIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006018802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006007978,Spontaneous,2020-05-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bone marrow failure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Subcutaneous]),"[RED BLOOD CELLS] (C - Product used for unknown indication - n/a - [n/a - n/a - Intravenous drip]),<BR><BR>[RED BLOOD CELLS] (C - n/a - n/a - [n/a - n/a - Intravenous drip]),<BR><BR>[STERILE WATER] (C - Chemotherapy - n/a - [n/a - 4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006007978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006009041,Spontaneous,2020-05-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abscess limb (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Febrile neutropenia (10d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Infective myositis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Staphylococcal abscess (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",VIDAZA 25 MG/ML POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [117d - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006009041&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006011057,Spontaneous,2020-05-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Chronic obstructive pulmonary disease (n/a - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 100mg - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006011057&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10006011500,Spontaneous,2020-05-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Acute myeloid leukaemia (n/a - Unknown - ),"VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Unknown])",[ALFUZOSIN HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10006011500&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005998347,Spontaneous,2020-05-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Bone marrow failure (n/a - Unknown - Caused/Prolonged Hospitalisation),"VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - 100mg - Subcutaneous])",[STERILE WATER] (C - Myelodysplastic syndrome - n/a - [n/a - 4mL - Subcutaneous]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005998347&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005999216,Spontaneous,2020-05-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Influenza like illness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Disabling)","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 10mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 149mg - Subcutaneous])","[ACETYLSALICYLIC ACID, ASPIRIN BP] (C - Product used for unknown indication - n/a - [n/a - 81mg - Unknown]),<BR><BR>[DIAZEPAM] (C - Anxiety - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIAZEPAM] (C - Product used for unknown indication - n/a - [n/a - 5mg - Unknown]),<BR><BR>[GABAPENTIN] (C - Product used for unknown indication - n/a - [n/a - 100mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005999216&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005987199,Spontaneous,2020-05-12 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dysuria (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Proctalgia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Urinary retention (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","VENCLYXTO [VENETOCLAX] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 150mg - Intravenous drip]),<BR><BR>[AMPHOTERICIN B, AMPHOTERICINE B, LIPOSOME] (S - Antifungal prophylaxis - Drug withdrawn - [n/a - 150mg - Intravenous drip]),<BR><BR>[BUPRENORPHINE HYDROCHLORIDE] (S - Drug dependence - Drug withdrawn - [n/a - 2mg - Oral]),<BR><BR>[MIANSERIN HYDROCHLORIDE] (S - Depression - Dose not changed - [n/a - 20mg - Oral]),<BR><BR>[TRAMADOL HYDROCHLORIDE] (S - Product used for unknown indication - Drug withdrawn - [n/a - 20[drp] - Oral])","[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - Dose not changed - [n/a - 800mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005987199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005991810,Spontaneous,2020-05-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cellulitis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Renal mass (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 75mg/m2 - Subcutaneous]),"GRASTOFIL [FILGRASTIM] (C - Neutropenia - n/a - [n/a - 300ug - Subcutaneous]),<BR><BR>GRASTOFIL [FILGRASTIM] (C - Prophylaxis - n/a - [n/a - 300ug - Subcutaneous]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - Acute myeloid leukaemia - n/a - [n/a - 100mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - n/a - n/a - [n/a - 200mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - n/a - n/a - [n/a - 400mg - Oral]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [n/a - 300mg - Oral]),<BR><BR>[ANHYDROUS LIDOCAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE, EPINEPHRINE, LIDOCAINE HYDROCHLORIDE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE MONOHYDRATE] (C - Anaesthesia - n/a - [n/a - 2% - Subcutaneous]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [17y - 5mg - Oral]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [17y - 2.5mg - Oral]),<BR><BR>[CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE, COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteoporosis - n/a - [n/a - 500mg - Oral]),<BR><BR>[CASSIA, CASSIA SENNA WHOLE, HYDROXYANTHRACENE GLYCOSIDES, SENNA PODS, SENNOSIDE B, SENNOSIDES] (C - Constipation prophylaxis - n/a - [n/a - 8.6mg - Oral]),<BR><BR>[CEFALEXIN, CEFALEXIN MONOHYDRATE] (C - Cellulitis - n/a - [n/a - 500mg - Oral]),<BR><BR>[CEFTRIAXONE, CEFTRIAXONE SODIUM] (C - Cellulitis - n/a - [n/a - 1g - Intravenous drip]),<BR><BR>[DIMENHYDRINATE] (C - Nausea - n/a - [18d - 50mg - Oral]),<BR><BR>[DIMENHYDRINATE] (C - Vomiting - n/a - [18d - 50mg - Oral]),<BR><BR>[DOCUSATE SODIUM] (C - Constipation prophylaxis - n/a - [6d - 100mg - Oral]),<BR><BR>[DOCUSATE SODIUM] (C - n/a - n/a - [6d - 100mg - Oral]),<BR><BR>[FUROSEMIDE] (C - Hypertension - n/a - [44d - 40mg - Oral]),<BR><BR>[FUROSEMIDE] (C - Oedema peripheral - n/a - [44d - 20mg - Intravenous drip]),<BR><BR>[FUROSEMIDE] (C - Prophylaxis - n/a - [44d - 20mg - Oral]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [44d - 20mg - Oral]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [44d - 40mg - Intravenous drip]),<BR><BR>[GLICLAZIDE] (C - Diabetes mellitus - n/a - [n/a - 60mg - Oral]),<BR><BR>[MAGNESIUM SULFATE] (C - Hypomagnesaemia - n/a - [n/a - 2g - Intravenous drip]),<BR><BR>[MAGNESIUM SULFATE] (C - n/a - n/a - [n/a - 2g - Intravenous drip]),<BR><BR>[MAGNESIUM SULFATE] (C - n/a - n/a - [n/a - 500mg - Oral]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - 1g - Oral]),<BR><BR>[ONDANSETRON] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 8mg - Oral]),<BR><BR>[PARACETAMOL] (C - Pelvic fracture - n/a - [n/a - n/a - Oral]),<BR><BR>[POTASSIUM CHLORIDE] (C - Hypokalaemia - n/a - [16d - 20meq - Oral]),<BR><BR>[POTASSIUM CHLORIDE] (C - Prophylaxis - n/a - [16d - 20meq - Oral]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Hypercholesterolaemia - n/a - [n/a - 20mg - Oral]),<BR><BR>[VITAMIN D] (C - Osteoporosis - n/a - [n/a - 1000[iU] - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005991810&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005992407,Spontaneous,2020-05-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Full blood count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Haematotoxicity (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Iron overload (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Neuropathy peripheral (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Neutropenia (n/a - Unknown - Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),<BR><BR>[THALIDOMIDE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005992407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005976456,Spontaneous,2020-05-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pericardial effusion (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pleural effusion (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Wheezing (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Subcutaneous]),"CYTARABINE [CYTARABINE] (C - Product used for unknown indication - n/a - [n/a - .2g - Intravenous drip]),<BR><BR>[ETORICOXIB] (C - Pain - n/a - [n/a - 60mg - Oral]),<BR><BR>[FLURBIPROFEN, FLURBIPROFEN PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - 40mg - Topical]),<BR><BR>[PIPERACILLIN, TAZOBACTAM] (C - Pneumonia - n/a - [n/a - 4.5g - Intravenous drip]),<BR><BR>[STERILE WATER] (C - Solvent sensitivity - n/a - [n/a - 4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005976456&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005979020,Spontaneous,2020-05-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Acute myeloid leukaemia refractory (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 75mg/m2 - Unknown]),"EPOETIN ALFA [EPOETIN ALFA] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CALCIUM FOLINATE, FOLINIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RAMIPRIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005979020&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005968065,Spontaneous,2020-05-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Acute myeloid leukaemia recurrent (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),"LEVOFLOXACIN [LEVOFLOXACIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[OMEPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005968065&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005958358,Spontaneous,2020-05-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Acute myeloid leukaemia recurrent (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bacterial infection (10d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fall (1d - Recovered/Resolved - ),<BR><BR>Hepatic enzyme increased (n/a - Recovered/Resolved - ),<BR><BR>Hepatic failure (n/a - Unknown - Other Medically Important Condition),<BR><BR>Infection (n/a - Unknown - ),<BR><BR>Renal failure (n/a - Unknown - Other Medically Important Condition)","CYTARABINE [CYTARABINE] (S - Acute myeloid leukaemia, Fms-like tyrosine kinase 3 positive - Unknown - [n/a - n/a - Unknown]),<BR><BR>GILTERITINIB [GILTERITINIB] (S - Acute myeloid leukaemia, Fms-like tyrosine kinase 3 positive - Dose not changed - [35d - 40mg - Oral]),<BR><BR>RYDAPT [MIDOSTAURIN] (S - Acute myeloid leukaemia, Fms-like tyrosine kinase 3 positive - Unknown - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia, Fms-like tyrosine kinase 3 positive - Unknown - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005958358&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005959860,Spontaneous,2020-05-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bacterial infection (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 100mg - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005959860&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005950663,Spontaneous,2020-05-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Myocardial infarction (n/a - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 100mg - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005950663&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005921300,Spontaneous,2020-04-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Neutropenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 35mg/m2 - Subcutaneous]),"[ALPRAZOLAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[NICARDIPINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005921300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005917779,Spontaneous,2020-04-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cytopenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disease progression (n/a - Unknown - Other Medically Important Condition),<BR><BR>Febrile neutropenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Septic shock (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Subcutaneous]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B, AMPHOTERICINE B, LIPOSOME] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LINEZOLID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM, POTASSIUM CHLORIDE, POTASSIUM GLYCEROPHOSPHATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM HYDROGEN TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005917779&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005905013,Spontaneous,2020-04-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Cardiac disorder (n/a - Fatal - Results in Death),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005905013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005888961,Spontaneous,2020-04-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Rash (n/a - Recovering/Resolving - ),VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005888961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005891989,Spontaneous,2020-04-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Application site discolouration (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Application site pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Infection (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Platelet count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Red blood cell count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>White blood cell count decreased (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 140mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005891989&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005882139,Spontaneous,2020-04-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Erythema nodosum (n/a - Not Recovered/Not Resolved - ),"VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005882139&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005885566,Spontaneous,2020-04-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site erythema (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Injection site mass (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Injection site pain (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pancytopenia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 150mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 75mg/m2 - Subcutaneous])","VENETOCLAX [VENETOCLAX] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Oral]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - Product used for unknown indication - n/a - [n/a - 10mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005885566&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005877048,Spontaneous,2020-04-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Application site burn (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Application site pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Application site reaction (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Blood count abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Immune system disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Red blood cell count decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 200mg - Unknown]),"[ERYTHROPOIETIN] (C - Red blood cell count decreased - n/a - [n/a - n/a - Subcutaneous]),<BR><BR>[ERYTHROPOIETIN] (C - Red blood cell count decreased - n/a - [n/a - n/a - n/a]),<BR><BR>[FILGRASTIM] (C - Immune system disorder - n/a - [n/a - n/a - Subcutaneous]),<BR><BR>[FILGRASTIM] (C - n/a - n/a - [n/a - n/a - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005877048&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005878548,Spontaneous,2020-04-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Application site mass (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Bedridden (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cardiac disorder (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Eating disorder (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Haemoglobin decreased (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lung disorder (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Oesophageal disorder (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Respiratory tract infection fungal (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Urinary tract disorder (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 8mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005878548&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005862217,Spontaneous,2020-04-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Central nervous system infection (n/a - Fatal - Results in Death),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005862217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005864490,Spontaneous,2020-04-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac arrest (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Leukocytosis (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Myelodysplastic syndrome (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Renal failure (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Unknown]),DECITABINE [DECITABINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005864490&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005866056,Spontaneous,2020-04-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Cardiac failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005866056&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005857167,Spontaneous,2020-04-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site erythema (n/a - Unknown - ),<BR><BR>Injection site extravasation (n/a - Unknown - ),<BR><BR>Injection site reaction (n/a - Unknown - ),<BR><BR>Injection site warmth (n/a - Unknown - )",VIDAZA [AZACITIDINE] (S - Acute myelomonocytic leukaemia - Unknown - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005857167&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005857365,Spontaneous,2020-04-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Febrile neutropenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 75mg/m2 - Subcutaneous]),"[ALPRAZOLAM] (C - Insomnia - n/a - [n/a - 1mg - Oral]),<BR><BR>[CALCIUM CARBONATE] (C - Osteoporosis - n/a - [n/a - 500mg - Oral]),<BR><BR>[FILGRASTIM] (C - Prophylaxis - n/a - [n/a - 300mg - Subcutaneous]),<BR><BR>[IBANDRONIC ACID] (C - Osteoporosis - n/a - [n/a - 150mg - Oral]),<BR><BR>[METOPROLOL SUCCINATE] (C - Hypertension - n/a - [n/a - 12.5mg - Oral]),<BR><BR>[PRACINOSTAT] (C - Acute myeloid leukaemia - n/a - [n/a - 60mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005857365&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005858129,Spontaneous,2020-04-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Feeding disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>General physical health deterioration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005858129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005848826,Spontaneous,2020-04-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute myeloid leukaemia (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition),<BR><BR>Asthenia (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition),<BR><BR>Fall (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition),<BR><BR>Pulmonary haemorrhage (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition),<BR><BR>Rib fracture (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Acute leukaemia - Drug withdrawn - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous])",VENETOCLAX [VENETOCLAX] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005848826&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005848828,Spontaneous,2020-04-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute leukaemia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Anaemia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Endocarditis (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","DECITABINE [DECITABINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 75mg/m2 - Subcutaneous])","ANTIHYPERTENSIVES [NOT AVAILABLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>TRANSFUSION [NOT AVAILABLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Intravenous drip])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005848828&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005851546,Spontaneous,2020-04-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Treatment failure (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 100mg - Unknown]),"JANUVIA [SITAGLIPTIN, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ANHYDROUS CALCIFEDIOL, CALCIFEDIOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CALCIUM CARBONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GLIMEPIRIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROXYCARBAMIDE] (C - Blast cells - n/a - [n/a - n/a - Oral]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005851546&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005836759,Spontaneous,2020-04-13 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Blood creatinine increased (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 25mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005836759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005839206,Spontaneous,2020-04-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Acute myeloid leukaemia (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005839206&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005828183,Spontaneous,2020-04-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diffuse alveolar damage (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary alveolar haemorrhage (n/a - Recovering/Resolving - Results in Death, Caused/Prolonged Hospitalisation)","CLADRIBINE [CLADRIBINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>CYTARABINE [CYTARABINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>LITAK [CLADRIBINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>MYCOPHENOLATE MOFETIL [MYCOPHENOLATE MOFETIL] (S - Prophylaxis against graft versus host disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (S - Product used for unknown indication - Not applicable - [n/a - 100mg - Unknown]),<BR><BR>THIOTEPA [THIOTEPA] (S - Bone marrow conditioning regimen - Not applicable - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 30mg/m2 - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Graft versus host disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[BUSULFAN] (S - Bone marrow conditioning regimen - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN A] (S - Prophylaxis against graft versus host disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE MONOHYDRATE] (S - Prophylaxis against graft versus host disease - Not applicable - [n/a - 50mg/kg - Unknown]),<BR><BR>[CYTARABINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[CYTARABINE] (S - n/a - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[DAUNORUBICIN, DAUNORUBICIN HYDROCHLORIDE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[DAUNORUBICIN, DAUNORUBICIN HYDROCHLORIDE] (S - n/a - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[FLUDARABINE] (S - Bone marrow conditioning regimen - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (S - Prophylaxis against graft versus host disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[IDARUBICIN] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE HEMISUCCINATE] (S - Product used for unknown indication - Not applicable - [n/a - 500mg - Intravenous (not otherwise specified)]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE HEMISUCCINATE] (S - n/a - Not applicable - [n/a - 125mg - Intravenous (not otherwise specified)]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE HEMISUCCINATE] (S - n/a - Not applicable - [n/a - 250mg - Intravenous (not otherwise specified)]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE HEMISUCCINATE] (S - n/a - Not applicable - [n/a - 80mg - Intravenous (not otherwise specified)])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - Product used for unknown indication - n/a - [n/a - 5mg - Unknown]),<BR><BR>[BISOPROLOL FUMARATE, BISOPROLOL FUMARATE, ACETYLSALICYLIC ACID, BISOPROLOL HEMIFUMARATE] (C - Product used for unknown indication - n/a - [n/a - 2.5mg - Unknown]),<BR><BR>[BUTYLSCOPOLAMINE, HYOSCINE BUTYLBROMIDE] (C - Product used for unknown indication - n/a - [n/a - 1{DF} - Unknown]),<BR><BR>[CICLOSPORIN] (C - Product used for unknown indication - n/a - [n/a - 25mg - Unknown]),<BR><BR>[COLECALCIFEROL] (C - Product used for unknown indication - n/a - [n/a - 1.5mL - Unknown]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE, ESOMEPRAZOLE SODIUM] (C - Product used for unknown indication - n/a - [n/a - 20mg - Unknown]),<BR><BR>[LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM ASPARTATE HYDROCHLORIDE, MAGNESIUM L-ASPARTATE HYDROCHLORIDE TRIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - 10mmol - Unknown]),<BR><BR>[PERINDOPRIL ARGININE] (C - Product used for unknown indication - n/a - [n/a - 2.5mg - Unknown]),<BR><BR>[PREDNISOLONE ACETATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - .4mg - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 500mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005828183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005830608,Spontaneous,2020-04-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Hepatitis B surface antibody positive (n/a - Unknown - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - 100mg - Intravenous drip])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005830608&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005830744,Spontaneous,2020-04-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diffuse alveolar damage (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary alveolar haemorrhage (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","MYCOPHENOLATE MOFETIL [MYCOPHENOLATE MOFETIL] (S - Prophylaxis against graft versus host disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>NOXAFIL [POSACONAZOLE] (S - Product used for unknown indication - Not applicable - [n/a - 100mg - Unknown]),<BR><BR>THIOTEPA [THIOTEPA] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia, Prophylaxis against graft versus host disease - Not applicable - [5d - 30mg/m2 - Subcutaneous - More in ICSR]),<BR><BR>[BUSULFAN] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN] (S - Prophylaxis against graft versus host disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[CYCLOPHOSPHAMIDE] (S - Prophylaxis against graft versus host disease - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[FLUDARABINE] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (S - Prophylaxis against graft versus host disease - Not applicable - [n/a - n/a - Unknown])","ETANERCEPT [ETANERCEPT] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - Product used for unknown indication - Not applicable - [n/a - 5mg - Unknown]),<BR><BR>[BISOPROLOL FUMARATE, BISOPROLOL FUMARATE, ACETYLSALICYLIC ACID, BISOPROLOL HEMIFUMARATE] (C - Product used for unknown indication - Not applicable - [n/a - 2.5mg - Unknown]),<BR><BR>[BUTYLSCOPOLAMINE, HYOSCINE BUTYLBROMIDE] (C - Product used for unknown indication - Not applicable - [n/a - 1{DF} - Unknown]),<BR><BR>[CICLOSPORIN] (C - Product used for unknown indication - Not applicable - [n/a - 25mg - Unknown]),<BR><BR>[COLECALCIFEROL] (C - Product used for unknown indication - Not applicable - [n/a - 1.5mL - Unknown]),<BR><BR>[ESOMEPRAZOLE MAGNESIUM] (C - Product used for unknown indication - Not applicable - [n/a - 20mg - Unknown]),<BR><BR>[LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE HYDROCHLORIDE] (C - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM ASPARTATE HYDROCHLORIDE, MAGNESIUM L-ASPARTATE HYDROCHLORIDE TRIHYDRATE] (C - Product used for unknown indication - Not applicable - [n/a - 10mmol - Unknown]),<BR><BR>[PERINDOPRIL ARGININE] (C - Product used for unknown indication - Not applicable - [n/a - 2.5mg - Unknown]),<BR><BR>[PERINDOPRIL ARGININE] (C - n/a - n/a - [n/a - .5{DF} - Unknown]),<BR><BR>[PREDNISOLONE ACETATE] (C - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - Not applicable - [n/a - 1600mg - Unknown]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - Product used for unknown indication - Not applicable - [n/a - .4mg - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - Not applicable - [n/a - 500mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005830744&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005818132,Spontaneous,2020-04-09 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pyoderma gangrenosum (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Intravenous (not otherwise specified)]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005818132&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005822601,Spontaneous,2020-04-09 00:00:00,Healthcare Professional,Non European Economic Area,Momoki M. The Case of Myelodysplastic Syndrome which Repeated Severe Infection by Aeromonas Hydrophila. The 658th Kanto Regional Meeting of the Japanese Society of Internal Medicine.,65-85 Years,Not Specified,No,Female,"Cellulitis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Liver abscess (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Necrotising fasciitis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Septic shock (n/a - Recovering/Resolving - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005822601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005825377,Spontaneous,2020-04-09 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Diarrhoea (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005825377&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005810065,Spontaneous,2020-04-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cellulitis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 134mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005810065&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005811343,Spontaneous,2020-04-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Apallic syndrome (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Cerebral haemorrhage (n/a - Unknown - Disabling, Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005811343&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005816492,Spontaneous,2020-04-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Brain neoplasm (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Cerebral haemorrhage (n/a - Fatal - Results in Death, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005816492&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005801551,Spontaneous,2020-04-07 00:00:00,Healthcare Professional,Non European Economic Area,"Tibes R, Kosiorek H, Dueck A, Palmer J, Slack J, Bogenberger J. A final report of the phase I/Ib study of the smoothened/ hedgehog pathway inhibitor sonidegib combined with azacitidine in relapsed or refractory aml and mds patients. Oncology Research and Treatment. 2020 FEB 01;217-217.",Not Specified,Not Specified,No,Not Specified,Fatigue (n/a - Unknown - Other Medically Important Condition),"SONIDEGIB [SONIDEGIB] (S - Acute myeloid leukaemia - Unknown - [n/a - 200mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 75mg/m2 - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005801551&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005803355,Spontaneous,2020-04-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Liver disorder (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neutropenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pancytopenia (n/a - Recovered/Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005803355&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005795344,Spontaneous,2020-04-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Pancytopenia (n/a - Unknown - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 100mg - Subcutaneous]),"[RED BLOOD CELLS] (C - Myelodysplastic syndrome - n/a - [n/a - 1.5[iU] - Unknown]),<BR><BR>[STERILE WATER] (C - Water loading test - n/a - [n/a - 4mL - Subcutaneous])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005795344&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005789575,Spontaneous,2020-04-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bone marrow failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005789575&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005783169,Spontaneous,2020-04-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Application site bruise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Injection site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Injection site swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Skin lesion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Transformation to acute myeloid leukaemia (n/a - Unknown - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 134mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - n/a - Intravenous drip])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005783169&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005777958,Spontaneous,2020-04-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute myeloid leukaemia (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Febrile neutropenia (11d - Recovered/Resolved - Results in Death, Caused/Prolonged Hospitalisation)","GLASDEGIB [GLASDEGIB] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 100mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 112.1mg/m2 - Subcutaneous])","CASPOFUNGIN ACETATE [CASPOFUNGIN ACETATE] (C - Infection prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Anal abscess - n/a - [n/a - n/a - Unknown]),<BR><BR>INSULIN GLARGINE [INSULIN GLARGINE] (C - Diabetes mellitus - n/a - [n/a - n/a - Unknown]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Infection prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>LINAGLIPTIN [LINAGLIPTIN] (C - Diabetes mellitus - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Infection prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACARBOSE] (C - Diabetes mellitus - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - n/a - Unknown]),<BR><BR>[ATOVAQUONE] (C - Infection prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE] (C - Multiple organ dysfunction syndrome - n/a - [n/a - n/a - Unknown]),<BR><BR>[CHLORPHENAMINE MALEATE] (C - Allergy prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIGOXIN] (C - Multiple organ dysfunction syndrome - n/a - [n/a - n/a - Unknown]),<BR><BR>[ESOMEPRAZOLE MAGNESIUM] (C - Gastritis prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[FUROSEMIDE] (C - Oedema peripheral - n/a - [n/a - n/a - Unknown]),<BR><BR>[HEPARINOID] (C - Dry skin - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROCORTISONE SODIUM SUCCINATE] (C - Tumour associated fever - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROXYANTHRACENE GLYCOSIDES, SENNOSIDES] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[ICOSAPENT ETHYL] (C - Dyslipidaemia - n/a - [n/a - n/a - Unknown]),<BR><BR>[LANDIOLOL HYDROCHLORIDE] (C - Multiple organ dysfunction syndrome - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[MEROPENEM, MEROPENEM ANHYDROUS] (C - Infection prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - Unknown]),<BR><BR>[MORPHINE SULFATE] (C - Anal abscess - n/a - [n/a - n/a - Unknown]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Anal abscess - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTETHINE] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Tumour associated fever - n/a - [n/a - n/a - Unknown]),<BR><BR>[TEICOPLANIN] (C - Anal abscess - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005777958&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005778606,Spontaneous,2020-04-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Disease progression (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Haematocrit decreased (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pancytopenia (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>White blood cell count decreased (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","DECITABINE [DECITABINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 100mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Not applicable - [n/a - n/a - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005778606&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005771255,Spontaneous,2020-04-01 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Blood creatinine increased (n/a - Unknown - ),<BR><BR>Iron overload (n/a - Not Recovered/Not Resolved - )","EXJADE [DEFERASIROX] (S - Myelodysplastic syndrome - Dose reduced - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005771255&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005763835,Spontaneous,2020-03-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Application site erythema (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005763835&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005746873,Spontaneous,2020-03-27 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Neutrophil count decreased (22d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (24d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (8d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","DULAGLUTIDE [DULAGLUTIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CANDESARTAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLEMASTINE, CLEMASTINE FUMARATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL SUCCINATE, METOPROLOL SUCCINATE (PH. EUR.)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PREDNISOLONE HYDROGEN SUCCINATE, PREDNISOLONE SODIUM SUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RAMIPRIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM POLYSTYRENE SULPHONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TORASEMIDE, TORASEMIDE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005746873&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005748218,Spontaneous,2020-03-27 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Neutrophil count decreased (6d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (100d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 2.5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - n/a - Drug withdrawn - [n/a - 2.5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown])","NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>TAMIFLU [OSELTAMIVIR, OSELTAMIVIR PHOSPHATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN TRIHYDRATE, POTASSIUM CLAVULANATE, AMOXICILLIN, CLAVULANIC ACID, AMOXICILLIN, POTASSIUM CLAVULANATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIHYDROCODEINE HYDRORHODANIDE, DIHYDROCODEINE THIOCYANATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM POLYSTYRENE SULPHONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005748218&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005739513,Spontaneous,2020-03-26 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Anaemia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>White blood cell count decreased (n/a - Not Recovered/Not Resolved - )","REVLIMID [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","CASPOFUNGIN [CASPOFUNGIN, CASPOFUNGIN ACETATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>LEVETIRACETAM [LEVETIRACETAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CANDESARTAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN A] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLARITHROMYCIN, CLARITHROMYCIN LACTOBIONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DEXAMETHASONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[IPRATROPIUM, IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE ANHYDROUS, IPRATROPIUM BROMIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LINEZOLID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MEROPENEM, MEROPENEM ANHYDROUS, MEROPENEM TRIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MORPHINE, MORPHINE HYDROCHLORIDE, MORPHINE SULFATE, MORPHINE SULFATE PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[NEBIVOLOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TERBUTALINE SULFATE, TERBUTALINE SULFATE PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TORASEMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005739513&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005739582,Spontaneous,2020-03-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Hyponatraemia (n/a - Unknown - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Inappropriate antidiuretic hormone secretion (n/a - Not Recovered/Not Resolved - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Sepsis (60d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005739582&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005732185,Spontaneous,2020-03-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Febrile neutropenia (9d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 100mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Drug withdrawn - [n/a - 200mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Drug withdrawn - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Intravenous drip])","LEUCOCYTES [LEUCOCYTES] (C - Diarrhoea - n/a - [n/a - n/a - Oral]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Infection prophylaxis - n/a - [n/a - 500mg - Oral]),<BR><BR>LIDOCAINE, PRILOCAINE [LIDOCAINE, PRILOCAINE] (C - Pain - n/a - [n/a - 2.5% - Topical]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Antiviral prophylaxis - n/a - [n/a - 800mg - Oral]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [n/a - 300mg - Oral]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - 5mg - Oral]),<BR><BR>[ASCORBIC ACID] (C - Cataract - n/a - [n/a - n/a - Ophthalmic]),<BR><BR>[ASCORBIC ACID] (C - Glaucoma - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Dyslipidaemia - n/a - [n/a - 80mg - Oral]),<BR><BR>[CLOTRIMAZOLE] (C - Candida infection - n/a - [n/a - 10mg - Sublingual]),<BR><BR>[COD-LIVER OIL] (C - Supplementation therapy - n/a - [n/a - 1000mg - Oral]),<BR><BR>[COLECALCIFEROL] (C - Supplementation therapy - n/a - [n/a - n/a - Oral]),<BR><BR>[MEGESTROL ACETATE] (C - Decreased appetite - n/a - [n/a - 5mL - Oral]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - 12.5mg - Oral]),<BR><BR>[SODIUM CHLORIDE] (C - Prophylaxis - n/a - [n/a - 1000mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 1000mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 500mL - Intravenous drip])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005732185&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005734584,Spontaneous,2020-03-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Leukopenia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytopenia (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 100mg - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005734584&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005734585,Spontaneous,2020-03-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Leukaemia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 100mg - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005734585&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005734856,Spontaneous,2020-03-25 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Neutrophil count decreased (n/a - Not Recovered/Not Resolved - ),"REVLIMID [LENALIDOMIDE] (S - Product used for unknown indication - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - n/a - Dose not changed - [n/a - 2.5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose reduced - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose reduced - [n/a - n/a - Unknown])","CARBIDOPA, LEVODOPA [CARBIDOPA, LEVODOPA] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VFEND [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BROMAZEPAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN A] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM HYDROGEN CARBONATE, CITRIC ACID ANHYDROUS, POTASSIUM CITRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[PRAMIPEXOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[QUETIAPINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TORASEMIDE, TORASEMIDE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ZOPICLONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005734856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005726956,Spontaneous,2020-03-24 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Neutrophil count decreased (36d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (3d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALIZAPRIDE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALIZAPRIDE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BECLOMETASONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOBETASOL PROPIONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[DEXAMETHASONE PHOSPHATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Ophthalmic]),<BR><BR>[FLUCONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HEPARIN, HEPARIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROMORPHONE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005726956&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005729918,Spontaneous,2020-03-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pleural effusion (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - HIV infection - Unknown - [n/a - n/a - Oral]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005729918&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005717794,Spontaneous,2020-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Takeuchi A. An Autopsy Case of Myelodysplastic Syndrome (MDS) Which was Suspected to be Associated with Progressive Multifocal Leukoencephalopathy (PML). The 219th Tohoku Regional Meeting of the Japanese Society of Internal Medicine..,18-64 Years,Not Specified,No,Female,"Altered state of consciousness (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Disseminated intravascular coagulation (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Multiple organ dysfunction syndrome (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Progressive multifocal leukoencephalopathy (n/a - Unknown - Results in Death, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 120mg - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005717794&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005713942,Spontaneous,2020-03-21 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Neutrophil count decreased (13d - Recovered/Resolved - ),<BR><BR>Upper respiratory tract infection (5d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (2d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - n/a - Dose not changed - [n/a - 2.5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","LETERMOVIR [LETERMOVIR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN, CLAVULANIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN, CLAVULANIC ACID] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HUMAN PLATELET, ALLOGENIC] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METAMIZOLE SODIUM, METAMIZOLE SODIUM MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RED BLOOD CELLS] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005713942&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005706802,Spontaneous,2020-03-20 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Neutrophil count decreased (42d - Recovered/Resolved - ),"REVLIMID [LENALIDOMIDE] (S - Product used for unknown indication - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - n/a - Dose not changed - [n/a - 2.5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Unknown])","CARBIDOPA, LEVODOPA [CARBIDOPA, LEVODOPA] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VFEND [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[BROMAZEPAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CICLOSPORIN A] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM, POTASSIUM CHLORIDE, POTASSIUM GLYCEROPHOSPHATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM HYDROGEN TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[PRAMIPEXOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[QUETIAPINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TORASEMIDE, TORASEMIDE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ZOPICLONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005706802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005708290,Spontaneous,2020-03-20 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Anaemia (3d - Recovered/Resolved - ),"REVLIMID [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","ERTAPENEM [ERTAPENEM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>POSACONAZOLE [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>PROTOPIC [TACROLIMUS, TACROLIMUS MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, CALCIUM, COLECALCIFEROL, CALCIUM CARBONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LINEZOLID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MEROPENEM, MEROPENEM ANHYDROUS] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PENTAMIDINE ISETIONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Respiratory (inhalation)]),<BR><BR>[PIPERACILLIN, TAZOBACTAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [204d - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [204d - n/a - Unknown]),<BR><BR>[TORASEMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALSARTAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005708290&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005709188,Spontaneous,2020-03-20 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Anaemia (n/a - Recovered/Resolved - ),<BR><BR>Blood bilirubin increased (n/a - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (n/a - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Product used for unknown indication - Dose reduced - [n/a - 5mg - Oral]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - n/a - Dose reduced - [n/a - 2.5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Unknown])","LETERMOVIR [LETERMOVIR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN, CLAVULANIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN, CLAVULANIC ACID] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METAMIZOLE SODIUM, METAMIZOLE SODIUM MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005709188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005710953,Spontaneous,2020-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Results in Death),<BR><BR>Septic shock (n/a - Fatal - Results in Death)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005710953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005699782,Spontaneous,2020-03-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Acute myeloid leukaemia recurrent (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005699782&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005702516,Spontaneous,2020-03-19 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Graft versus host disease in eye (223d - Recovered/Resolved - ),<BR><BR>Graft versus host disease in skin (447d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Product used for unknown indication - Unknown - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Unknown])","ERTAPENEM [ERTAPENEM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>POSACONAZOLE [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>PROTOPIC [TACROLIMUS, TACROLIMUS MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LINEZOLID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MEROPENEM, MEROPENEM ANHYDROUS] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE ACEPONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PENTAMIDINE ISETIONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PIPERACILLIN, TAZOBACTAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [204d - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [204d - n/a - Unknown]),<BR><BR>[TORASEMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALSARTAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005702516&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005702653,Spontaneous,2020-03-19 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Neutrophil count decreased (46d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (12d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Product used for unknown indication - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Unknown])","[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005702653&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005702714,Spontaneous,2020-03-19 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Constipation (18d - Recovered/Resolved - ),<BR><BR>Fungal infection (21d - Recovered/Resolved - ),<BR><BR>Neutrophil count decreased (14d - Recovered/Resolved - ),<BR><BR>Platelet count decreased (10d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (21d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (42d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown])","NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMPHOTERICIN B] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FLUCONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PAROXETINE, PAROXETINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005702714&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005687547,Spontaneous,2020-03-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pneumonitis (21d - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myeloid leukaemia - Dose reduced - [n/a - 135mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005687547&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005693306,Spontaneous,2020-03-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Myelofibrosis (n/a - Unknown - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Unknown - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005693306&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005695683,Spontaneous,2020-03-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Haemorrhoid infection (54d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pancytopenia (51d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",VIDAZA 25 MG/ML POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [5d - 116mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005695683&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005674392,Spontaneous,2020-03-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Febrile bone marrow aplasia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Tooth abscess (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","VENCLYXTO [VENETOCLAX] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 75mg/m2 - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005674392&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005678323,Spontaneous,2020-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Sepsis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Intravenous (not otherwise specified)]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005678323&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005679477,Spontaneous,2020-03-17 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Neutrophil count decreased (49d - Recovered/Resolved - ),<BR><BR>White blood cell count decreased (14d - Recovered/Resolved - )","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 5mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR.] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALIZAPRIDE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALIZAPRIDE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Unknown]),<BR><BR>[BECLOMETASONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOBETASOL PROPIONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Topical]),<BR><BR>[DEXAMETHASONE PHOSPHATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[FLUCONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HEPARIN, HEPARIN SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROMORPHONE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM HEMISUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005679477&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005665348,Spontaneous,2020-03-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute myeloid leukaemia refractory (n/a - Unknown - ),<BR><BR>Drug ineffective (n/a - Unknown - )",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),"HYDROXYCARBAMIDE [HYDROXYCARBAMIDE] (C - Leukocytosis - n/a - [n/a - n/a - Unknown]),<BR><BR>MERCAPTOPURINE [MERCAPTOPURINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>POSACONAZOLE [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROXYCARBAMIDE] (C - Leukocytosis - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TIMOLOL MALEATE, HYDROCHLOROTHIAZIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005665348&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005670170,Spontaneous,2020-03-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blast cell count decreased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Blood lactate dehydrogenase increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Capillary leak syndrome (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Coagulopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cytokine release syndrome (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Differentiation syndrome (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pleural effusion (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Weight increased (n/a - Unknown - Other Medically Important Condition)","VENCLYXTO [VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 100mg - Oral]),<BR><BR>VENCLYXTO [VENETOCLAX] (S - n/a - Dose not changed - [n/a - 200mg - Oral]),<BR><BR>VENCLYXTO [VENETOCLAX] (S - n/a - Dose not changed - [n/a - 300mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown])","MICAFUNGIN [MICAFUNGIN] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>POSACONAZOLE [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005670170&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005671776,Spontaneous,2020-03-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Erythema (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Skin exfoliation (n/a - Unknown - )",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005671776&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005655592,Spontaneous,2020-03-13 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Acute myeloid leukaemia (n/a - Unknown - ),<BR><BR>Treatment failure (n/a - Unknown - )",VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),"[HYDROXYCARBAMIDE] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCARBAMIDE] (C - Leukostasis syndrome - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - 100mg - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 100mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005655592&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005658206,Spontaneous,2020-03-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Respiratory syncytial virus infection (n/a - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown]),"[ACICLOVIR, ACICLOVIR SODIUM] (C - Infection prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[FLUCONAZOLE] (C - Infection prophylaxis - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005658206&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005658553,Spontaneous,2020-03-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Left ventricular dysfunction (n/a - Recovered/Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 138mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005658553&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005660723,Spontaneous,2020-03-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pelvic mass (n/a - Unknown - Results in Death),<BR><BR>Sudden death (n/a - Fatal - Results in Death)","REVLIMID [LENALIDOMIDE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 10mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 100mg - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005660723&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005645865,Spontaneous,2020-03-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Neutropenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose reduced - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005645865&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005646125,Spontaneous,2020-03-12 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Febrile bone marrow aplasia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","VENCLYXTO [VENETOCLAX] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 75mg/m2 - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005646125&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005638068,Spontaneous,2020-03-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Osteonecrosis (n/a - Recovering/Resolving - ),VIDAZA 25 MG/ML POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - n/a - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005638068&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005643997,Spontaneous,2020-03-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Nausea (n/a - Unknown - ),<BR><BR>Neutropenia (2d - Recovered/Resolved - )",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 100mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005643997&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005634410,Spontaneous,2020-03-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,Neoplasm progression (n/a - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005634410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005634416,Spontaneous,2020-03-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Nausea (0d - Recovered/Resolved - Results in Death),<BR><BR>Neoplasm progression (n/a - Fatal - Results in Death)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Not applicable - [n/a - 100mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005634416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005629366,Spontaneous,2020-03-09 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Acute myeloid leukaemia refractory (n/a - Unknown - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Subcutaneous]),"[ACETYLSALICYLIC ACID, ASPIRIN BP] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[OMEPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005629366&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005612686,Spontaneous,2020-03-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abscess (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Cholecystitis acute (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Colitis (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Escherichia sepsis (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Febrile neutropenia (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Pneumonitis (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Pulmonary oedema (n/a - Recovering/Resolving - Life Threatening)",VIDAZA 25 MG/ML POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005612686&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005619041,Spontaneous,2020-03-06 00:00:00,Healthcare Professional,Non European Economic Area,Karimata K. A case of Successful cord blood transplantation with ST combination for MDScomplicated with disseminated Stenotrophomonas Maltophilia infection;. The 42nd Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation..,18-64 Years,Not Specified,No,Male,"Bacteraemia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Febrile neutropenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscle mass (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin mass (n/a - Recovered/Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Intravenous drip]),"BUSULFAN [BUSULFAN] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown]),<BR><BR>[FLUDARABINE] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown]),<BR><BR>[MELPHALAN] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005619041&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005619043,Spontaneous,2020-03-06 00:00:00,Healthcare Professional,Non European Economic Area,Nakamura F. Haploidentical Stem Cell Transplantation for an Elderly Patient of Progressive Myelodysplastic Syndrome With Pneumonia. The 42nd Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation..,65-85 Years,Not Specified,No,Male,Pneumonia (n/a - Recovering/Resolving - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Intravenous drip]),"BUSULFAN [BUSULFAN] (C - Product used for unknown indication - n/a - [n/a - 3.2mg/kg - Intravenous drip]),<BR><BR>MYCOPHENOLATE MOFETIL [MYCOPHENOLATE MOFETIL] (C - Prophylaxis - n/a - [n/a - 15mg/kg - Oral]),<BR><BR>TACROLIMUS [TACROLIMUS, TACROLIMUS MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - .01mg/kg - Intravenous drip]),<BR><BR>[CYCLOPHOSPHAMIDE] (C - Prophylaxis - n/a - [n/a - 40mg/kg - Intravenous drip]),<BR><BR>[FLUDARABINE] (C - Product used for unknown indication - n/a - [n/a - 30mg/m2 - Unknown]),<BR><BR>[WHOLE BLOOD] (C - Product used for unknown indication - n/a - [n/a - n/a - Intravenous drip])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005619043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005619045,Spontaneous,2020-03-06 00:00:00,Healthcare Professional,Non European Economic Area,Yoshino A. A Case of Muscle Abscess due to Mucormycosis Which Developed Just Before Hematopoietic Stem Cell Transplantation. The 42nd Annual Meeting of the Japan Society for Hematopoietic Cell transplantation.,18-64 Years,Not Specified,No,Male,"Abscess limb (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neutropenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Recovering/Resolving - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Leukaemia recurrent - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005619045&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005619046,Spontaneous,2020-03-06 00:00:00,Healthcare Professional,Non European Economic Area,Nakamura H. Two Cases of Treatment Resistant FLT3ITD Mutation Positive Acute Myeloid Leukemia Which Were Saved by Cord Blood Transplant After Successuful of Hematological Remission by Gilteritinib. The 42nd Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation.,18-64 Years,Not Specified,No,Male,"Autoimmune haemolytic anaemia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pancytopenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Transformation to acute myeloid leukaemia (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Unknown]),"CYTARABINE [CYTARABINE] (C - Product used for unknown indication - n/a - [n/a - 100mg - Unknown]),<BR><BR>[CHLORPHENAMINE MALEATE, SODIUM CITRATE, AMMONIUM CHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005619046&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005619048,Spontaneous,2020-03-06 00:00:00,Healthcare Professional,Non European Economic Area,K. Y. A Case of Pneumonia due to Mycobacterium Abscessus After two Allogeneic Transplantation for Myelodysplastic syndrome. The 42nd Annual Meeting of the Japan Society for Hematopoietic Cell.,18-64 Years,Not Specified,No,Female,Pneumonia (n/a - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Intravenous (not otherwise specified)]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005619048&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005586556,Spontaneous,2020-03-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Neutropenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Thrombocytopenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",VIDAZA 25 MG/ML POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Myelodysplastic syndrome - Dose reduced - [n/a - 175mg - Intravenous (not otherwise specified)]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005586556&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005577281,Spontaneous,2020-02-29 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Renal failure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),<BR><BR>[PIPERACILLIN, PIPERACILLIN, TAZOBACTAM] (S - Pneumonia - Drug withdrawn - [n/a - n/a - Intravenous (not otherwise specified)])","POSACONAZOLE [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LINEZOLID] (C - Pneumonia - Drug withdrawn - [n/a - 600mg - Oral]),<BR><BR>[ONDANSETRON] (C - Nausea - Drug withdrawn - [n/a - 8mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005577281&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005571199,Spontaneous,2020-02-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pneumonia (n/a - Unknown - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005571199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005562074,Spontaneous,2020-02-27 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Angioimmunoblastic T-cell lymphoma (n/a - Unknown - ),"VIDAZA [AZACITIDINE] (S - Angioimmunoblastic T-cell lymphoma - Drug withdrawn - [n/a - n/a - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Off label use - Drug withdrawn - [n/a - n/a - n/a])","[BENDAMUSTINE, BENDAMUSTINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CYCLOPHOSPHAMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GEMFIBROZIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PREDNISONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ROMIDEPSIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VINCRISTINE, VINCRISTINE SULFATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005562074&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005550113,Spontaneous,2020-02-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hypokalaemia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypotension (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute monocytic leukaemia - Not applicable - [n/a - 84mg - Subcutaneous]),"ABASAGLAR [INSULIN GLARGINE] (C - n/a - n/a - [n/a - 10[iU] - Subcutaneous]),<BR><BR>NOVORAPID [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - Subcutaneous]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 30mg - Oral]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - 2{DF} - Oral]),<BR><BR>[PREDNISOLONE METASULFOBENZOATE SODIUM] (C - n/a - n/a - [n/a - 1{DF} - Oral]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - Oral]),<BR><BR>[TRIMETHYLPHLOROGLUCINOL, PHLOROGLUCINOL DIHYDRATE] (C - n/a - n/a - [n/a - 2{DF} - Oral]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - 7.5mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005550113&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005550920,Spontaneous,2020-02-26 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Gastritis (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Unknown]),[CORTISONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005550920&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005555203,Spontaneous,2020-02-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diverticulitis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Respiratory disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005555203&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005543972,Spontaneous,2020-02-25 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Adverse drug reaction (n/a - Unknown - ),<BR><BR>Gastritis (n/a - Unknown - )",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005543972&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005545163,Spontaneous,2020-02-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Melaena (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),"HYDROXYCARBAMIDE [HYDROXYCARBAMIDE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Drug withdrawn - [n/a - 100mg - Unknown])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005545163&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005545165,Spontaneous,2020-02-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac tamponade (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pericardial effusion (n/a - Recovering/Resolving - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - 75mg/m2 - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005545165&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005546531,Spontaneous,2020-02-25 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Disease progression (n/a - Unknown - ),<BR><BR>Treatment failure (n/a - Unknown - )","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Refractory cytopenia with unilineage dysplasia - Unknown - [n/a - n/a - Unknown])",LUSPATERCEPT [LUSPATERCEPT] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005546531&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005546747,Spontaneous,2020-02-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anaemia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neutrophil count decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","CYTARABINE [CYTARABINE] (S - Product used for unknown indication - Unknown - [n/a - 100mg - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 75mg/m2 - Intravenous drip])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005546747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005546749,Spontaneous,2020-02-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Cerebral haemorrhage (1d - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Not applicable - [n/a - 75mg/m2 - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005546749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005546750,Spontaneous,2020-02-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Platelet count decreased (n/a - Recovered/Resolved - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 35mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005546750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005546845,Spontaneous,2020-02-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Neutropenia (22d - Recovered/Resolved - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>XOSPATA [GILTERITINIB] (S - Acute myeloid leukaemia - Drug withdrawn - [39d - 120mg - Oral - More in ICSR]),<BR><BR>XOSPATA [GILTERITINIB] (S - Acute myeloid leukaemia - n/a - [39d - 120mg - Oral - More in ICSR])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005546845&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005547211,Spontaneous,2020-02-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Pulmonary alveolar haemorrhage (23d - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Sepsis (6d - Recovered/Resolved - Results in Death, Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 125mg/m2 - Subcutaneous])","[ITRACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LANSOPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[OLMESARTAN MEDOXOMIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[RAMOSETRON HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005547211&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005537714,Spontaneous,2020-02-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Neutropenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose reduced - [n/a - 100mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose reduced - [n/a - 100mg - Unknown])","[ESOMEPRAZOLE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[METFORMIN] (C - Product used for unknown indication - n/a - [n/a - 500mg - Oral]),<BR><BR>[PIOGLITAZONE HYDROCHLORIDE, ALOGLIPTIN BENZOATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Prophylaxis - n/a - [n/a - n/a - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005537714&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005525242,Spontaneous,2020-02-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Acute myeloid leukaemia (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Unknown]),"NOXAFIL [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - 100mg - Unknown]),<BR><BR>[ALPRAZOLAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[DIOSMECTITE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - 20mg - Unknown]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - 5mg - Unknown]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [n/a - 18.7ug - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PHLOROGLUCINOL DIHYDRATE, PHLOROGLUCINOL, TRIMETHYLPHLOROGLUCINOL, TRIMETHYLPHLOROGLUCINOL, PHLOROGLUCINOL DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[POTASSIUM CHLORIDE, POTASSIUM CHLORIDE, ETHYLCELLULOSE MICROENCAPSULATED 80-90%] (C - Product used for unknown indication - n/a - [n/a - 600mg - Oral]),<BR><BR>[RACECADOTRIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM HYDROGEN CARBONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 500mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005525242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005527951,Spontaneous,2020-02-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Acute myeloid leukaemia (n/a - Unknown - ),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Lymphangioleiomyomatosis - Unknown - [n/a - n/a - Unknown])","POSACONAZOLE [POSACONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROXYCARBAMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005527951&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005516065,Spontaneous,2020-02-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypokalaemia (7d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypophosphataemia (7d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypouricaemia (7d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Renal tubular disorder (7d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","EXJADE [DEFERASIROX] (S - Iron overload - Drug withdrawn - [n/a - 90mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 100mg - Subcutaneous]),<BR><BR>[AMOXICILLIN SODIUM, CLAVULANIC ACID, AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN TRIHYDRATE, POTASSIUM CLAVULANATE, AMOXICILLIN, CLAVULANIC ACID, AMOXICILLIN, POTASSIUM CLAVULANATE] (S - Infection - Drug withdrawn - [n/a - 3g - Oral])","NOXAFIL 300 MG CONCENTRATE FOR SOLUTION FOR INFUSION [POSACONAZOLE] (C - Antifungal prophylaxis - n/a - [n/a - 300mg - n/a]),<BR><BR>[ATOVAQUONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[LENOGRASTIM] (C - Neutropenia - n/a - [n/a - n/a - n/a]),<BR><BR>[SOTALOL HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 80mg - n/a]),<BR><BR>[VALACICLOVIR HYDROCHLORIDE] (C - Prophylaxis - n/a - [n/a - n/a - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005516065&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005522416,Spontaneous,2020-02-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,Thrombocytopenia (n/a - Recovering/Resolving - Other Medically Important Condition),"VIDAZA [AZACITIDINE] (S - Non-Hodgkin's lymphoma - Dose not changed - [n/a - 121.5mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Off label use - Dose not changed - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005522416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005513815,Spontaneous,2020-02-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Interstitial lung disease (n/a - Recovering/Resolving - Other Medically Important Condition),"CICLOSPORIN [CICLOSPORIN] (S - Pyoderma gangrenosum - Dose reduced - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Subcutaneous])","[CICLOSPORIN] (C - Pyoderma - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHYLPREDNISOLONE] (C - Pyoderma - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005513815&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005514184,Spontaneous,2020-02-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Affect lability (n/a - Unknown - Disabling),<BR><BR>Gait disturbance (n/a - Unknown - Disabling),<BR><BR>Injection site pain (n/a - Recovering/Resolving - Disabling),<BR><BR>Injection site reaction (n/a - Recovering/Resolving - Disabling)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 138mg - Subcutaneous]),"[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - 200mg - Unknown]),<BR><BR>[BISOPROLOL FUMARATE, BISOPROLOL FUMARATE, ACETYLSALICYLIC ACID, BISOPROLOL HEMIFUMARATE] (C - Blood pressure measurement - n/a - [n/a - 5mg - Oral]),<BR><BR>[METFORMIN] (C - Diabetes mellitus - n/a - [n/a - 1g - Oral]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[VITAMIN D] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005514184&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005514210,Spontaneous,2020-02-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Febrile neutropenia (18d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Sepsis (15d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 134mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Unknown - [n/a - 42mg - Subcutaneous]),<BR><BR>[DIPHENHYDRAMINE] (S - Senile xerosis - Unknown - [n/a - n/a - Unknown])","FEBUXOSTAT [FEBUXOSTAT] (C - Prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Infection prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - n/a - Unknown]),<BR><BR>[CLOSTRIDIUM BUTYRICUM] (C - Diarrhoea - n/a - [n/a - n/a - Unknown]),<BR><BR>[ESZOPICLONE] (C - Insomnia - n/a - [n/a - n/a - Unknown]),<BR><BR>[FAMOTIDINE] (C - Prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[MECOBALAMIN] (C - Vitamin B12 deficiency - n/a - [n/a - n/a - Unknown]),<BR><BR>[POLAPREZINC] (C - Prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM CHLORIDE, GLUCOSE, SODIUM LACTATE] (C - Fluid replacement - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005514210&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005498225,Spontaneous,2020-02-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Treatment failure (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005498225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005503057,Spontaneous,2020-02-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Asthenia (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Bedridden (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Death (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Full blood count decreased (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Lung neoplasm malignant (n/a - Unknown - Results in Death, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Unknown]),[EPOETIN ALFA] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005503057&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005503188,Spontaneous,2020-02-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Graft versus host disease (n/a - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005503188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005492157,Spontaneous,2020-02-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Neoplasm malignant (n/a - Unknown - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Drug withdrawn - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005492157&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005492221,Spontaneous,2020-02-17 00:00:00,Healthcare Professional,Non European Economic Area,Tatsumi N. Myelodysplastic Syndrome Which Occured Disseminated Nontuberculous Mycobacteriosis by Mycobacterium Abscessus During the Administration of Azacitidine. The 226th Kinki Regional Meeting of the Japanese Society of Internal Medicine. 2019 DEC 21;.,More than 85 Years,Not Specified,No,Male,Atypical mycobacterial infection (n/a - Unknown - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005492221&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005475381,Spontaneous,2020-02-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Agranulocytosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 128mg - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005475381&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005475806,Spontaneous,2020-02-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pancytopenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - n/a - [n/a - 75mg - Subcutaneous]),"BINOCRIT 4000 IU/0.4 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE [EPOETIN ALFA] (C - n/a - n/a - [n/a - 4000[iU] - n/a]),<BR><BR>NIVESTIM [FILGRASTIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOVORAPID [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOXAFIL 100 MG GASTRO-RESISTANT TABLETS [POSACONAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE, LYSINE ASPIRIN, LYSINE, ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[BISOPROLOL FUMARATE] (C - n/a - n/a - [n/a - 50mg - n/a]),<BR><BR>[BUMETANIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DEXCHLORPHENIRAMINE MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DIGOXIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ENOXAPARIN SODIUM] (C - n/a - n/a - [n/a - n/a - Subcutaneous]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 500mg - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM CHLORIDE, POTASSIUM CHLORIDE, ETHYLCELLULOSE MICROENCAPSULATED 80-90%] (C - n/a - n/a - [n/a - n/a - Oral]),<BR><BR>[SPIRONOLACTONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - n/a - n/a - [n/a - 500mg - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005475806&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005480459,Spontaneous,2020-02-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemoglobin decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>White blood cell count decreased (n/a - Unknown - Other Medically Important Condition)","VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown])","[ACICLOVIR, ACICLOVIR SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMLODIPINE BESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ATORVASTATIN CALCIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CETIRIZINE DIHYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[GLYCERYL TRINITRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METOPROLOL TARTRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ONDANSETRON HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[THIAMINE HYDROCHLORIDE, ASCORBIC ACID, BIOTIN, FOLIC ACID, NICOTINAMIDE, PHYTOMENADIONE, RIBOFLAVIN, ZINC, CALCIUM, IODINE, PANTOTHENIC ACID, POTASSIUM, PYRIDOXINE HYDROCHLORIDE, URIDINE, CYTIDINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VITAMIN D] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005480459&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005480464,Spontaneous,2020-02-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Sepsis (4d - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 75mg/m2 - Subcutaneous]),"HYDROXYCARBAMIDE [HYDROXYCARBAMIDE] (C - Chemotherapy - n/a - [n/a - 500mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Unknown]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [17y - 5mg - Oral]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [17y - 2.5mg - Oral]),<BR><BR>[CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE, COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteoporosis - n/a - [n/a - 500mg - Oral]),<BR><BR>[CASSIA, CASSIA SENNA WHOLE, HYDROXYANTHRACENE GLYCOSIDES, SENNA PODS, SENNOSIDE B, SENNOSIDES] (C - Constipation prophylaxis - n/a - [n/a - 8.6mg - Oral]),<BR><BR>[DIMENHYDRINATE] (C - Nausea - n/a - [n/a - 50mg - Oral]),<BR><BR>[DIMENHYDRINATE] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[DOCUSATE SODIUM] (C - Constipation - n/a - [n/a - 100mg - Oral]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Prophylaxis - n/a - [n/a - 20mg - Oral]),<BR><BR>[GLICLAZIDE] (C - Diabetes mellitus - n/a - [n/a - 60mg - Oral]),<BR><BR>[LEVOFLOXACIN HEMIHYDRATE] (C - Infection prophylaxis - n/a - [n/a - 500mg - Oral]),<BR><BR>[MAGNESIUM SULFATE] (C - Hypomagnesaemia - n/a - [n/a - 500mg - Oral]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - 2g - Unknown]),<BR><BR>[ONDANSETRON] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 8mg - Oral]),<BR><BR>[PARACETAMOL] (C - Pelvic fracture - n/a - [n/a - n/a - Oral]),<BR><BR>[POTASSIUM CHLORIDE] (C - Prophylaxis - n/a - [16d - 40meq - Oral]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - n/a - [16d - 20meq - Oral]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Hypercholesterolaemia - n/a - [n/a - 20mg - Unknown]),<BR><BR>[VITAMIN D] (C - Osteoporosis - n/a - [n/a - 1000[iU] - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005480464&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005481936,Spontaneous,2020-02-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cough (1mo - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (1mo - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dysphagia (1mo - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza (1mo - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (1mo - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pharyngeal swelling (1mo - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Throat clearing (1mo - Recovered/Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Intravenous drip]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005481936&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005440012,Spontaneous,2020-02-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Febrile neutropenia (15d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Febrile neutropenia (7d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Unknown - [n/a - n/a - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - 75mg/m2 - Intravenous drip])","FEBUXOSTAT [FEBUXOSTAT] (C - Tumour lysis syndrome - n/a - [n/a - 10mg - Unknown]),<BR><BR>FESOTERODINE FUMARATE [FESOTERODINE FUMARATE] (C - Hypertonic bladder - n/a - [n/a - 4mg - Unknown]),<BR><BR>INSULIN HUMAN [INSULIN HUMAN] (C - Hyperglycaemia - n/a - [n/a - 6[iU] - Unknown]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Infection prophylaxis - n/a - [n/a - 250mg - Unknown]),<BR><BR>SILODOSIN [SILODOSIN] (C - Benign prostatic hyperplasia - n/a - [n/a - 8mg - Unknown]),<BR><BR>[ALENDRONATE SODIUM HYDRATE] (C - Osteoporosis prophylaxis - n/a - [n/a - 35mg - Unknown]),<BR><BR>[BROMFENAC SODIUM] (C - Dry eye - n/a - [n/a - .1% - Ophthalmic]),<BR><BR>[CARBAZOCHROME SODIUM SULFONATE] (C - Gastrointestinal haemorrhage - n/a - [n/a - 100mg - Unknown]),<BR><BR>[ESOMEPRAZOLE MAGNESIUM] (C - Gastritis prophylaxis - n/a - [n/a - 20mg - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HEPARIN SODIUM] (C - Thrombosis prophylaxis - n/a - [n/a - 10mL - Unknown]),<BR><BR>[HEPARINOID] (C - Dry skin - n/a - [n/a - n/a - Unknown]),<BR><BR>[HEPARINOID] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROXYANTHRACENE GLYCOSIDES, SENNOSIDES] (C - Constipation - n/a - [n/a - 12mg - Unknown]),<BR><BR>[KETOPROFEN] (C - Dry skin - n/a - [n/a - 3% - Unknown]),<BR><BR>[KETOPROFEN] (C - Intervertebral disc protrusion - n/a - [n/a - 120mg - Unknown]),<BR><BR>[KETOPROFEN] (C - n/a - n/a - [n/a - 120mg - Unknown]),<BR><BR>[KETOPROFEN] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[L-ISOLEUCINE, L-LEUCINE] (C - Hypoproteinaemia - n/a - [n/a - 500mL - Unknown]),<BR><BR>[LOXOPROFEN SODIUM HYDRATE] (C - Intervertebral disc protrusion - n/a - [n/a - n/a - Unknown]),<BR><BR>[LOXOPROFEN SODIUM HYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[OMEPRAZOLE] (C - Gastrointestinal haemorrhage - n/a - [n/a - 40mg - Unknown]),<BR><BR>[POLAPREZINC] (C - Hypozincaemia - n/a - [n/a - 75mg - Unknown]),<BR><BR>[POLAPREZINC] (C - n/a - n/a - [n/a - 150mg - Unknown]),<BR><BR>[PREDNISOLONE SODIUM SUCCINATE] (C - Vasculitis - n/a - [n/a - 40mg - Unknown]),<BR><BR>[PREDNISOLONE] (C - Rheumatoid arthritis - n/a - [n/a - 1mg - Unknown]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - 1mg - Unknown]),<BR><BR>[RIBOFLAVIN SODIUM PHOSPHATE, THIAMINE HYDROCHLORIDE, ASCORBIC ACID, NICOTINAMIDE, PANTHENOL, PYRIDOXINE HYDROCHLORIDE] (C - Prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[SODIUM CHLORIDE, GLUCOSE, SODIUM LACTATE] (C - Prophylaxis - n/a - [n/a - 11.5mL - Unknown]),<BR><BR>[SODIUM CHLORIDE, GLUCOSE, SODIUM LACTATE] (C - n/a - n/a - [n/a - 500mL - Unknown]),<BR><BR>[SODIUM CHLORIDE] (C - Hyponatraemia - n/a - [1d - 20mL - Unknown]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [1d - 60mL - Unknown]),<BR><BR>[SODIUM HYALURONATE] (C - Dry skin - n/a - [n/a - .1% - Ophthalmic]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Infection prophylaxis - n/a - [n/a - n/a - Unknown]),<BR><BR>[TRANEXAMIC ACID] (C - Gastrointestinal haemorrhage - n/a - [n/a - 250mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005440012&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005441707,Spontaneous,2020-02-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Myelodysplastic syndrome (363d - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Staphylococcal sepsis (n/a - Recovering/Resolving - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005441707&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005428084,Spontaneous,2020-02-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anaemia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Ear injury (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Immune system disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005428084&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005430084,Spontaneous,2020-02-07 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Bone marrow failure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Inflammation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Injection site reaction (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Sepsis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005430084&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005431361,Spontaneous,2020-02-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Febrile bone marrow aplasia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Organising pneumonia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","NEXAVAR 200 MG FILM-COATED TABLETS [SORAFENIB, SORAFENIB TOSILATE] (S - Acute myeloid leukaemia - n/a - [n/a - 200mg - Oral]),<BR><BR>VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Acute myeloid leukaemia - n/a - [n/a - 117mg - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005431361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005431526,Spontaneous,2020-02-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Purpura (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash scarlatiniform (n/a - Not Recovered/Not Resolved - )","PREGABALIN MYLAN [PREGABALIN] (S - Pain - Not applicable - [n/a - n/a - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Intravenous drip]),<BR><BR>[IOMEPROL] (S - Computerised tomogram - Not applicable - [n/a - 1{DF} - Intravenous drip]),<BR><BR>[PIPERACILLIN, TAZOBACTAM] (S - Infection - Not applicable - [n/a - n/a - Intravenous drip]),<BR><BR>[PRISTINAMYCIN] (S - Infection - Drug withdrawn - [n/a - n/a - Intravenous drip])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005431526&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005432058,Spontaneous,2020-02-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Posterior reversible encephalopathy syndrome (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling)","VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Intravenous (not otherwise specified)]),<BR><BR>[AMOXICILLIN, AMOXICILLIN SODIUM, AMOXICILLIN TRIHYDRATE] (S - Diarrhoea - Drug withdrawn - [n/a - n/a - n/a]),<BR><BR>[RISEDRONATE MONOSODIUM, RISEDRONATE SODIUM] (S - Polychondritis - Dose not changed - [n/a - 35mg - Oral])","ARANESP [DARBEPOETIN ALFA] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>EXJADE [DEFERASIROX] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM, COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM CHLORIDE, POTASSIUM CHLORIDE, ETHYLCELLULOSE MICROENCAPSULATED 80-90%] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005432058&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005417152,Spontaneous,2020-02-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Acute myeloid leukaemia (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005417152&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005417947,Spontaneous,2020-02-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Febrile neutropenia (23d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 75mg/m2 - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - 75mg/m2 - Intravenous drip])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Gastritis - n/a - [n/a - 20mg - Oral]),<BR><BR>FEBUXOSTAT [FEBUXOSTAT] (C - Hyperuricaemia - n/a - [n/a - 20mg - Oral]),<BR><BR>FEBUXOSTAT [FEBUXOSTAT] (C - Prophylaxis - n/a - [n/a - 60mg - Oral]),<BR><BR>FEBUXOSTAT [FEBUXOSTAT] (C - n/a - n/a - [n/a - 20mg - Oral]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Infection prophylaxis - n/a - [44d - 500mg - Oral]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Sepsis - n/a - [44d - 500mg - Oral]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - n/a - n/a - [44d - 500mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Infection prophylaxis - n/a - [n/a - 150mg - Oral]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Pneumonia - n/a - [n/a - 300mg - Oral]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Sepsis - n/a - [n/a - 360mg - Intravenous drip]),<BR><BR>[ALUMINIUM OXIDE, HYDRATED, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, CINNAMON, POWDERED, EQUISETUM, FENNEL, GLYCYRRHIZA GLABRA, MAGNESIUM CARBONATE] (C - Gastritis - n/a - [n/a - 1.3g - Oral]),<BR><BR>[DEQUALINIUM CHLORIDE] (C - Dry mouth - n/a - [12d - .25mg - Oropharingeal]),<BR><BR>[DEQUALINIUM CHLORIDE] (C - Pharyngitis - n/a - [12d - .25mg - Oropharingeal]),<BR><BR>[POTASSIUM CHLORIDE, SODIUM CHLORIDE, GLUCOSE, SODIUM LACTATE] (C - Prophylaxis against dehydration - n/a - [71d - 500mL - Intravenous drip]),<BR><BR>[POTASSIUM CHLORIDE, SODIUM CHLORIDE, GLUCOSE, SODIUM LACTATE] (C - n/a - n/a - [71d - 500mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - Prophylaxis - n/a - [n/a - 1000mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 1000mL - Intravenous drip]),<BR><BR>[SODIUM CHLORIDE] (C - n/a - n/a - [n/a - 2000mL - Intravenous drip]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Infection prophylaxis - n/a - [n/a - 1{DF} - Oral]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Hepatic enzyme increased - n/a - [n/a - 100mg - Unknown]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Prophylaxis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005417947&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005409014,Spontaneous,2020-02-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Skin reaction (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005409014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005410320,Spontaneous,2020-02-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Febrile neutropenia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Septic shock (32d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005410320&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005410645,Spontaneous,2020-02-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Haemoglobin decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Immunodeficiency (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Transformation to acute myeloid leukaemia (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005410645&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005410647,Spontaneous,2020-02-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Injection site hypersensitivity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neutropenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Unknown - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Chronic myelomonocytic leukaemia - Unknown - [n/a - 150mg - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - n/a])","[ONDANSETRON HYDROCHLORIDE] (C - Antiemetic supportive care - n/a - [n/a - n/a - Sublingual]),<BR><BR>[ONDANSETRON HYDROCHLORIDE] (C - Nausea - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005410647&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005410650,Spontaneous,2020-02-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Myelodysplastic syndrome (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Platelet count decreased (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>White blood cell count decreased (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005410650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005398930,Spontaneous,2020-02-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Myelodysplastic syndrome (n/a - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005398930&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005382490,Spontaneous,2020-01-31 00:00:00,Healthcare Professional,Non European Economic Area,"Kuriyama C. A case Which Developed DLBCL in Remission Phase of Acute Myeloid Leukemia (AML, NOS) and new Leukemia (AML With MRc) During R-cHoP Regimen. The 121th Shikoku Regional Meeting of the Japanese Society of Internal Medicine..",65-85 Years,Not Specified,No,Male,Infection (n/a - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 100mg - Unknown]),RITUXIMAB [RITUXIMAB] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005382490&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005373752,Spontaneous,2020-01-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Pancytopenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 100mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Dose not changed - [n/a - 200mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Dose not changed - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 75mg/m2 - Subcutaneous])","ANAGRELIDE [ANAGRELIDE] (C - Myelofibrosis - n/a - [n/a - 2.5mg - Oral]),<BR><BR>CLOPIDOGREL HYDROGEN SULFATE [CLOPIDOGREL HYDROGEN SULFATE] (C - Cerebrovascular accident prophylaxis - n/a - [n/a - 75mg - Oral]),<BR><BR>CLOPIDOGREL HYDROGEN SULFATE [CLOPIDOGREL HYDROGEN SULFATE] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>IRON [IRON] (C - Anaemia - n/a - [n/a - 18mg - Oral]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Antibiotic prophylaxis - n/a - [n/a - 250mg - Oral]),<BR><BR>RASBURICASE [RASBURICASE] (C - Prophylaxis - n/a - [n/a - 7.5mg - Intravenous drip]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [n/a - 300mg - Oral]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - 100mg - Oral]),<BR><BR>[ASCORBIC ACID] (C - Supplementation therapy - n/a - [n/a - 500mg - Oral]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Hypercholesterolaemia - n/a - [n/a - 10mg - Oral]),<BR><BR>[DUTASTERIDE] (C - Benign prostatic hyperplasia - n/a - [n/a - .5mg - Oral]),<BR><BR>[FLUCONAZOLE] (C - Antifungal prophylaxis - n/a - [n/a - 200mg - Oral]),<BR><BR>[FUROSEMIDE] (C - Oedema peripheral - n/a - [n/a - 40mg - Oral]),<BR><BR>[LACTULOSE] (C - Constipation - n/a - [n/a - 15mL - Oral]),<BR><BR>[POTASSIUM CHLORIDE] (C - Electrolyte substitution therapy - n/a - [n/a - 10meq - Oral]),<BR><BR>[PREDNISONE] (C - Temporal arteritis - n/a - [n/a - 5mg - Oral]),<BR><BR>[PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE] (C - Nausea - n/a - [n/a - n/a - n/a]),<BR><BR>[PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE] (C - Vomiting - n/a - [n/a - 10mg - Oral]),<BR><BR>[ZOLPIDEM TARTRATE] (C - Insomnia - n/a - [n/a - 10mg - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005373752&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005374963,Spontaneous,2020-01-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Application site erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Contusion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Immunosuppression (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Injection site mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005374963&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005361896,Spontaneous,2020-01-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Transformation to acute myeloid leukaemia (n/a - Unknown - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),"KOMBOGLYZE [METFORMIN HYDROCHLORIDE, SAXAGLIPTIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>TELMISARTAN [TELMISARTAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[CALCITRIOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[METHOTREXATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PREDNISONE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005361896&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005362491,Spontaneous,2020-01-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,3-11 Years,Not Specified,No,Female,Disease progression (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"VENETOCLAX [VENETOCLAX] (S - Refractory cancer - Not applicable - [n/a - 80mg - Nasal]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Not applicable - [n/a - 170mg - Nasal]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Not applicable - [n/a - 350mg - Nasal]),<BR><BR>VIDAZA [AZACITIDINE] (S - Refractory cancer - Not applicable - [n/a - n/a - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Not applicable - [n/a - 75mg/m2 - Intravenous drip])","DECITABINE [DECITABINE] (C - Refractory cancer - n/a - [n/a - 20mg/m2 - Intravenous drip]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Bacterial infection - n/a - [n/a - 220mg - Nasal]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Unknown]),<BR><BR>OLANZAPINE [OLANZAPINE] (C - Nausea - n/a - [n/a - 2.5mg - Nasal]),<BR><BR>OLANZAPINE [OLANZAPINE] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>PEGASPARGASE [PEGASPARGASE] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Antiviral prophylaxis - n/a - [n/a - 500mg - Nasal]),<BR><BR>[ALLOPURINOL] (C - Prophylaxis - n/a - [11d - 100mg - Nasal]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [11d - 100mg - Nasal]),<BR><BR>[COLECALCIFEROL] (C - Vitamin supplementation - n/a - [n/a - 2000[iU] - Nasal]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - Cardiac disorder - n/a - [n/a - 1mg - Nasal]),<BR><BR>[GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS, GLUCOSE, ANHYDROUS, GLUCOSE MONOHYDRATE, MAGNESIUM CHLORIDE HEXAHYDRATE, SODIUM CHLORIDE, CALCIUM CHLORIDE DIHYDRATE, GLUCOSE MONOHYDRATE, SODIUM LACTATE] (C - Prophylaxis - n/a - [n/a - 2mL - Intravenous drip]),<BR><BR>[GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS, GLUCOSE, ANHYDROUS, GLUCOSE MONOHYDRATE, MAGNESIUM CHLORIDE HEXAHYDRATE, SODIUM CHLORIDE, CALCIUM CHLORIDE DIHYDRATE, GLUCOSE MONOHYDRATE, SODIUM LACTATE] (C - n/a - n/a - [n/a - 37mL - Intravenous drip]),<BR><BR>[GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS, GLUCOSE, ANHYDROUS, GLUCOSE MONOHYDRATE, MAGNESIUM CHLORIDE HEXAHYDRATE, SODIUM CHLORIDE, CALCIUM CHLORIDE DIHYDRATE, GLUCOSE MONOHYDRATE, SODIUM LACTATE] (C - n/a - n/a - [n/a - 75mL - Intravenous drip]),<BR><BR>[GRANISETRON HYDROCHLORIDE] (C - Prophylaxis of nausea and vomiting - n/a - [n/a - 1mg - Nasal]),<BR><BR>[LORAZEPAM] (C - Nausea - n/a - [n/a - .6mg - Nasal]),<BR><BR>[LORAZEPAM] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM CARBONATE] (C - Mineral supplementation - n/a - [n/a - 54mg - Nasal]),<BR><BR>[OMEPRAZOLE SODIUM] (C - Gastrooesophageal reflux disease - n/a - [n/a - 20mg - Nasal]),<BR><BR>[OXYCODONE, OXYCODONE HYDROCHLORIDE] (C - Pain - n/a - [n/a - 2mg - Nasal]),<BR><BR>[PARACETAMOL] (C - Neutropenia - n/a - [1d - 29mL - Nasal]),<BR><BR>[PARACETAMOL] (C - Pyrexia - n/a - [1d - 256mg - Nasal]),<BR><BR>[SULFAMETHOXAZOLE] (C - Infection prophylaxis - n/a - [n/a - 60mg - Nasal])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005362491&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005282040,Spontaneous,2020-01-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Back disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Creatinine renal clearance decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemoglobin decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Intravenous (not otherwise specified)]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005282040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005284228,Spontaneous,2020-01-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Hyponatraemia (16d - Recovered/Resolved - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 142.5mg - Subcutaneous]),"PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - 300mg - Oral]),<BR><BR>[FINASTERIDE] (C - Product used for unknown indication - n/a - [n/a - 5mg - Oral]),<BR><BR>[FLUCONAZOLE] (C - Prophylaxis - n/a - [n/a - 4{DF} - Unknown]),<BR><BR>[FUSIDIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [n/a - 150ug - Oral]),<BR><BR>[METOCLOPRAMIDE] (C - Product used for unknown indication - n/a - [n/a - 10mg - Oral]),<BR><BR>[ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - 1{DF} - Oral]),<BR><BR>[ONDANSETRON] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - 40mg - Oral]),<BR><BR>[PERINDOPRIL TERT-BUTYLAMINE, INDAPAMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral]),<BR><BR>[VALACICLOVIR] (C - Product used for unknown indication - n/a - [n/a - 500mg - Oral]),<BR><BR>[VITAMIN B12] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005284228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005273129,Spontaneous,2020-01-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Cardiac disorder (n/a - Fatal - Results in Death),<BR><BR>Cytopenia (n/a - Fatal - Results in Death)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - 400mg - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005273129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005255443,Spontaneous,2020-01-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Disease progression (n/a - Fatal - Results in Death),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Unknown]),<BR><BR>[VENETOCLAX] (S - Acute myeloid leukaemia - Not applicable - [n/a - n/a - Oral])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005255443&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005242436,Spontaneous,2020-01-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bronchopneumopathy (n/a - Recovering/Resolving - ),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose reduced - [n/a - 100mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005242436&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005249948,Spontaneous,2020-01-21 00:00:00,Healthcare Professional,European Economic Area,"CARDIAC FAILURE IN PATIENTS TREATED WITH AZACITIDINE, A PYRIMIDINE ANALOGUE: CASE REPORTS AND DISPROPORTIONALITY ANALYSES IN VIGIBASE. British journal of clinical pharmacology.",65-85 Years,Not Specified,No,Male,Cardiac failure (n/a - Unknown - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005249948&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005250752,Spontaneous,2020-01-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Hypotension (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose not changed - [n/a - 75mg/m2 - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose not changed - [n/a - n/a - Subcutaneous])","CANNABIDIOL [CANNABIDIOL] (C - Arthralgia - n/a - [n/a - 25mg - Unknown]),<BR><BR>ENTRESTO [VALSARTAN, SACUBITRIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Antibiotic prophylaxis - n/a - [n/a - 500mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Oral]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Coronary artery disease - n/a - [n/a - 2{DF} - Oral]),<BR><BR>[LIDOCAINE, LIDOCAINE HYDROCHLORIDE] (C - Bone pain - n/a - [n/a - 30mg - Unknown]),<BR><BR>[LORAZEPAM] (C - Anxiety - n/a - [n/a - .5mg - Intravenous drip]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[MELOXICAM] (C - Product used for unknown indication - n/a - [n/a - 75mg - Unknown]),<BR><BR>[METOPROLOL SUCCINATE] (C - Hypertension - n/a - [n/a - 25mg - Oral]),<BR><BR>[MORPHINE, MORPHINE HYDROCHLORIDE] (C - Biopsy bone marrow - n/a - [n/a - 1mg - Intravenous drip]),<BR><BR>[MORPHINE, MORPHINE HYDROCHLORIDE] (C - Bone pain - n/a - [n/a - 2mg - Intravenous drip]),<BR><BR>[SIMVASTATIN] (C - Hyperlipidaemia - n/a - [n/a - 80mg - Oral]),<BR><BR>[TETRYZOLINE HYDROCHLORIDE] (C - Back pain - n/a - [n/a - 4mg - Unknown]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Pain prophylaxis - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005250752&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005251514,Spontaneous,2020-01-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Febrile neutropenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vertigo positional (25d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Not applicable - [n/a - 75mg/kg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Not applicable - [n/a - 75mg/kg - Unknown])","LEVOFLOXACIN [LEVOFLOXACIN] (C - Infection prophylaxis - n/a - [n/a - 500mg - Unknown]),<BR><BR>[CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - 8mg - Unknown]),<BR><BR>[GLYCEROL] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[HEPARINOID] (C - Dry skin - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYDROXYANTHRACENE GLYCOSIDES, SENNOSIDES] (C - Constipation - n/a - [n/a - n/a - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - Constipation - n/a - [n/a - 990mg - Unknown]),<BR><BR>[MAGNESIUM OXIDE] (C - n/a - n/a - [n/a - 990mg - Unknown]),<BR><BR>[METOCLOPRAMIDE HYDROCHLORIDE] (C - Dizziness - n/a - [n/a - 1{DF} - Unknown]),<BR><BR>[PIPERACILLIN SODIUM, TAZOBACTAM SODIUM, PIPERACILLIN, TAZOBACTAM] (C - Product used for unknown indication - n/a - [n/a - 18g - Unknown]),<BR><BR>[SODIUM PICOSULFATE] (C - Constipation - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005251514&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005240253,Spontaneous,2020-01-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Febrile neutropenia (40d - Fatal - Results in Death, Life Threatening)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - 128.2mg - Subcutaneous]),"FILGRASTIM [FILGRASTIM] (C - Product used for unknown indication - n/a - [n/a - 75ug - Unknown]),<BR><BR>FILGRASTIM [FILGRASTIM] (C - n/a - n/a - [n/a - 75ug - Unknown]),<BR><BR>[GRANULOCYTE COLONY-STIMULATING FACTOR] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ISOSORBIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005240253&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005240257,Spontaneous,2020-01-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Brain stem haemorrhage (273d - Fatal - Results in Death),VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005240257&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005220718,Spontaneous,2020-01-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pyoderma gangrenosum (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),VIDAZA POWDER FOR SUSPENSION FOR INJECTION [AZACITIDINE] (S - Refractory anaemia with an excess of blasts - Drug withdrawn - [n/a - 75mg/m2 - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005220718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005223976,Spontaneous,2020-01-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition)","VENETOCLAX [VENETOCLAX] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 400mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - Subcutaneous])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005223976&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005215145,Spontaneous,2020-01-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Back pain (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Influenza (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonitis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary pain (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005215145&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005208516,Spontaneous,2020-01-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Injection site discolouration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Thrombocytopenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Transformation to acute myeloid leukaemia (n/a - Unknown - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - n/a - n/a]),<BR><BR>VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Subcutaneous])",VENETOCLAX [VENETOCLAX] (C - Myelodysplastic syndrome - n/a - [n/a - n/a - Unknown]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005208516&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005211828,Spontaneous,2020-01-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Female,"Acute myeloid leukaemia (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Aplasia (n/a - Fatal - Results in Death, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - n/a - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005211828&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005200035,Spontaneous,2020-01-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Rash macular (n/a - Recovered/Resolved - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Dose not changed - [n/a - 75mg/m2 - Subcutaneous]),"NOXAFIL [POSACONAZOLE] (C - Antifungal prophylaxis - n/a - [n/a - 100ug - Unknown]),<BR><BR>[CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, COLECALCIFEROL CONCENTRATE (OILY FORM)] (C - Vitamin D deficiency - n/a - [n/a - 500ug - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005200035&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005202473,Spontaneous,2020-01-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Rash (n/a - Recovering/Resolving - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - 100mg - Subcutaneous]),[STERILE WATER] (C - Prophylaxis - n/a - [n/a - 4mL - Subcutaneous]),"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005202473&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005203461,Spontaneous,2020-01-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Appetite disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blood count abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bronchial disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased activity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemoglobin decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemorrhagic diathesis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Red blood cell count decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Weight increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wound haemorrhage (n/a - Unknown - Other Medically Important Condition)","VIDAZA [AZACITIDINE] (S - Myelofibrosis - Drug withdrawn - [n/a - n/a - Unknown]),<BR><BR>[RUXOLITINIB] (S - Myelofibrosis - Dose not changed - [n/a - 10mg - Oral]),<BR><BR>[RUXOLITINIB] (S - Primary myelofibrosis - Dose not changed - [n/a - 10mg - Oral])","[ALLOPURINOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[COLECALCIFEROL] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[LOVASTATIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TRAZODONE, TRAZODONE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[TRIAMTERENE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VITAMIN B12] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005203461&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005191070,Spontaneous,2020-01-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Accidental exposure to product (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovered/Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - 100mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005191070&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005186298,Spontaneous,2020-01-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pneumonia (n/a - Unknown - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005186298&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005181024,Spontaneous,2020-01-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Gastrointestinal infection (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytopenia (n/a - Unknown - Caused/Prolonged Hospitalisation)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Unknown - [n/a - 100mg - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005181024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005173704,Spontaneous,2020-01-09 00:00:00,Healthcare Professional,European Economic Area,Not available,12-17 Years,Not Specified,No,Male,Acute myeloid leukaemia refractory (n/a - Unknown - ),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - Off label use - Unknown - [n/a - n/a - n/a])","HUMAN NORMAL IMMUNOGLOBULIN (IV) [HUMAN NORMAL IMMUNOGLOBULIN (IV)] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SALMETEROL, SALMETEROL XINAFOATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005173704&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005174769,Spontaneous,2020-01-09 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Acute myeloid leukaemia (n/a - Unknown - ),"VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Drug withdrawn - [n/a - n/a - Unknown]),<BR><BR>[ENASIDENIB] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - 100mg - Oral])","BUSILVEX [BUSULFAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>CYTARABINE [CYTARABINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>CYTARABINE [CYTARABINE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - Product used for unknown indication - n/a - [n/a - 10mg - Unknown]),<BR><BR>DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - n/a - n/a - [n/a - 10mg - Unknown]),<BR><BR>GILTERITINIB [GILTERITINIB] (C - Acute myeloid leukaemia - n/a - [n/a - 120mg - Unknown]),<BR><BR>[CYTARABINE] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Unknown]),<BR><BR>[LOMUSTINE] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005174769&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005166207,Spontaneous,2020-01-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bone marrow failure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - 100mg - Subcutaneous]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005166207&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005166259,Spontaneous,2020-01-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Bone marrow failure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Infection (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Unknown - [n/a - 100mg - Unknown]),<BR><BR>VIDAZA [AZACITIDINE] (S - Chemotherapy - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005166259&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005166477,Spontaneous,2020-01-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Cardiac disorder (n/a - Fatal - Results in Death),"VENETOCLAX [VENETOCLAX] (S - Product used for unknown indication - Not applicable - [n/a - n/a - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - Unknown])","PLAVIX [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005166477&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005149233,Spontaneous,2020-01-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Full blood count decreased (n/a - Recovering/Resolving - Other Medically Important Condition),VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Drug withdrawn - [n/a - n/a - Unknown]),"[ATORVASTATIN] (C - Product used for unknown indication - n/a - [n/a - 10mg - Unknown]),<BR><BR>[DEFERASIROX] (C - Product used for unknown indication - n/a - [n/a - 720mg - Unknown]),<BR><BR>[DILTIAZEM, DILTIAZEM HYDROCHLORIDE] (C - Raynaud's phenomenon - n/a - [n/a - 60mg - Unknown]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Product used for unknown indication - n/a - [n/a - 50ug - Unknown]),<BR><BR>[OMEPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - 40mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005149233&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005150150,Spontaneous,2020-01-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,3-11 Years,Not Specified,No,Female,"Disseminated intravascular coagulation (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Febrile neutropenia (24d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Febrile neutropenia (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Febrile neutropenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","VENETOCLAX [VENETOCLAX] (S - Refractory cancer - Dose not changed - [n/a - 120mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Dose not changed - [n/a - 250mg - Oral]),<BR><BR>VENETOCLAX [VENETOCLAX] (S - n/a - Dose not changed - [n/a - 500mg - Oral]),<BR><BR>VIDAZA [AZACITIDINE] (S - Refractory cancer - Dose reduced - [n/a - 75mg/m2 - Subcutaneous]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose reduced - [n/a - 75mg/m2 - Subcutaneous])","CHLORHEXIDINE GLUCONATE [CHLORHEXIDINE GLUCONATE] (C - Gingival hypertrophy - n/a - [n/a - 15mL - Sublingual]),<BR><BR>LEVOFLOXACIN [LEVOFLOXACIN] (C - Antibiotic prophylaxis - n/a - [n/a - 250mg - Oral]),<BR><BR>MICAFUNGIN [MICAFUNGIN] (C - Antifungal prophylaxis - n/a - [n/a - 36mg - Intravenous drip]),<BR><BR>VORICONAZOLE [VORICONAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACICLOVIR SODIUM] (C - Antiviral prophylaxis - n/a - [n/a - 400mg - Oral]),<BR><BR>[AMINOCAPROIC ACID] (C - Mucosal haemorrhage - n/a - [n/a - 8mL - Unknown]),<BR><BR>[ASCORBIC ACID] (C - Vitamin supplementation - n/a - [n/a - 2mL - Oral]),<BR><BR>[CALCIUM CARBONATE] (C - Blood calcium decreased - n/a - [n/a - 1000mg - Oral]),<BR><BR>[DIPHENHYDRAMINE HYDROCHLORIDE] (C - Nausea - n/a - [n/a - 25mg - Oral]),<BR><BR>[DIPHENHYDRAMINE HYDROCHLORIDE] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[DOCUSATE SODIUM, CASANTHRANOL] (C - Constipation - n/a - [n/a - 100mg - Oral]),<BR><BR>[ERGOCALCIFEROL] (C - Vitamin supplementation - n/a - [n/a - 2mL - Oral]),<BR><BR>[FRESH FROZEN PLASMA] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[FUROSEMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HUMAN PLATELET, ALLOGENIC] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[HYOSCINE] (C - Nausea - n/a - [n/a - n/a - Transdermal]),<BR><BR>[LACTULOSE] (C - Constipation - n/a - [n/a - 15mL - Oral]),<BR><BR>[LORAZEPAM] (C - Nausea - n/a - [n/a - .5mg - Oral]),<BR><BR>[LORAZEPAM] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[NICOTINAMIDE] (C - Vitamin supplementation - n/a - [n/a - 2mL - Oral]),<BR><BR>[ONDANSETRON HYDROCHLORIDE] (C - Nausea - n/a - [n/a - 8mg - Sublingual]),<BR><BR>[ONDANSETRON HYDROCHLORIDE] (C - Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[OXYCODONE HYDROCHLORIDE] (C - Pain management - n/a - [n/a - 3mL - Unknown]),<BR><BR>[PENTAMIDINE ISETIONATE] (C - Opportunistic infection prophylaxis - n/a - [n/a - 144mg - Intravenous drip]),<BR><BR>[POTASSIUM CHLORIDE] (C - Blood potassium decreased - n/a - [n/a - n/a - Unknown]),<BR><BR>[RANITIDINE HYDROCHLORIDE] (C - Antacid therapy - n/a - [n/a - 75mg - Oral]),<BR><BR>[RETINOL] (C - Vitamin supplementation - n/a - [n/a - 2mL - Oral]),<BR><BR>[RIBOFLAVIN] (C - Vitamin supplementation - n/a - [n/a - 2mL - Oral]),<BR><BR>[SENNA ALEXANDRINA LEAF] (C - Constipation - n/a - [n/a - 17.2mg - Oral]),<BR><BR>[THIAMINE] (C - Vitamin supplementation - n/a - [n/a - 2mL - Oral])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005150150&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005136537,Spontaneous,2020-01-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pruritus (n/a - Unknown - ),"VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Dose not changed - [n/a - n/a - Intravenous drip]),<BR><BR>VIDAZA [AZACITIDINE] (S - n/a - Dose not changed - [n/a - n/a - Intravenous drip])","[HYDROXYZINE DIHYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE] (C - Pruritus - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005136537&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005137560,Spontaneous,2020-01-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Treatment failure (n/a - Unknown - ),VIDAZA [AZACITIDINE] (S - Acute myeloid leukaemia - Drug withdrawn - [n/a - n/a - Unknown]),"[HYDROXYCARBAMIDE] (C - Product used for unknown indication - n/a - [n/a - 500mg - Unknown]),<BR><BR>[HYDROXYCARBAMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - Product used for unknown indication - n/a - [n/a - 5mg - Unknown]),<BR><BR>[TAMIBAROTENE] (C - Acute myeloid leukaemia - n/a - [n/a - n/a - Unknown]),<BR><BR>[VALACICLOVIR] (C - Product used for unknown indication - n/a - [n/a - 500mg - Unknown])","<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005137560&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005141075,Spontaneous,2020-01-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Full blood count decreased (n/a - Unknown - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005141075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005141403,Spontaneous,2020-01-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Leukaemia (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Urinary tract infection (n/a - Unknown - Results in Death, Other Medically Important Condition),<BR><BR>Urosepsis (n/a - Fatal - Results in Death, Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Not applicable - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005141403&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10005133434,Spontaneous,2020-01-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Application site burn (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Application site discolouration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Application site erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Application site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Skin exfoliation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",VIDAZA [AZACITIDINE] (S - Myelodysplastic syndrome - Dose not changed - [n/a - n/a - Unknown]),Not reported,"<a target=""_blank"" href=""https://bi.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10005133434&_xpt=1&_xf=pdf"">ICSR</a>"
